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ABSTRACT
REGULATION OF MAMMALIAN PHOTORECEPTOR PHOSPHODIESTERASE 
(PDE) BY ITS NONCATALYTIC GAF DOMAINS AND ITS TWO SMALL 
SUBUNITS, GAMMA AND DELTA
By
Hongmei Mou 
University ofNew Hampshire, December, 2001
cGMP phosphodiesterase (PDE) is the central effector of visual transduction in 
retinal rod photoreceptors. Upon activation by transducin (a G-protein), PDE hydrolyzes 
cytoplasmic cGMP to induce the hyperpolarization of the plasma membrane in the outer 
segment of the rod cell. The extent and lifetime of activation of PDE must be precisely 
regulated in order to control the exquisite sensitivity, speed, and adaptational properties 
of the visual transduction pathway. The overall goal of this work was to investigate the 
possible regulatory mechanisms of PDE in mammalian rod photoreceptors by its 
noncatalytic cGMP binding sites on the PDE catalytic dimer (PaP), and by the 
interactions between the inhibitory Py subunit and Pap in their phosphorylated and non- 
phosphorylated states.
First, the binding of cGMP to the noncatalytic sites on membrane-associated PDE 
(PDE-M) and soluble PDE (PDE-S) was characterized. We found that PDE-M 
holoenzyme contains 2 non-identical high-affinity cGMP binding sites; one of the cGMP 
binding sites is functionally nonexchangeable. In contrast, PDE-S can release and bind
xii
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cGMP at both noncatalytic sites. Activation of PDE reduces more than 100-fold its 
cGMP binding affinity at one site, while the second cGMP binding site exhibits a 3-fold 
reduction in binding affinity. We postulate that cGMP dissociation from these two non­
identical binding sites might contribute differently to controlling the activation and 
inactivation kinetics of PDE6 during visual transduction in rod photoreceptors.
We also studied interactions between Py and the mammalian PaP catalytic dimer. 
It was found that Py binds to two distinct sites on the catalytic Pap dimer. cGMP 
occupancy at the noncatalytic binding sites is responsible for this binding heterogeneity. 
Although cGMP binding positively enhances Py binding affinity to Pap, it has no effect 
on PDE catalytic activity. Two major domains on Py interact with Pap independently. 
The N-terminal half of Py functions to restore and stabilize cGMP binding at the GAF 
domain with a binding affinity 50-fold greater than its C-terminal, inhibitory region.
Phosphorylation is an important regulatory mechanism in the visual transduction 
pathway. Our results showed that both Py and PaP could be stoichiometrically 
phosphorylated in vitro. Py phosphorylation has modest effects on its binding affinity to 
PaP and its overall inhibitory potency. However, phosphorylation at Thr22 mildly 
decreases the ability of the central region of Py to bind to PaP and to stabilize cGMP 
binding at the GAF domains. Similar to PDE5, phosphorylation of photoreceptor Pap 
regulates cGMP binding at the GAF domains. These results suggest a potential role of 
Pap phosphorylation in regulating PDE by regulating cGMP levels in photoreceptor 
cells.
xiii
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INTRODUCTION
A. Vision and Photoreceptor Cells
Cells process a diverse range of stimuli, from hormones and neurotransmitters to 
sensory signals, such as odorants and light. Light is perceived within the retina of the eye. 
The retina consists of five distinct layers: outer nuclear layer (ONL, containing 
photoreceptor cells), outer plexiform layer (OPL, consisting of synaptic processes of 
photoreceptor, bipolar and horizontal cells), inner nuclear layer (INL, containing bipolar, 
horizontal and amacrine cells), inner plexiform layer (IPL, consisting of synaptic contacts 
between processes of bipolar, amacrine and ganglion cells), and ganglion cell layer 
(containing ganglion cells). Vertebrate photoreceptors consist of two types of cells: rods 
and cones. Cone photoreceptor cells, which have higher temporal resolution than rods, 
function in bright light and are responsible for color vision. In humans, there are three 
different classes of cones, long-wavelength cones (red cones, 560-565 nm maximal 
sensitivity), medium-wavelength cones (green cones, 535-540 nm maximal sensitivity) 
and short-wavelength cones (blue cones, 440 maximal sensitivity). Rods are the 
receptors for dim light conditions and night vision. Compared to cones, rods are 
achromatic and have lower temporal resolution. Many more rods than cones (20:1) exist 
in mammalian retinas. For example, a human retina has about 1.2xl08 rods but only 
3xl06 cones. Both types of photoreceptors function to transduce a photon of light into 
atomic motion and then into a discrete nerve impulse. The information provided by the 
photoreceptors is further processed by an intricate array of nerve cells within the retina,
1
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then sent to the brain by the fibers of the optic nerve, and ultimately is processed by the 
visual cortex.
As shown in Figure 1.1, photoreceptors are highly compartmentalized and consist 
of two major segments, an inner segment (IS) and an outer segment (OS), which are
joined by a slender immotile 
connecting cilium. The outer 
segment of a rod is specialized for 
photoreception, containing a stack of 
about 1000 discs. The visual receptor 
molecules are densely packed in 
these membranous structures. The 
composition of the OS is better 
characterized than any other 
membrane involved in signal 
transduction: the mass is half protein 
and half lipid (Fliesler and 
Anderson, 1983). Rhodopsin and 
transducin are the two most 
abundant proteins in the OS and comprise 70% and 17% of the total protein, respectively. 
The remaining proteins are involved in'regulating cyclic nucleotide metabolism (such as 
phosphodiesterase and guanylate cyclase) and protein phosphorylations. The inner 
segment is rich in mitochondria and ribosomes and functions to generate ATP at a very 









Figure 1.1 Rod and Cone photoreceptors
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B. Visual Transduction Pathway
1. Visual Excitation
The photoresponse in vertebrate photoreceptors is now understood at a molecular 
level. It begins when a photon of light activates an enzymatic cascade involving 
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Figure 1.2. Schematic of the visual excitation cascade
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Rhodopsin is a 40-kDa integral membrane protein containing seven trans­
membrane helices. The 11-cis-retinal chromophore lies in a hydrophilic pocket of the 
protein, near the center of the membrane. Transducin is a member of the heterotrimeric 
G-protein family and functions as a signal-coupling protein in visual excitation. This 
peripheral membrane protein consists of a  (39 kDa), (3 (36 kDa), and y (8 kDa) subunits. 
The a  subunit (Gta) has a guanyl-nucleotide-binding site, and it interconverts between an 
inactive GDP-bound state and an active GTP-bound state. Photoexcited rhodopsin (R*) 
activates transducin by forming a complex with it and catalyzing the exchange of GTP
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
for bound GDP. The binding of GTP to transducin leads to the release ofR* for another 
round of transducin activation. Indeed, -100 transducin can be activated during the 
lifetime of a single R*. The conformational change induced by the binding of GTP also 
induces the dissociation of Gta-GTP from Gt0y. Gta-GTP, the active form of transducin, 
will in turn activate phosphodiesterase (PDE), the central effector enzyme in the 
photoresponse. Rod PDE is a tetramer consisting of a catalytic heterodimer (PaP) to 
which two inhibitory y subunits (Py) bind. Transducin activation causes Py to be 
displaced from its inhibitory sites on PaP. Hydrolysis of cGMP by activated PDE 
decreases the cGMP level in the photoreceptor cells. cGMP is a diffusible intracellular 
second messenger used in many signal transduction systems. In rod photoreceptors, R, Gt 
and PDE are localized to the disk membrane. cGMP is thus responsible for transmitting 
the visual excitation signal from the disk membrane to the plasma membrane (Lagnado, 
2000).
The plasma membrane of the rod photoreceptor contains cGMP-gated cationic 
channels. In the dark when cGMP levels are high, the cGMP is bound to the channels and 
the channels are kept open. Sodium ions flow into the outer segment because the 
electrochemical gradient for Na+ is large. This gradient is maintained by Na+-K+ ATPase 
pumps located in the inner segment. When cGMP levels decrease following light 
activation, cGMP dissociates from the channels, causing the channel to close. 
Consequently, the influx of Na+ decreases, and the plasma membrane becomes 
hyperpolarized (more negative on the inside). This light-induced hyperpolarization is 
then passively transmitted by the plasma membrane from the outer segment to the
4
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synaptic body (for review, see (Pugh, Jr. and Lamb, 2000; Lagnado, 2000; Palczewski 
and Saari, 1997).
2. Termination and adaptation of the photoresponse
After the light is extinguished, the rod photoreceptor cell quickly recovers from 
light excitation so that it can respond to the next light stimulus. In addition to response 
termination, photoreceptor cells are also able to adjust their light sensitivity over a broad 
range of background levels of illumination. This process, called light adaptation (or 
background adaptation), maintains the working range of the transduction cascade within a 
physically useful region of light intensities. The photoreceptor’s sensitivity is also 
reduced by previous exposure to light bright enough to bleach a substantial fraction of the
photopigment (greater than 5%). This desensitization and subsequent recovery of 
sensitivity occurring in darkness is called bleaching adaptation. The recovery from 
bleaching adaptation is also known as dark adaptation. There is a strong similarity 
between bleaching adaptation and background adaptation. During bleaching adaptation, 
the retina behaves as if it is being illuminated by a steady light of gradually decreasing 
intensity.
Although photoreceptor recovery and adaptation is not the simple reverse of the 
photo-excitation, response recovery and adaptation mechanisms feed back onto many 
steps of the excitation pathway (for reviews, see (Fain et al., 2001; Pugh, Jr. and Lamb, 
2000; Pugh, Jr. et al., 1999; Detwiler and Gray-Keller, 1996; Fain et al., 1996)).
5
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a. Termination and desensitization of R*
First, activated rhodopsin needs to be deactivated so that it does not continue to 
catalyze the activation of transducin. Deactivation of rhodopsin is initiated by rhodopsin 
phosphorylation at multiple sites in its carboxyl-terminal region by rhodopsin kinase 
(RK). The C-terminus of rhodopsin contains seven serines and threonines that are capable 
of being phosphorylated in vitro. Nevertheless, it is likely that in vivo only one or a few 
amino acids get phosphorylated and contribute to rhodopsin turnoff (Ohguro and 
Palczewski, 1995; Kennedy et al., 2001). After phosphorylation, rhodopsin itself has 
decreased ability to bind with transducin and to stimulate the GTP/GDP exchange on Gta  
(Langlois et al., 1996; Xu et al., 1997). A complete inactivation of R* requires the 
binding of arrestin (Gurevich and Benovic, 1993; Wilden, 1995; Krupnick and Benovic, 
1998; Krupnick et al., 1997; Krupnick and Benovic, 1998). Arrestin binds specifically the 
phosphorylated rhodopsin at its carboxyl-terminal sequence (Krupnick et al., 1994). Once 
bound, arrestin completely blocks the interaction of transducin with rhodopsin.
b. Termination of Gta*-PDE*
To return to the dark state, activated PDE also needs to be turned off so that it 
stops hydrolyzing cGMP. The turnoff of activated PDE is a key step and also a rate- 
limiting step of response termination. Gta* is deactivated by the hydrolysis of GTP 
bound to Gta* and PDE activity is inhibited upon re-association of the catalytic subunits 
of PDE with Py. Gta has an intrinsic GTPase activity (Fung et al., 1981). However, 
turnover numbers of intrinsic GTPase are reported to be 1-2 m in1, nearly 100-fold too 
slow (Sitaramayya and Liebman, 1983) to account for turnoff of the electrical response. 
Therefore, there should exist GTPase-activating proteins (GAPs) in the rod outer segment.
6
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The first GAP identified was Py itself (Arshavsky and Bownds, 1992). Later, it was 
reported that Py alone is insufficient for activating transducin GTPase and that one or 
more factors in addition to Py must also be present in the outer segment (Angleson and 
Wensel, 1993; Angleson and Wensel, 1994; Antonny et al., 1993; Arshavsky et al., 1994). 
This supplementary factor was found to be RGS9-l(He et al., 1998). RGS9-1 is a 
member of the RGS (the regulators of G protein signaling) family of GTPase accelerating 
proteins. In the photoreceptor cell, RGS9-1 forms a tight complex with a G protein 3 
subunit 5 type long splice variant (G35L) and functions to stabilize the Gta- GTP in a 
conformation most favorable for hydrolyzing bound GTP (Slep et al., 2001) (Bourne,
1997). Actually, Py itself does not activate transducin GTPase but it enhances the 
catalytic action of RGS9-1 by recruiting RGS9-1 for hydrolytic transition-state 
stabilization (Slep et al., 2001). Deletion of the RGS9-1 gene in mice results in profound 
slowing of photoresponse recovery and GTP hydrolysis by transducin in both rods (Chen 
et al., 2000) and cones (Lyubarsky et al., 2001). hnmunolocalization of RGS9-1 reveals 
that RGS9-1 is present in cones at significantly higher levels than in rods (Cowan et al.,
1998). This might account in part for the faster response kinetics and lower sensitivity of 
cones compared to rods (Lyubarsky et al., 2001; Cowan et al., 1998).
c. Restoration of cGMP level by cGMP synthesis
Activation of the PDE hydrolyzes free cGMP, and the free concentration of 
cGMP declines rapidly. Therefore, the restoration of the dark state also requires the re­
synthesis of cyclic GMP so that the free cGMP concentration can reach a steady-state 
concentration to produce a steady-state probability of opening of the cGMP-gated 
channels. The synthesis of cGMP is largely produced by specialized photoreceptor
7
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guanylyl cyclases (retGC-1 and retGC2) (Lowe et al., 1995; Shyjan et al., 1992; Yang et 
al., 1995). Both retGC-1 and retGC2 are members of a family of membrane-bound 
cyclases and present in both rod and cone outer segments. However, retGC-1 is 
apparently more abundant in cones.
3. Role of Ca in regulation of visual termination and adaptation
The concentration of Ca2+ is regulated by both the cGMP-gated channel and the 
Na+/Ca2+-K+ exchanger. The cGMP-gated channels of both rods and cones are permeable 
to a variety of monovalent cations (including Na+, K+, and Li+) as well as divalent cations 
(including Ca2+). In darkness, the cGMP-gated channels are partially open and there is a 
steady influx of Ca2+ into the photoreceptor. Ca2+ is transported out of the outer segments 
by a Na+/Ca2+-K+ exchanger which exchanges four Na+ (inward) for one Ca2+ and one K+ 
(outward). In the light, the influx of Ca2+ into the outer segment decreases when the 
cGMP-gated channels close. However, Na+/Ca2+-K+ exchange is not affected directly by 
illumination so that Ca2+ continues to be transported out of the photoreceptor cells. This 
results in a decrease in the intracellular Ca2+ concentration. The concentration of Ca2+ is 
-500-700 nM in darkness and is -30-50 nM in saturating light (-10-20 fold change in the 
free Ca2+ concentration) (Matthews and Fain, 2001; Sampath et al., 1999).
Ca2+-dependent modulation of visual transduction is the most important 
mechanism for light adaptation in both rods and cones. Ca2+ regulates most of the turnoff 
and restoration processes accompanying the photoresponse, including (a) alteration of the 
lifetime of R* by modulation the activity of rhodopsin kinase (b) regulation of GC 
activity; (c) regulation of the affinity of the outer segment channels for cGMP. Recently,
8
with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Bums and Balyor have suggested that Ca2+ is also involved in the alteration of the gain of 
the transduction cascade (Bums and Baylor, 2001).
a. Modulation of R* shutoff
During the response recovery and light adaptation, Ca2+ and recoverin (Rec) alter 
the lifetime of R* by modulating the activity of RK. In the dark when the Ca2+ 
concentration is high, most of the recoverin is in the Ca2+-bound state. Rec-Ca2+ forms a 
complex with RK at the membrane, blocking its activity. When Ca2+ drops during the
 ^I
light response, Rec releases its Ca and dissociates from RK. The elevated concentration 
of free RK permits the rapid phosphorylation of R*. Arrestin then binds, substantially 
quenching the R* activity. Recoverin has been shown to be important in mediating Ca2+- 
dependent modulation of RK activity in vitro (Chen et al., 1995) and in vivo (Xu et al.,
1997).
b. Regulation of cGMP synthesis
The activity of the photoreceptor specific guanylate cyclase (ret-GC) is Ca2+- 
sensitive (Lolley and Racz, 1982) and its cyclase activity increases as the Ca2+ 
concentration declines (Dizhoor et al., 1991; Gorczyca et al., 1994; Frins et al., 1996; 
Koutalos et al., 1995). At least two small-molecular-weight Ca2+-binding proteins, named 
as GC activating proteins (GCAPs), confer such a Ca2+ sensitivity on retGC (Cuenca et 
al., 1998; Kachi et al., 1999). GCAP has three Ca2+-binding EF-hand regions (Palczewski 
et al., 1994) and has high affinity for Ca2+. In a low Ca2+ situation, unoccupied GCAPs 
stimulate the activity of retGC through dimerization of cyclase subunits (Yu et al., 1999). 
When the Ca2+ concentration is elevated, GCAP in its Ca2+-loaded form inhibits the 
catalysis of retGCs. In addition to GCAPs, another GC regulatory protein, called GC
9
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inhibitory protein (GCIP) was recently discovered in amphibian photoreceptors (Li et al.,
1998). GCIP is also a small molecular-weight protein and shares some conserved 
sequences with GCAP. GCIP does not stimulate ret-GC in low Ca2+ concentration, but it 
inhibits the ret-GC activity when Ca2+ concentration rises. The role of GCIP in cyclase 
regulation is presently unclear, 
c: Regulation of cGMP-gated channel
The cGMP-gated channel from bovine rods also can be modulated by Ca2+ (Hsu 
and Molday, 1993; Gordon et al., 1995; Bauer, 1996; Haynes and Stotz, 1997). In the (3 
subunit of the channel, there exists a calmodulin (CaM) binding site which binds CaM at 
high Ca2+ concentration (Chen et al., 1994; Weitz et al., 1998). Lowering Ca2+ 
concentration over the physiological range during illumination releases the CaM from the 
channel, increasing the affinity of the channel for cGMP and leading to opening more 
channels. Ca2+ also modulates the sensitivity of channel for cGMP by stimulating the 
phosphorylation of the channel. One specific tyrosine (Tyr498) in the a-subunits appears 
to be site of the phosphorylation by a membrane-associated protein kinase. After 
phosphorylation, the sensitivity of cGMP-gated channel increases so that less cGMP is 
required to keep it open (Gordon et al., 1992).
10
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C. Overview of PDE Superfamily
At present, 11 classes of PDE (>20 different genes products) have been reported 
(Gopal et al., 2001). Each family is distinguished by its unique combination of enzymatic 
characteristics, pharmacological inhibitory profiles and their distinct regulatory 
mechanism, as well as their specific tissue, cellular and sometimes also subcellular 
distributions (Table 1.1).
1. Catalytic Domains 
All PDEs have an approximately 270 amino acid homology region in the carboxyl 
half which forms the catalytic domain (Charbonneau, 1990; Conti, 2000). Different PDEs 
have different substrate specificities. PDE1, PDE10 and PDE 11 hydrolyze both cAMP 
and cGMP well. PDE2, PDE3, PDE4, PDE7, and PDE8 prefer cAMP as substrate while 
PDE5, PDE6 and PDE9 prefer cGMP as substrate. PDE7 and PDE8 have the highest 
affinity for cAMP and PDE9 has the highest affinity for cGMP. Of all PDE types, PDE6 
has the highest kcat/Km value (Mou et al., 1999a; Norton et al., 2000; Leskov et al., 2000), 
which approaches the substrate diffusion limit.
11

















Table 1.1: Phos ihodiesterase superfamily
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? cGMP Not reported (Soderling and Beavo, 2000; Juilfs 
etal., 1999)





GAF cAMP and 
cGMP
Not reported (Soderling and Beavo, 2000)
PDE 11 PDE11A cAMP and cGMP 
hydrolyzing PDE
Prostate GAF cGMP and 
cAMP
Not reported (Yuasa et al., 2001; Yuasa et al., 
2000; Fawcett et al., 2000)
to
2. Regulatory Domains
PDEs have regulatory domains in the N-terminal half of the primary sequence.
For example, PDE1 has a CaM binding site immediately adjacent to the N-terminus, 
which can bind Ca2+-CaM with high affinity. PDE4 has a PAS domain (named for their 
occurrence in Drosophila Period protein, vertebrate aryl hydrocarbon nuclear translocator, 
and Drosophila Single-minded protein) in the N-terminal region but its function is 
presently unclear. PDE2, PDE5, PDE6 , PDE 10 and PDE11 have two cGMP binding 
repeats, called GAF domains (named for their occurrence in cyclic GMP -regulated 
PDEs, some adenylyl cyclase and the bacterial transcription factor FhlA) (Aravind and 
Ponting, 1997) (Fig. 1.3). The GAF domains of all PDEs are set apart from most others 
GAF domain-containing proteins by the presence of a (R/K)XmNKnD motif (Turko et al., 
1996; Granovsky et al., 1998b; Ho et al., 2000). PDE6-GAF has the highest affinity for 
cGMP (Gillespie and Beavo, 1989; Mou et al., 1999a; Norton et al., 2000). Homologous 
GAF domains in PDE10A and PDE11A seem to lack a high-affinity allosteric cGMP 
binding ability (Soderling et al., 1999; Fawcett et al., 2000). cGMP occupancy of the 
GAF domains regulates, directly or indirectly, the catalytic rate of these PDE enzymes. 
cGMP binding to the GAF domains of PDE2 allosterically increases the affinity of the 
catalytic site for substrate by direct allosteric interactions. cGMP binding to the GAF 
domains of PDE5 makes it a very good substrate for PKG (cGMP-dependent protein 
kinase) orPKA (cAMP-dependent protein kinase). Once phosphorylated, catalysis is 
stimulated at the active sites.
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Figure 1.3. The domain structure of GAF-containing phosphodiesterases.
3. Regulation of PDE by phosphorylation
PDE1, PDES, PDE4, and PDE5 are reported to be regulated and activated by 
serine/threonine phosphorylation mechanisms. The kinases responsible for 
phosphorylation and the possible functions of phosphorylation are listed in Table 1.2. 
Phosphorylation of PDE 1 by PKA or CaM kinase II has not been shown to alter the 
catalytic properties of this enzyme directly, but it does decrease the affinity of the 
enzyme for Ca2+/CaM (Hashimoto et al., 1989; Sharma and Wang, 1985; Sharma and 
Wang, 1986; Florio et al., 1994). In the cell, this is equivalent to decreasing the affinity 
for Ca2+. The phosphorylation of PDE3 by PKA or insulin-dependent kinase stimulates 
its activity directly and is used as a mechanism for attenuating the amplitude of the 
cAMP signal in the cell (Macphee et al., 1988; Rascon et al., 1994; Smith et al., 1991;
14
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Ahmad et al., 2000). Phosphorylation also is an important mechanism of regulation of 
the activity of PDE4 to rapidly decrease cAMP levels (Sette et al., 1994a). As mentioned 
above, the major effect of phosphorylation of PDE5 is to cause a modest decrease in the 
Km for cGMP and to allosterically enhance the cGMP-binding abilities (Corbin et al., 
2000).
Table 1.2. Phosphorylation of PDE superfamily







decrease the affinity 
of enzyme for CaM
(Hashimoto et al., 
1989; Sharma and 
Wang, 1985; 
Sharma and Wang, 







Increase the enzyme 
activity for cAMP
(Macphee et al., 
1988; Rascon et al., 










Increase the enzyme 
activity for cAMP
(Sette et al., 1994b)
PDE5 PDE5A PKA
PKG
Increase the affinity 
of enzyme for 
cGMP at the active 
sites and the 
noncatalytic cGMP 
binding sites
(Corbin et al., 2000; 
Turko et al., 1998)
*: PKA: cAMP-dependent icinase; PKG: cGMP-dependent kinase; PKC: protein kinase cdk5: cyclin-
dependent kinase type 5; MAP kinase: myosin-dependent kinase; CaMII: CaM-dependent kinase II
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D. Structure and Regulation of PDE6
1. PDE Structure and Function
Photoreceptor PDE (PDE6) is the key effector enzyme in the vertebrate visual 
transduction cascade. There are several isoforms of PDEs in photoreceptors: a 
membrane-associated rod PDE (PDE-M), a soluble rod PDE (PDE-S) and a cone PDE 
(PDE-C).
a. PDE-M
PDE-M is the most abundant photoreceptor PDE and is a tetramer containing two 
similar but nonidentical catalytic subunits, a  (99.2 kDa) and p (98.3 kDa), as well as two 
identical y subunits (9.7 kDa) (Baehr et al., 1979; Ovchinnikov et al., 1986; Ovchinnikov 
et al., 1987; Lipkin et al., 1988; Deterre et al., 1988). On each Pa and Pp, there is a 
catalytic site and a noncatalytic cGMP binding site. Py functions to inhibit the cGMP 
hydrolysis at the active sites (Hurley and Stryer, 1982) as well as to stimulate and 
stabilize cGMP binding at noncatalytic cGMP binding sites (Yamazaki et al., 1982; Cote 
et al., 1994; Mou et al., 1999b; Cote et al., 1994). Py also has recognition sites for binding 
transducin (Yamazaki et al., 1990; Granovsky et al., 1998a; Ford et al., 1998; Skiba et al., 
1995; Skiba et al., 1995; Morrison et al., 1989; Cunnick et al., 1990).
b. PDE-S
PDE-S has the same Pa, Pp and Py subunits to those of PDE-M, except that PDE- 
S has a unique subunit, P8 . P8 was first identified as a 17 kDa protein that 
immunoprecipitated with bovine retinal PDE (Hurwitz et al., 1985), and is supposed to 
keep PDE-S soluble by interacting with the methylated, prenylated C-terminus of the 
PDE catalytic subunits (Cook et al., 2000).
16
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c. PDE-C
The subunit stoichiometry of cone PDE is not as well defined as other isoforms of 
PDE6 but is thought to consist of two identical a ’-subunits (Pa’), one or two 9.3 kDa 
inhibitory y subunits (Py’), and one or two 17 kDa 8 subunits (P5). However, the 
immunocytochemistry experiment on bovine retinal sections indicates that P8 exists only 
rod outer segments (Florio et al., 1996), suggesting that PS bound to PDE-C may be a 
artifact.
2. Regulation of PDE6 function by interaction of Py with PDE
Interactions between Py and the PaP are essential for the regulation of PDE 
function in vertebrate rod photoreceptors during visual transduction (Fig. 1.4). Although 
extensive studies have shown the significance of the interaction between PaP and Py, 
actual binding affinity ofPy for PaP has never been conclusively determined. By 
measuring the effects of dilution on the catalytic activities of membrane-bound native 
PDE and purified PDE in solution, the dissociation constant of the bovine rod PDE has 
been estimated indirectly to be less than 10 pM (Wensel and Stryer, 1986) and of the frog 
rod PDE to be about 28 pM (D'Amours and Cote, 1999). High affinity binding of Py with 
PaP results in very low basal activity in the dark-adapted state.
Previous peptide studies have indicated that two major regions on Py provide the 
major interactions with PaP: (a) the carboxyl terminus amino acids (Lipkin et al., 1988; 
Artemyev and Hamm, 1992; Takemoto et al., 1992; Brown, 1992; Skiba et al., 1995; 
Granovsky et al., 1997)and (b) the central polycationic region (Granovsky et al., 1998a;
17
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Artemyev et al., 1996). The C-terminal region of Py, especially the last 7-10 amino acids, 
interacts directly with the active sites (Artemyev and Hamm, 1992; Granovsky et al., 
1997). The binding of the C-terminal region to the active sites is regulated in a reciprocal 
manner by noncatalytic cGMP occupancy at the GAF domain of frog PDE (D'Amours et 
al., 1999). The central lysine-rich region of Py also interacts with Pap with high affinity, 
but the function of this region ofPy is not quite clear. Cross-linking experiments 
indicated that the site on P oeB  that interacts with Py is between the second GAF domains 
and catalytic sites (Natochin and Artemyev, 1996), raising the possibility that the central 
region ofPy might be responsible for the regulation of noncatalytic cGMP binding. 
Actually, it has been reported that a Py central peptide (Py24-45) was able to restore high 
affinity cGMP binding to bovine cone PDE (Granovsky et al., 1998b).
3. Regulation of PDE function by interaction of Py with transducin
a. Models for transducin activation of PDE
When photoreceptor cells are exposed to light, Gta* -GTP binds to Py and 
displaces it from its inhibitory site on PaP, causing activation of PDE. The activation of 
PDE by transducin is the key step in the visual transduction and has been investigated 
extensively. A number of models have been proposed for the mechanism of PDE 
activation and for the subunit composition of the activated complexes. In addition, the 
activation process has been reconstituted on membranes with purified PDE and purified 
transducin (Fung and Nash, 1983; Tyminski and O'Brien, 1984; Wensel and Stryer, 1986; 
Bennett and Clerc, 1989; Malinski and Wensel, 1992; Otto-Bruc et al., 1993; Melia et al., 
2000).
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The first model is that two transducins bind a single PDE with equal affinity and 
each transducin contributes equally to PDE activation (Wensel and Stryer, 1990). To 
support this, co-immunoprecipitation experiments have revealed a GTP-specific 
interaction between Gta and Py in a one-to-one stoichiometry (Fung and Griswold- 
Prenner, 1989). A direct measurement also suggested that Gta  bound per PDE ratio at 
saturation is close to 2 (Clerc and Bennett, 1992).
However, there is evidence that the binding of the first high affinity Gta* to PDE 
elicit 80-100% of the maximal activity of PDE, whereas the binding of the second low 
affinity Gto* to PDE elicits little or no additional activation of PDE (Bruckert et al., 
1994). In this case, PDE would be nearly maximally activated through its interaction with 
only one Gta* in the physiological situation. The interaction of the second transducin to 
PDE might function to ensure a rapid deactivation of Gta* through the enhancement of 
the rate of GTP hydrolysis (Bruckert et al., 1994). A recent reconstitution experiment 
with purified PDE and transducin on cationic membranes was consistent with this model 
that PDE is maximally activated when one Gta-GTPyS bound to the vesicles per PDE 
(Melia et al., 2000). If this is true, then either there is only one catalytic site on PDE that 
can be relieved of its inhibitory constraint by Py (Berger et al., 1999), or the two catalytic 
sites on PDE are simultaneously activated by a single Gta-GTPyS.
The third model is that a higher affinity transducin contributing 30% or less of the 
catalytic activity, with occupation of a second lower affinity transducin needed for full 
activation (Bennett and Clerc, 1989; Clerc et al., 1992). This model has suggested that 
transducin activation could stimulate the maximum catalytic potential of the PaP 
catalytic dimer. However, Norton et al. showed that the rate of cGMP hydrolysis for
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taPDE is only half of the rate of trypsinized PDE (Norton et al., 2000). Therefore, 
transducin activation fails to relieve completely Py inhibition at both active sites. 
Activation of PDE catalysis by one, not two, activated transducin molecules in frog ROS 
homogenates further confirms that the third model is unlikely,
b. Sites of interaction of Gta with Py
There are multiple distinct sites of interaction between activated Gta and Py (Fig. 
1.4). The interaction between Gta-293-314 and Py46-87 is important for PDE activation, 
especially the residue lie87, which is involved in relieving the inhibitory constraint ofPy 
to allow the entry of substrate into the active pocket (Slep et al., 2001; Sondek et al., 
1994). Trp70 is important for Py GAP activity (Slepak et al., 1995) A second site of 
interaction involves the polycationic region Py24-45 and residues 250-275 on the Gta  
subunit (Cunnick et al., 1994; Artemyev et al., 1993). This interaction is supposed to 
function as an anchor for transducin to form a complex with PDE6 during activation. A 
Gta-induced conformational change in the Py24-46 region may result in a decreased 
affinity ofPy for PaP and an increased affinity for Gta (Artemyev et al., 1993).
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Figure 1.4. Model of multiple sites of interaction of Py with PaP, Gta, RGS9 and 
other proteins.
4. Regulation of PDE6 function by its GAF domains
The physiological function of the noncatalytic sites on PDE6 differs from what is 
known about the regulatory properties of the PDE2 or PDE5 GAF domains. Two possible 
regulatory mechanisms have been proposed for noncatalytic cGMP binding sites: (1) 
regulating the free cGMP concentration by binding and buffering the cytoplasmic cGMP 
concentration (Yamazaki et al., 1996) and (2) regulating the duration of PDE6 activation 
by altering Py ability to act as a GAP for transducin inactivation (Cote et al., 1994).
a. Regulating the free cGMP concentration
In dark-adapted rod outer segments, the cytoplasmic cGMP concentration is about 
3.5 pM, consistent with predictions of the cytoplasmic cGMP concentration based on 
activation of the cGMP-gated ion channel of rod photoreceptors. However, the total 
cGMP concentration is 60 pM (Cote and Bownds, 1984). About 95% of the total cellular 
cGMP is bound to two classes of cGMP binding sites on PDE (Cote and Brunnock, 1993). 
During visual excitation when cytoplasmic cGMP concentration is decreased, the bound
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cGMP is dissociated from the lower affinity cGMP binding sites. However, whether this 
mechanism can help to restore the cGMP concentration in the cytoplasmic is questionable. 
First, kinetics of cGMP dissociation from the high affinity binding sites is too slow to 
participate in restoring cGMP concentration during the time of visual excitation and 
recovery (Cote and Brunnock, 1993; Cote et al., 1994; Yamazaki et al., 1996; Norton et 
al., 2000; Mou et al., 1999a). Second, only 50% or less of bound cGMP can be released 
to buffer the cytosolic cGMP concentration during the visual excitation (Cote et al 1984; 
Cote et al., 1986; Cote et al., 1989). Finally, the dissociated cGMP would be hydrolyzed 
in milliseconds, if PDE remained activated (Calvert et al., 1998; Arshavsky et al., 1992).
b. Regulating the lifetime of Gta* by altering Py affinity for acting as a GAP
It has been reported that cGMP binding to the PDE noncatalytic sites modulates, 
in a reciprocal way, the binding affinity of Py to both amphibian Pa(3 (D'Amours and 
Cote, 1999) and mammalian PaP (Mou et al., 1999a; Mou and Cote, 2001a). In 
amphibian PDE, cGMP binding to the non-catalytic sites lowers basal activity of PDE 
holoenzyme. By gradually diluting frog ROS homogenates to the picomolar 
concentration of PDE, D'Amours and Cote have estimated that the apparent binding 
affinity of Py for PDE was 28 pM when cGMP occupied the non-catalytic sites, whereas 
the binding affinity ofPy was 16-fold weaker when the sites were empty (D'Amours and 
Cote, 1999). In mammalian PDE, cGMP binding to the non-catalytic sites increase the 
binding affinity ofPy at least 10-fold at one of the binding site (Mou and Cote, 2001b).
Py, in combination with RGS9 and G05L, serves as a GTPase-activating protein 
for transducin, accelerating transducin inactivation (Arshavsky et al., 1992; Arshavsky 
and Bownds, 1992; Makino et al., 1999; Skiba et al., 2001; Skiba et al., 2000; Kovoor et
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al., 2000; Chen et al., 2000; Cowan et al., 1998; He et al., 1998). Py in its dissociated 
form has a higher GAP activity than Py bound to the PDE-transducin complex (Tsang et 
al., 1998; Cowan et al., 2000). Therefore, noncatalytic cGMP binding to the GAF 
domains of PDE regulates some aspects of photoreceptor light adaptation by altering the 
ability Py to act as a GAP.
Fig 1.5 describes a model of how the GAF domain regulates the lifetime of PDE 
during visual excitation. When the sites are occupied by cGMP, Py has a higher affinity 
for PDE and PDE forms a complex with activated transducin. In this state, the rate of 
GTP hydrolysis is relatively slower, and PDE stays active for a relatively longer time. If 
photoreceptors are exposed to continuous light, the cytoplasmic cGMP will be lowered, 
inducing cGMP dissociation from the GAF domains. Emptying cGMP binding sites 
induces a conformational change on PaJ3 so that Py has relatively lower affinity for PDE. 
Activated transducin then removes Py from the PDE catalytic subunits. As a consequence, 
the rate of GTP hydrolysis is accelerated by the Py-RGS9-1 -G(35L complex and the 
duration of PDE activation is reduced.
Whether or not the two PDE noncatalytic cGMP binding sites play an equal role 
in the regulation of GTPase activity is not clear. In the nonactivated state, cGMP 
dissociation from each of the PDE noncatalytic sites is independent of the occupation 
state of the other site and there is a lack of cooperativity in cGMP binding to the 
noncatalytic sites (Cote and Brunnock, 1993; Mou et al., 1999a; Norton et al., 2000). 
However, once activated by transducin, cGMP dissociation from two noncatalytic 
binding sites becomes heterogeneous. Removing the Py subunit results in rapid release of 
cGMP from only one of the noncatalytic sites on frog PDE, and cGMP dissociation from
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the second binding site remains similar to that of the nonactivated PDE (Norton et al., 
2000). It is possible that cGMP dissociation from two different noncatalytic sites act to 
regulate transducin GTPase based on the duration and/or intensity of light stimulation. 
The former one is important to regulate the lifetime of PDE* in a short light response, 




Figure 1.5. Model for how cGMP binding to the GAF domains on PDE determines 
the rate at which PDE is inactivated by transducin GTPase.
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5. Regulation of PDE function by GARP
GARPs are a class of glutamic acid-rich proteins. In rod photoreceptor cells, three 
GARPs have been found: GARP1 (130 kDa) and GARP2 (62 kDa) are both soluble, 
while the third one is the p-subunit of the cyclic nucleotide-gated channel (240 kDa) 
(Sugimoto et al., 1991; Korschen et al., 1995; Ardell et al., 1995; Finn et al., 1996).
In mammalian rod outer segments, GARPs are restricted to the rim region and 
incisures of discs and function as multivalent proteins that interact with the some key 
players of cGMP signaling, such as PDE and guanylate cyclase, and retina-specific ATP- 
binding cassette transporter (ABCR) (Korschen et al., 1999). The assembly of these 
signaling molecules into macromolecular complexes may provide intracellular signaling 
pathway with higher specificity, sensitivity and speed in rod photoreceptors. Recently, 
work done in our lab suggested that GARP2 also exists in frog photoreceptor cells 
(Maftei et al., 2000). Immunoaffinity chromatography and co-immunoprecipitation 
analyses suggested that frog GARP2 forms a tight complexes with PDE, transducin, and 
RGS9 (Maftei et al., 2000). No similar GARPs have been found in cones (Korschen et al.,
1999). GARP2 potently inhibits PDE activity and associates more strongly with light- 
activated than nonactivated PDE (Korschen et al., 1999). This sequestration of PDE 
independent of inactivation of transducin might be a an important inactivation 
mechanism at high light intensities, when a significant fraction of active PDE is reaching 
the disc margin. In this way, GARPs may function to down-regulate cGMP turnover in 
the daylight when rod function is saturated.
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6. Regulation of PDE6 function by post-translational modifications 
a: Isoprenylation/methylation of PDE6
Many proteins in the visual excitation pathway (such as rhodopsin, transducin and 
PDE) as well as other regulators of transduction [rhodopsin kinase (RK), arrestin and its 
homologues, RGS9-GJ35L, etc.] are either membrane-associated or integral membrane 
protein. About 70-80% of the phosphodiesterase activity found in bovine rod outer 
segments is membrane-bound (Cook et al., 2001). In frog rod outer segments, > 90% rod 
PDE is membrane-associated (Norton et al., 2000). The association of multiple cascade 
components to the membrane facilitates the interaction of these proteins during signaling 
so that vertebrate photoreceptors can respond to light as a 2 -dimentional collision 
process, ensuring both a high degree of signal amplification and fast signal termination 
on the physiological subsecond time scale.
Rod PDE is anchored to the disc membrane through its C-terminal isoprenylated 
and carboxymethylated modifications (Cook et al., 2001; Qin et al., 1992). Limited 
proteolysis of the C-terminus of the PDE catalytic subunits correlates with loss of 
membrane binding (Catty and Deterre, 1991; Wensel and Stryer, 1986; Ong et al., 1989), 
suggesting that C-terminal modifications are the major contributor to PDE interaction 
with disc membranes. The Pa subunit is modified by a farnesyl (C-15) group on the 
cysteine of the C-terminal motif CCVQ, whereas the Pj3 subunit is modified by a 
geranylgeranyl (C-20) group on the cysteine of CRIL (Qin et al., 1992; Anant et al., 
1992). In addition, both C-termini are methylated (Ong et al., 1989).
The 17 kDa P8 subunit has previously been shown to co-purify with the soluble 
form of PDE6 , and it functions to solubilize the membrane-bound form by interaction
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with the methylated, isoprenylated C-terminus of the PDE catalytic subunits (Cook et al., 
2000). After released from the disc membrane, PDE cannot be activated by transducin. 
Therefore, solubilization of PDE by PS might be a possible desensitization mechanism 
during light adaptation. The binding of PS to membrane-associated PDE is regulated by 
the C-terminal prenylation and methylation of the catalytic subunits. Prenylation and 
methylation are both potentially reversible and regulated by prenyl (methyl) transferase 
and prenylester (methylester) hydrolase (Rando, 1996). 
b: ADP-ribosylation of Py
ADP-ribosylation of Py has also been demonstrated as a potential mechanism for 
the regulation of the interaction between Py and Gta. Rod outer segments contain two 
endogenous glycosylphosphatidylinositol-anchored ADP-ribosyltransferase isozymes, 
and these two isozymes have similar properties in ADP-ribosylating Py. Two arginines 
(Arg33 and Arg36) in the central region of Py are ADP-ribosylated when Py is free or 
complexed with the catalytic subunits of PDE (Bondarenko et al., 1999; Bondarenko et 
al., 1997). After ADP-ribosylation, Py loses its interaction with Gtcc-GTP (Bondarenko et 
al., 1999). ADP-ribosylation ofPy is reversible. Bondarenko et al. have shown that a 
soluble fraction ofROS contains an enzyme(s) to release the radioactivity of [32P]ADP- 
ribosylated Py in a concentration- and time-dependent manners (Bondarenko et al., 1999). 
This suggests that reversible Py ADP-ribosylation may function as a negative regulator of 
transducin-dependent activation of PDE in phototransduction,
c. Phosphorylation of Py and PaP
There are 8 potential phosphorylation sites in the Py sequence. The central region 
ofPy contains most of the predicted phosphorylation sites. To date, several protein
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kinases have been found to exist in ROS and some of them have predicted 
phosphorylation sites on Py (Table 1.3).
Py phosphorylation has been studied both in vivo (Hayashi, 1994; Matsuura et al.,
2000) and in vitro by several protein kinases, including phosphatidylinositol (PI)- 
stimulated kinase (Hayashi et al., 1991), protein kinase C (PKC) (Udovichenko et al., 
1994), PKA (Xu et al., 1998), and cdk5 (originally termed “Py kinase”) (Tsuboi et al., 
1994b; Tsuboi et al., 1994a; Hayashi et al., 2000; Matsuura et al., 2000).







RK (Lee et al., 1981) - Thr62
PKA (Walter, 1984) RX1.2S/TX Thr15
PKC (Kelleher and Johnson, 1985; 
Udovichenko et al., 1997)
XS/TXR/K Thrj5
PKG (Taylor and Uhler, 2000) (R/K)2.3XS/TX ThrJi
MAP kinase (Ko et al., 2001) PXS/TP Thr22......~
Cdk5 (Py 
kinase)
(Hayashi et al., 2000) KS/TPXK Thr22
CaMII (Liu et al., 2000) RXXS/TX Thr14
CKII (Hollander et al., 1999) XS/TXXD/E Not Found
Protein-tyrosine 
kinase (such as 
Src)
(Bell et al., 2000) Tyr*4
*: RK: Rhodopsin kinase; PKA: cAMP-dependent kinase; PKG: cGMP-dependent kinase; PKC: protein 
kinase cdk5: cyclin-dependent kinase type 5; MAP kinase: mitogen-activated protein kinase; CaMII: CaM- 
dependent kinase II
The physiological function of Py phosphorylation is not clear in the current 
scheme of phototransduction. However, Py phosphorylation by the PKA, PKC or cdk5 
has been reported to enhance the inhibitory effect of Py on Pap catalysis (Xu et al., 1998; 
Udovichenko et al., 1994). In addition, phosphorylation of Py by PKC is reported to
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eliminate the binding heterogeneity of Py to PaP, resulting in a single class of Py binding 
sites (Udovichenko et al., 1994). These earlier studies suffered from several deficiencies 
that limited their usefulness. For example, the concentration of PDE used in their assays 
was in the nanomolar range, whereas the Py affinity occurs in the pM range; thus, Py 
should inhibit the catalysis of PDE in a concentration-dependent manner and the effect of 
Py phosphorylation would be obscured. In addition, PDE preparations used in the earlier 
studies also contained transducin which can also bind Py, further complicating analysis of 
Py phosphorylation.
Yamazaki and his colleagues have also suggested that phosphorylated Py loses or 
decreases its ability to interact with Gta*. Phosphorylated Py has less ability to inhibit 
GTPyS binding to Gta or to inhibit GTPase activity of Gta, but it gains a 10-15 times 
higher ability to inhibit Gta-activated PDE than that of non-phosphorylated Py (Xu et al., 
1998; Tsuboi et al., 1994b; Hayashi et al., 2000). They proposed that the Py 
phosphorylation is probably involved in the PDE inactivation and light recovery phase of 
phototransduction and that it operates without shutoff of Gta*. They also reported that Py 
in frog ROS homogenates can be phosphorylated in vivo in a light-stimulated manner 
(Tsuboi et al., 1994b; Hayashi et al., 2000). However, the total phosphorylation level of 
Py is rather low (<10%) so that the real physiological function of Py phosphorylation is 
remained uncertain.
To date, there is only one report demonstrating phosphorylation of PDE catalytic 
subunits in vitro by recombinant PKA or PKC (Udovichenko et al., 1993). PKC 
phosphorylates only Pa subunit of PDE holoenzyme or trypsinized PDE. In contrast, 
PKA phosphorylates both Pa and PP subunits. In addition, PKA does not phosphoiylate
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trypsin-activated PDE. Since trypsinization removes the part of C-terminal regions from 
Pap, it is possible that PKA phosphorylates PDE catalytic subunits at its C-terminal 
region while PKC phosphorylates PDE catalytic subunits at other region. Udovichenko et 
al. reported that a synthetic peptide AKVISNLLGPREAAV (Pa30-44) inhibited 
phosphorylation of PDE catalytic subunits by PKC from ROS, suggesting that Ser34 of 
Pa subunit is a likely phosphorylation sites for PKC. Currently, the function of PDE 
catalytic subunit phosphorylation on PDE regulation is not clear.
E: Goal and Hypotheses to be Tested
The overall goal of my dissertation research to define the regulatory mechanisms 
that determine how long, and to what extent, this central enzyme in vision remains 
activated following exposure of mammalian rod photoreceptors to light. My whole work 
is divided into three sections:
(1) Study how cGMP catalysis and binding to noncatalytic sites on mammalian rod 
PDE is regulated by its small molecular weight subunits (y and 8)
Photoreceptor PDE (PDE6) associated with membranes in rods is an oligomer 
consisting of similar a  and p catalytic subunits and two identical inhibitory y subunits 
(aPyy) (Deterre et al., 1988). On each a  and P subunit there is one catalytic site 
preferring cGMP to cAMP as a substrate, and one noncatalytic site which binds cGMP 
with high affinity. cGMP is the primary intracellular messenger for controlling the 
physiological response of both rod and cone photoreceptor cells to light (Pugh, Jr. and 
Lamb, 1993; Yau, 1994; Pugh, Jr. et al., 1999). Characterization of the binding of cGMP 
to the noncatalytic sites in PDE will help to evaluate their role in regulating PDE during
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phototransduction. For the photoreceptor PDE, most of our knowledge about the role of 
the noncatalytic sites in PDE regulation has been obtained with amphibian rod PDE. It 
has been found that cGMP occupancy at the noncatalytic binding sites of frog 
photoreceptor PDE enhances the association of Py with PaP in a reciprocal manner, and 
it has been postulated that cGMP binding at the noncatalytic binding sites may determine 
whether the Py subunit can participate as an accessory GTPase-activating protein for 
accelerating transducin inactivation (Arshavsky et al., 1992; Cote et al., 1994). In 
addition, the noncatalytic sites on frog rod PDE have been postulated to serve as a 
cytoplasmic buffer for cGMP, possibly serving to help restore cGMP levels during 
recovery from the light stimulation (Cote and Brunnock, 1993; Yamazaki et al., 1996). 
Compared to amphibian PDE, much less is known about the cGMP binding properties to 
noncatalytic cGMP-binding sites on photoreceptor PDE from mammalian rod 
photoreceptors. In this part of my work, my goal is to characterize the properties of 
cGMP binding to noncatalytic sites on mammalian rod photoreceptor PDE, and also 
investigate how they are regulated by Py and P5.
(2) Functionally map the domains on Py that interact with and regulate PDE 
function
Interactions between Py and the PaP catalytic dimer are essential for the 
regulation of cGMP levels in vertebrate rod photoreceptors during visual transduction. Py 
has multiple functions: it functions to inhibit the cGMP hydrolysis at the active sites 
(Hurley and Stryer, 1982) as well as to stimulate and stabilize cGMP binding at 
noncatalytic cGMP binding sites (Yamazaki et al., 1982; Cote et al., 1994); Py also has 
recognition sites for binding transducin (Skiba et al., 1995; Morrison et al., 1989;
31
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Cunnick et al., 1990); In addition, Py serves as a GTPase-activating protein (GAP) 
together with RGS9 (Arshavsky & Bownds, 1992; He et al, 1997). By using synthetic 
peptides of Py or site-directed mutants of recombinant Py, it has been found that Py 
contains at least two regions that interact with PaP: a central cationic region and a 
hydrophobic C-terminal region (Artemyev & Hamm, 1992; Takemoto et al., 1992). 
Cross-linking studies have shown that the carboxyl-terminus ofPy interacts with the 
catalytic sites of PaP both physically and functionally (Artemyev et al., 1996). The 
central region is also important in the interaction ofPy with PaP but does not directly 
contribute to PDE inhibition (Artemyev et al., 1996). Cross-linking experiments have 
also localized a region just past the end of the second noncatalytic cGMP-binding domain 
that binds to the central polycationic domain of Py (Artemyev et al., 1996). This suggests 
that the central region ofPy might be responsible for the regulation of noncatalytic cGMP 
binding. It has been reported that a Py central peptide (Py24-45) was able to restore high 
affinity cGMP binding to bovine cone PDE (Granovsky et al., 1998), but a similar 
peptide has no major effect on frog rod PDE (D'Amours & Cote, 1999). Thus, how Py 
stimulates and stabilizes high affinity cGMP binding is still elusive. In this part, I will 
first measure carefully the binding affinity of the full-length Py to PDE catalytic PaP 
subunits. Then I will functionally map the distinct domains on the inhibitory Py subunit 
which regulate cGMP binding at the noncatalytic binding sites as well as cGMP catalysis 
at the active sites of mammalian rod PDE6 .1 will also identify the region that contributes 
most to the high binding affinity ofPy to Pap. This work will help us to understand how 
cGMP binding at noncatalytic binding sites and cGMP catalysis at the active sites of 
mammalian rod PDE6 are regulated by distinct domains of the inhibitory Py subunit.
32
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
(3) Investigate the role of Py and PaP phosphorylation in regulating PDE during 
phototransduction.
A role for Py phosphorylation in modulating the interaction between Py and PaP 
as well as with the transducin a  subunit has been suggested in several studies (Xu et al., 
1998; Tsuboi et al., 1994a and 1994b). In addition, several protein kinases known to exist 
in rod photoreceptors have potential phosphorylation sites on Py. However, the 
mechanism for PDE to be regulated by Py phosphorylation during the photoresponse is 
still not known. Furthermore, we do not know if Pap phosphorylation also participates in 
regulating photoreceptor PDE. In this work, I will examine how Py or PaP 
phosphorylation regulates PDE by modifying the interaction between Py and Pap, as well 
as the catalytic properties of PDE at its active site and the noncatalytic cGMP binding 
affinity to its GAF domains. I hypothesize that Py or Pap phosphorylation does not 
regulate directly Py binding affinity or PDE catalysis, but rather serves to regulate its 
allosteric cGMP binding properties.
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Chapter I 
cGMP binding to noncatalytic sites on mammalian rod photoreceptor 
phosphodiesterase is regulated by binding of its y and 8 subunits* 
Abstract
The binding of cGMP to the noncatalytic sites on two isoforms of the 
phosphodiesterase (PDE) from mammalian rod outer segments has been characterized to 
evaluate their role in regulating PDE during phototransduction. Nonactivated, membrane- 
associated PDE (PDE-M; 01PY2) has one exchangeable site for cGMP binding; 
endogenous cGMP remains nonexchangeable at the second site. Non-activated, soluble 
PDE (PDE-S; 0^ 728) can release and bind cGMP at both noncatalytic sites; the 8 subunit 
is likely responsible for this difference in cGMP exchange rates. Removal of the 8 and/or 
y subunits yields a catalytic a|3 dimer with identical catalytic and binding properties for 
both PDE-M and PDE-S: high affinity cGMP binding is abolished at one site (K d  >  1 
pM); cGMP binding affinity at the second site (Kd ~ 60 nM) is reduced 3-4 fold 
compared to he nonactivated enzyme; the kinetics of cGMP exchange to activated PDE- 
M and PDE-S are accelerated to similar extents. The properties of nonactivated PDE can 
be restored upon addition of y subunit. Occupancy of the noncatalytic sites by cGMP may 
modulate the interaction of the y subunit with the a(3 dimer and thereby regulate
*. This chapter was published in its entirety in J. Biol Chem. (274, 18813-18820, 1999) 
and was Scientific Contribution no. 1994 from the New Hampshire Agricultural 
Experiment Station. This work was supported by NIH grants EY-05798 (R.H.C.) and 
EY-08197 (J.A.B.).
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cytoplasmic cGMP concentration and the lifetime of activated PDE during visual 
transduction in photoreceptor cells.
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Introduction
The cGMP phosphodiesterase (PDE) 1 present in rod and cone retinal 
photoreceptors is the central effector enzyme for vertebrate visual excitation. Photo­
activation of the visual pigment rhodopsin leads to G-protein (transducin) activation, 
which then proceeds to the activation of PDE. The activated a-subunit of transducin (at- 
GTP) is believed to activate the membrane-associated rod PDE holoenzyme (subunit 
stoichiometry: 0 ,372) by displacing the inhibitory y subunits (Py) from the active sites of 
the catalytic heterodimer (Pa{3). The enhanced hydrolytic activity of the activated PDE 
rapidly reduces cytoplasmic cGMP levels, and then leads to dissociation of bound cGMP 
from the cGMP-gated ion channel, closure of the ion channel, and finally a 
hyperpolarization of the membrane. These steps constitute the excitation pathway for 
vertebrate visual transduction (for reviews, see (Pugh, Jr. and Lamb, 1993; Helmreich 
and Hofmann, 1996; Palczewski and Saari, 1997; Helmreich and Hofmann, 1996; 
Palczewski and Saari, 1997)).
The photoreceptor PDE is a member of a family of phosphodiesterases that all 
share the ability to hydrolyze cyclic nucleotides. The PDE in rods and cones (classified as 
PDE6; (Beavo, 1995)) is most closely related to the cGMP-specific PDE (PDE5) based 
on several criteria, including overall amino acid sequence similarity, substrate preference 
for cGMP over cAMP, inhibition of catalysis by isozyme-selective drugs, and the 
presence of a consensus sequence in the N-terminal half of the protein that represents 
noncatalytic cGMP binding domains. In the case of PDE5, binding of cGMP to the 
noncatalytic cGMP binding sites may regulate activity indirectly via protein 
phosphorylation of the enzyme (reviewed in ref. (Bums et al, 1996)). The cGMP-
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stimulated PDE (PDE2) also contains noncatalytic cGMP binding sites that allosterically 
regulate catalysis at the active site (Martins et al., 1982).
For the photoreceptor PDE, most of our current knowledge about the role of the 
noncatalytic sites in PDE regulation has been obtained with amphibian rod PDE. It has 
been found that cGMP occupancy at the noncatalytic binding sites of frog photoreceptor 
PDE enhances the association of Py with Pap in a reciprocal manner, and it has been 
postulated that cGMP binding at the noncatalytic binding sites may determine whether 
the Py subunit can participate as an accessory GTPase-activating protein for accelerating 
transducin inactivation (Yamazaki et al., 1980; Yamazaki et al., 1982; Arshavsky et al., 
1992; Cote et al., 1994; Yamazaki et al., 1982; Arshavsky et al., 1992; Cote et al., 1994). 
In addition, the noncatalytic sites on frog rod PDE have been postulated to serve as a 
cytoplasmic buffer for cGMP, possibly serving to help restore cGMP levels during 
recovery from the light stimulation (Cote and Brunnock, 1993; Yamazaki et al., 1996; 
Yamazaki et al., 1996).
Much less is known about the function of noncatalytic cGMP binding sites on 
photoreceptor PDE during visual transduction in mammalian rod photoreceptors. Two 
distinct isoforms of rod PDE have been described in bovine rod photoreceptors, a 
membrane-associated PDE (PDE-M) and a soluble PDE (PDE-S) (Baehr et al., 1979; 
Gillespie et al., 1989; Gillespie et al., 1989). The only known difference between the two 
isoforms is the presence of a 17 kDa 8 subunit (P8) associated with PDE-S but not PDE-
1. The abbreviations used are: PDE, photoreceptor phosphodiesterase; PDE-M, 
membrane-associated bovine rod PDE; PDE-S, soluble bovine rod PDE; nPDE, non­
activated PDE; tPDE, trypsinized PDE; Pa(3, catalytic dimer of PDE; Py, inhibitory 10 
kDa y subunit of PDE; P8 , 17 kDa 8 subunit associated with PDE-S; KD, dissociation 
constant.
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M (Gillespie et al., 1989). The PS subunit can solubilize membrane-associated PDE in 
vitro (Florio et al., 1996), but its role in visual transduction has not been determined. The 
noncatalytic cGMP binding sites on bovine PDE-M have been shown to bind and release 
cGMP very slowly (Gillespie and Beavo, 1989a), and little is known about the cGMP 
binding properties of PDE-S. Thus, it remains unclear whether the noncatalytic sites on 
mammalian rod PDE play a similar physiological role to what has been proposed for the 
amphibian system.
In this chapter, we first show that PDE-M and PDE-S in their nonactivated states 
have different cGMP binding properties. Both high affinity cGMP sites on PDE-S are 
slowly exchangeable, whereas PDE-M contains one exchangeable and one 
nonexchangeable noncatalytic site. The presence of the 8 subunit in PDE-S suggests a 
role for this subunit in enhancing cGMP exchange at one noncatalytic site that is 
nonexchangeable in PDE-M. Second, activation of the two isoforms leads to similar 
behavior of PDE-S and PDE-M in terms of: (1) a large decrease in cGMP binding affinity 
at one noncatalytic site; (2) a ~ 10-fold acceleration of cGMP exchange at the remaining 
high affinity site; and (3) similar hydrolytic rates at the active site. While it is unlikely 
that cGMP binding and release at the noncatalytic sites regulate PDE activity during the 
early events of visual excitation, changes in cGMP occupancy at the noncatalytic sites 
may help regulate the lifetime of activated PDE during later stages of the visual 
transduction pathway.
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E x pe r im e n t a l  P r o c e d u r e s
Materials—Bovine retinas were purchased from W.L. Lawson, Inc. Radiochemicals were 
obtained from NEN Life Sciences Products, and scintillation fluid (Ultima Gold) was 
from Packard Instrument Co. Zaprinast was a gift of Rhone-Poulenc Rorer (Dagenham, 
U.K.). Sulfolink coupling gel was obtained from Pierce. Pefabloc was obtained from 
Boehringer-Mannheim. cGMP antisera for radioimmunoassays were purchased from 
Chemicon. Filtration and ultrafiltration products were from Millipore. Superdex 200 and 
Mono Q columns, as well as pGEX-2T vector and glutathione-Sepharose 4B were from 
Pharmacia. The thrombin cleavage capture kit was from Novagen. The reverse-phase 
columns for Py purification were from Vydac. Electrophoretic reagents and 
immunochemicals were from Bio-Rad. All other chemicals were obtained from Sigma. 
Preparation o f nonactivated PDE-S (nPDE-S) and PDE-M (nPDE-M) —Both PDE-S and 
PDE-M were first partially purified from frozen bovine retinas by modifications of the 
ion exchange and immunoaffinity chromatography procedures described previously 
(Gillespie et al., 1989; Gillespie and Beavo, 1989a; Gillespie and Beavo, 1988; Gillespie 
and Beavo, 1989a; Gillespie et al., 1989). Under infrared illumination, thawed retinas 
were stirred in a beaker containing 1.5 ml per retina ofROS Buffer (60 mM KC1, 30 mM 
NaCl, 2 mM MgCl2, 20 mM MOPS, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl 
fluoride, pH 7.2) containing 47.5% (w:v) sucrose. The retinal homogenate was 
centrifuged for 1 hat 8,000 x g (4°C), and the supernatant (containing both membrane- 
associated and soluble PDE isozymes) was removed from the pellet. The pellet was 
homogenized in 0.4 ml ROS Buffer per retina to extract additional soluble PDE
39
with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
isozymes, and then centrifuged at 96,000 x g for 45 min at 4°C. The supernatant resulting 
from this spin was pooled with the soluble PDE isozymes obtained below.
The sucrose-containing supernatant from the first centrifugation was diluted 2- 
fold with ROS Buffer, and then centrifuged (23,000 x g for 45 min at 4°C). The pellet 
contained crude ROS which were used to extract PDE-M. The supernatant of this spin 
(containing soluble PDE isozymes) was combined with the other soluble PDE-containing 
supernatant. DE-52 anion exchange chromatography was employed to separate cone PDE 
from PDE-S, essentially as described by Gillespie and Beavo (Gillespie and Beavo,
1988). PDE-S was further purified by immunoaffmity chromatography using the 
monoclonal antibody ROS 1 (Hurwitz et al., 1984) immobilized on a Sulfolink agarose 
gel.
The crude ROS pellet (containing PDE-M) was restispended in ROS buffer, 
homogenized, and centrifuged at 27,000 x g for 45 min at 4°C to remove soluble proteins. 
After repeating this isotonic washing and centrifugation of the ROS membranes twice, 
the ROS membranes were exposed to light at 4°C. PDE-M was extracted four times from 
the ROS membranes by the following sequence: (1) resuspension and homogenization of 
the ROS membrane pellet in 0.5 ml/retina of 10 mM Tris, 1 mM MgCfe, 1 mM 
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride (pH 7.5); (2) centrifugation at 
96,000 x g for 45 min at 4°C; (3) collection of the PDE-M-containing supernatant. 
Immunoaffmity purification of the hypotonically extracted PDE-M was then performed.
Immunopurified PDE (PDE purity, ~80%) was concentrated in a Centricon 
concentrator, and placed in storage buffer (100 mMNaCl, 2 mM MgCfj, 10 mM Tris, 2 
mM dithiothreitol, 0.4 mM Pefabloc, pH 7.5) containing 50% glycerol at -20°C. Both
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PDE-S and PDE-M were further purified by gel filtration chromatography on a Superdex 
200 HR 10/30 column equilibrated with Buffer A (120 mM NaCl, 5 mM MgCfe, 25 mM 
HEPES, pH 7.5, 2 mM dithiothreitol, 0.2 mM Pefabloc). After elution, the purified PDE 
was concentrated and stored as described above. SDS polyacrylamide gel electrophoresis 
of the purified, non-activated PDE-S (nPDE-S) and non-activated PDE-M (nPDE-M; Fig. 
1 A, lanes 5 and 6, respectively) shows that >90% of the Coomassie-stained bands 
represent the catalytic and low molecular weight subunits of PDE. For five different 
purified PDE preparations, we recovered 2.6 ± 1.1 nmol of purified nPDE-M and 1.0 ± 
0.4 nmol nPDE-S per 100 bovine retinas using these procedures.
Preparation o f trypsinized PDE-M (tPDE-M) and PDE-S (tPDE-S)—To prepare 
Pap dimers from nPDE-S and from nPDE-M, limited proteolysis with L-1 -tosylamido-2- 
phenylethyl chloromethyl ketone-treated trypsin was performed (Baehr et al., 1979; Miki 
et al., 1975; Hurley and Stryer, 1982; Baehr et al., 1979; Hurley and Stryer, 1982). 
Purified nPDE (0.8 -  1.0 mg/ml) was prepared in 25 mM MOPS (pH 7.5) containing 
25% glycerol, and incubated at 4°C with 50 pg/ml of trypsin for 35-40 min. These 
conditions were optimized to obtain complete enzyme activation (using a PDE activity 
assay) without causing the appearance of a 70 kDa proteolytic fragment of the catalytic 
subunits (as judged by Coomassie-stained SDS polyacrylamide gels of the trypsinized 
enzymes [Fig. 1.1 A, lanes 3 and 4; see also (Catty and Deterre, 1991; Artemyev et al., 
1996; Artemyev et al., 1996)]. Proteolysis was halted with a 10-fold weight excess of 
soybean trypsin inhibitor. Analysis of the trypsinized PDE-S (tPDE-S) preparation at this 
stage showed that the P8 subunit was not degraded to a significant extent (Fig. 1.1B, lane 
4).
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The trypsinized PDE (tPDE) was then diluted >500-fold into Buffer A to enhance 
dissociation of the low molecular weight subunits and their proteolytic fragments. 
Ultrafiltration (BioMax, 30,000 molecular weight cut-off) of the tPDE was performed to 
concentrate the enzyme. Substantial amounts of a -4,500 kDa band that immunoreacted 
with the C-terminal Py polyclonal antibody (UNH9710-4P) remained in the tPDE 
samples at this stage (Fig. 1.1B, lanes 3 and 4).
To prepare pure Pa|3 preparations from the trypsinized enzyme preparations, the 
tPDE was further purified by Superdex-200 chromatography using Buffer A as the 
mobile phase. This was followed by anion exchange chromatography on a Mono Q HR 
5/5 column equilibrated in 250 mM NaCl, 1 mM MgCk, 25 mM Tris (pH 7.5), 1 mM 
DTT, and 0.2 mM phenylmethylsulfonyl fluoride, using a linear gradient from 250 to 500 
mM NaCl to elute Pa(3 dimers. The purity of the Pa(3-S or Pa(3-M prepared from tPDE-S 
ortPDE-M, respectively, was found to be >90% by Coomassie stained gels (Fig. 1.1 A, 
lanes 3 and 4), with undetectable levels of Py or P5 immunoreactivity (Fig. 1.1B, lanes 5 
and 6).
Determination o f the catalytic constant (kcat) for trypsin-activated PDE~W e routinely 
determined the concentration of native PDE by measuring the maximum hydrolytic 
activity (Vmax) of a PDE-containing sample following limited proteolysis to fully activate 
the enzyme (described above); using activity measurements instead of total protein 
determinations to estimate the PDE concentration distinguishes native (i.e., non­
denatured) PDE from denatured enzyme and minor impurities present in our PDE 
preparations.
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To calculate the concentration of enzyme from the equation, [Pa3] = ^W/kcat, we 
needed to accurately determine the catalytic constant (kcat) for our PDE-M and PDE-S 
preparations. The determination of the kcat required independent knowledge of the PDE 
concentration, which was obtained by total protein determinations (Bradford method) and 
by measuring the maximum cGMP binding site density (Bmax). The latter approach relies 
on observations that bovine nPDE-M can bind 2.0 mol of cGMP per mol catalytic dimer 
(Gillespie and Beavo, 1989a) and that tPDE is capable of binding only 1 mol of 
[3H]cGMP per mol of catalytic dimer under our conditions (see Results). For the case of 
PDE-M, the trypsin-activated enzyme has a kcat -  5550 ± 100 mol cGMP 
hydrolyzed/s/mol [3H]cGMP bound (n = 24) at 22°C. Trypsin-activated PDE-S is able to 
hydrolyze 5620 ±110 mol cGMP/s/mol [3H]cGMP bound (n = 16). We have used the 
average value, kcat = 5600 cGMP hydrolyzed/Pafl/s, in our calculations of PDE 
concentration. This value is 22 ± 3% (n = 4) higher than that obtained in identical PDE-S 
and PDE-M samples in which the Bradford assay was used to quantitate PDE 
concentration (kcat = 4930 cGMP hydrolyzed/PDE/s).
Purification ofPyand PS— The recombinant bovine rod Py subunit was expressed 
in bacteria as described in (Artemyev et al., 1998) with the following modifications. 
Following cation exchange chromatography, Py was chromatographed on a preparative 
€18 reverse-phase column (300 A, 22 x 250 mm) using a linear gradient of 30-50% 
acetonitrile in 0.1% trifluoroacetic acid. The purity of the Py peak was verified on an 
analytical Vydac C4 reverse-phase column (300 A, 4.6 x 25 mm) and by SDS 
polyacrylamide gel electrophoresis (Fig. 1.1 A, lane 1). The concentration ofPy was 
routinely measured spectrophotometrically after having empirically determined the
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extinction coefficient (S277 -  7550 cm-M'1 in 45% acetonitrile, 0.1% trifluoroacetic acid) 
in conjunction with amino acid analysis. The inhibitory activity of Py preparations was 
assessed as described previously (Hamilton et al., 1993), and was typically >95% active.
The recombinant P8 subunit was expressed and purified by two different methods 
(this work was done by Terry A. Cook, University of Washington, Seattle, WA). In the 
first method, the PS subunit was overexpressed in Sf9 cells using a baculovirus 
expression system; the protein was then purified by anion exchange chromatography and 
ultrafiltration, as described in detail in Florio et al. (Florio et al., 1996). The second 
method was to subclone the 17K-11 PS coding sequence (Florio et al., 1996) into the 
pGEX2T expression vector and to express the P8-GST fusion protein following standard 
procedures. Following purification on a glutathione-Sepharose affinity column, the fusion 
partner was cleaved and the protease removed with the use of a thrombin cleavage 
capture kit according the manufacturer’s instructions. The PS was concentrated by 
ultrafiltration and stored in 50% glycerol at -20°C. [Upon sequencing the P8-GST 
construct, a PCR artifact was discovered that caused an amino acid substitution at 
position 85 from glutamine to arginine. No functional differences could be detected when 
the cleaved fusion protein containing the substitution was compared with the PS 
expressed from Sf9 cells.]
The concentration of PS was determined using the Bradford assay. The purity of 
different PS preparations was found to exceed 80% for both methods (e.g., Fig. 1.1A 
lane 2); immunoblot analysis with the 17K-II PS antibody revealed a single 
immunoreactive band at -17 kDa.
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Measurements o f cGMP binding to noncatalytic sites on PDE—Two different 
methods were used to quantitate cGMP binding to the noncatalytic sites on PDE, cGMP 
radioimmunoassay and a membrane filtration assay. Purified, concentrated PDE was first 
diluted in Buffer B (77 mM KC1, 35 mMNaCl, 2,0 mMMgCl2, 1.0mMCaCl2, 1.18mM 
EGTA ([C a2+free] -  240 nM), 10 mM HEPES, pH 7.5) supplemented with final 
concentrations of: 1.0 mM dithiothreitol, 0.5 jig/ml leupeptin, 0.2 mM Pefabloc, and 0.7 
pg/ml pepstatin. In experiments where depletion of endogenous nucleotides was 
attempted by incubating the PDE at 37°C (24 h for nPDE, 2 h for tPDE), Buffer B was 
supplemented with 5-fold greater concentrations of protease inhibitors and dithiothreitol, 
as well as 0.1 mg/ml bovine serum albumin and 30% glycerol [to minimize loss of PDE 
activity (<20% over the 24 h period)]; before use, the nucleotide-depleted PDE was 
diluted > 10-fold in Buffer B lacking the supplements.
To measure the amount of endogenous cGMP remaining bound to PDE following 
purification, a cGMP radioimmunoassay was used. Briefly, PDE-containing samples 
were quenched with 50% HC1 in ethanol, then centrifuged to remove precipitated 
material. The acidic supernatant was dried down under vacuum, and the neutralized 
sample was resuspended in 0.1 M citrate, pH 6.2. The radioimmunoassay was performed 
as described in Cote et al. (Cote, 2000), with an operating range of 0.15 to 3 pmol of 
cGMP per sample, as judged by comparison with a standard curve using known amounts 
of cGMP treated identically to the unknown samples.
To determine the equilibrium and kinetic properties of [3H]cGMP binding to the 
various PDE preparations, a membrane filtration assay was used (Cote, 2000). PDE- 
containing samples in Buffer B were incubated with the indicated concentrations of
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[3H]cGMP in the presence of 0.1 or 0.8 mM zaprinast, a photoreceptor PDE catalytic site 
inhibitor (Gillespie and Beavo, 1989b). The higher zaprinast concentration was used with 
activated PDE samples to insure that the extent of [3H]cGMP hydrolysis during the 
incubation period was <10% under all conditions tested. In separate experiments, we 
verified that 2 -  1000 pM zaprinast was unable to compete with [3H]cGMP bound to the 
noncatalytic sites of nPDE-M to which excess Py had been added to prevent ligand 
hydrolysis.
Following incubation of PDE with the radiolabeled cGMP, portions were directly 
filtered on prewet nitrocellulose membranes (Millipore HA membrane, 0.45 pm), and 
quickly (< 4 s) rinsed with three 1-ml portions of ice-cold Buffer B Nonspecific binding 
was determined as described previously (Cote and Brunnock, 1993). The membrane 
filtration technique is useful for measuring relatively high affinity ligand binding (Kd < 1 
pM); lower affinity cGMP binding sites are likely to release bound cGMP during the 
washing procedure and may go undetected.
Analytical procedures—A colorimetric, coupled-enzyme assay was employed for 
measurements of cGMP hydrolytic rates, as described in detail in (Cote, 2000). SDS 
polyacrylamide gel electrophoresis followed the procedure ofLaemmli (Laemmli, 1970). 
Immunoblot analyses of the Py and P5 subunits were performed with polyclonal 
antiserum UNH9710-4P to the C-terminal region (a. a. 63-87) ofPy or antiserum 17K-II 
to residues 23-41 of the P8 protein (Florio et al., 1996) along with a goat anti-rabbit 
secondary antibody coupled to horse-radish peroxidase, using standard protocols 
(Gallagher, 1998). Protein concentrations were estimated with the Bradford assay 
(Bradford, 1976) using bovine serum albumin as a standard; a correction factor of 1.2
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was applied for estimates of purified PDE catalytic subunit concentrations (Gillespie and 
Beavo, 1989a). Data analysis was performed using Sigmaplot (SPSS, Inc.) and KELL 
(Biosoft). All experiments were repeated at least three times, and error estimates 
represent the S.E.M.
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Figure 1.1. Purity and subunit composition of nonactivated and trypsin-activated 
PDE-M and PDE-S enzymes used in this study. A. 15% SDS polyacrylamide gels 
stained with Coomassie Blue. Purity of proteins analyzed was >90% except where noted. 
Lane 1, recombinant bovine Py (0.42 nmol); Lane 2, recombinant bovine PS (2.5 jig; 
~80% purity). Lane 3, purified Pa(3-S (80 pmol); Lane 4, purified Pa{3~M (80 pmol); 
Lane 5, nPDE-S (120 pmol); Lane 6, nPDE-M (80 pmol; Lane 7, molecular weight 
markers (in kDa). B. Immunoblot analysis using PS antibody 17K-II (upper panel) or Py 
antibody UNH9710-4P (lower panel). In lanes 1 - 6 ,1  pmol of the indicated enzyme was 
loaded. Lane 1, nPDE-M; Lane 2, nPDE-S; Lane 3, tPDE-M after concentration but prior 
to gel filtration, showing an inununoreactive 4.5 kDa Py proteolytic product; Lane 4, 
tPDE-S before concentration or purification, showing undegraded PS immunoreactivity 
and a 4.5 kDa Py peptide; Lane 5, purified Pa(3-M; Lane 6, purified Pcc(3-S; Lane 7, Py (6 
pmol); Lane 8, PS (20 ng); Bars, molecular weight markers.
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R esu l t s
The soluble and membrane-associated isoforms o f bovine rod PDE have different 
cGMP binding properties in their nonactivated states—As reported previously, the 
nonactivated, membrane-associated PDE (nPDE-M; affyz) of bovine rod photoreceptors 
binds 2 mol of cGMP per mol PDE very tightly and exchanges its bound cGMP very 
slowly (Gillespie and Beavo, 1989a). To directly compare the cGMP binding properties 
of the soluble PDE (nPDE-S; a j^ S )  with nPDE-M, we measured both the amount of 
endogenous cGMP remaining bound to purified, nonactivated PDE (nPDE) by cGMP 
radioimmunoassay, and the amount of exchangeable [3H]cGMP binding sites by a 
membrane filtration assay (see “Experimental Procedures”). For the case of the 
membrane-associated isoform, we found that purified nPDE-M retained 1.9 ± 0.04 mol 
cGMP per PDE holoenzyme (a(3y2) as judged by a cGMP radioimmunoassay (Fig. 1.2). 
Approximately 0.1 ± 0.04 mol [3H]cGMP was able to bind to nPDE-M in this condition. 
These results are identical to previous measurements where tightly bound, endogenous 
cGMP (1.8 ± 0.3 mol cGMP/PDE) as well as [3H]cGMP binding (0.1 mol cGMP/PDE) 
were analyzed by HPLC (Gillespie and Beavo, 1989a). Incubation of nPDE-M for 24 h at 
37°C resulted in the loss of 1 mol of endogenous cGMP per PDE with the concomitant 
ability to bind 1 mol of [3H]cGMP per PDE (Fig. 1.2). We conclude that nPDE-M 
consists of 2 high affinity, noncatalytic cGMP binding sites, of which only one is able to 
release its bound cGMP under these conditions.
The nonactivated, soluble isoform of rod PDE (nPDE-S) also retains bound 
endogenous cGMP following its extensive purification (1.7 ± 0.04 mol cGMP/mol PDE; 
Fig. 2). Upon addition of exogenous [3H]cGMP, the total binding stoichiometry is 2.0 ±
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Figure 1.2. Effects of temperature and added Py and PS subunits on the noncatalytic 
cGMP binding sites of nPDE-M and nPDE-S. Purified nPDE-M and nPDE-S were 
diluted to 50 nM concentration in Buffer B (containing the higher levels of supplements, 
including 30% glycerol and 0.1 mg/ml bovine serum albumin as stabilizers), as described 
in the Experimental Procedures. The PDE samples were then incubated under the 
following conditions, as indicated in the heading: -37°C, 24 h at 4°C; +37°C, 24 h at 
37°C; +Py, addition of 10 mol Py/mol Pa{3 to PDE at onset of 37°C incubation; +P5, 
addition of 5 mol PS/mol Paf3 at onset of 37°C incubation. After the incubation period, 
portions were removed for analysis of endogenous cGMP remaining bound by cGMP 
radioimmunoassay (hatched bars). Other portions were incubated with 1 pM [3H]cGMP 
for 30 min at 4°C, and then membrane filtration performed (open bars). The y-axis is 
expressed as mol cGMP bound per mol PDE holoenzyme for each assay, as well as the 
sum of the endogenous and [3H]cGMP binding (filled bars).
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0.1 mol cGMP/mol PDE, identical to nPDE-M. One major difference between nPDE-M 
and nPDE-S is the ability of the soluble isoform to release -90% of its endogenous 
cGMP upon 24 h incubation at 37°C, as well as being able to bind 1.9 ± 0.08 mol 
[3H]cGMP/PDE. We conclude that both high affinity noncatalytic binding sites on nPDE- 
S are able to undergo nucleotide exchange, whereas only one site is exchangeable in 
nPDE-M.
One obvious difference between nPDE-M and nPDE-S is the presence of the PS 
subunit associated with nPDE-S. To test whether the PS subunit could account for the 
different cGMP binding properties noted above, we incubated nPDE-M with an excess of 
recombinant PS subunit. As shown in Fig. 1.2, incubation with PS can cause the release 
of endogenous cGMP from the formerly “nonexchangeable” binding site on nPDE-M; 
only 0.3 ±0.03 mol cGMP/mol PDE remain bound after a 24 h incubation at 37°C, while 
addition of [3H]cGMP to the nucleotide-depleted enzyme permits 1.9 ± 0.05 mol 
cGMP/mol PDE to bind. This result indicates that PS can bind to nPDE-M (in accord 
with a previous reconstitution study (Florio et al., 1996)) and enhance the rate of cGMP 
exchange at one of the noncatalytic cGMP binding sites that is essentially 
nonexchangeable when PS is absent.
We also examined the effects of adding a 10-fold molar excess of Py on the 
cGMP binding properties of nPDE-M and nPDE-S. In all cases where Py was added, the 
amount of endogenous cGMP that was retained following the 24 h incubation was 
increased to -  1.4 mol cGMP/mol PDE, regardless of whether the PS subunit was also 
added in molar excess (Fig. 1.2). The ability of [3H]cGMP to bind was reduced in a 
corresponding manner (-0.5 -  0.6 mol [3H]cGMP/mol PDE) for both nPDE-M and
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nPDE-S. We conclude that the Py subunit acts to reduce the rate of cGMP dissociation 
from exchangeable noncatalytic sites on both nPDE-M and nPDE-S.
Activation o f PDE by limited proteolysis o f the Py subunit alters the cGMP 
binding properties o f PDE— Since addition of Py reduces the amount of endogenous 
cGMP released as well as the amount of [3H]cGMP that could associate with the 
noncatalytic sites of nPDE-M or nPDE-S (Fig. 1.2), we reasoned that removal of the Py 
subunits from the holoenzyme would enhance the ability of cGMP to exchange between 
the bound and free state. To test this, we exposed a preparation of purified nPDE-S to 
mild trypsin proteolysis (Hurley and Stryer, 1982) for various times at 4°C. As described 
in the “Experimental Procedures,” this treatment degrades the Py subunit and relieves 
inhibition of catalysis at the active site, with no detectable effect on the apparent 
molecular weights of P5 or Pap on SDS polyacrylamide gels (Fig. 1.1). We then 
measured the ability of 1 pM [3H]cGMP to occupy the noncatalytic sites, as well as the 
maximum hydrolytic rate of tPDE-S. Fig. 1.3 shows that the time course of activation by 
trypsin correlated well with the ability to bind up to 1 mol [3H]cGMP per catalytic dimer. 
[Identical trypsin time course experiments performed on nPDE-M gave essentially 
identical results to those shown for nPDE-S in Fig. 1.3 (data not shown).] Separate 
measurements by radioimmunoassay of the endogenous cGMP remaining bound to fully 
activated tPDE-S at the time when the [3H]cGMP was added (< 0.3 cGMP/PDE) 
indicated that >85% of the total bound cGMP had dissociated and been degraded by the 
activated enzyme. Therefore, the inability to bind more than 1 mol cGMP per mol PDE 
could not be due to endogenous bound cGMP preventing [3H]cGMP association. One 
possible conclusion from this result is that the proteolytic destruction ofPy had lowered
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(below the level of detection by membrane filtration) the binding affinity for cGMP at 
only one of the two noncatalytic sites. Another possibility we considered was that trypsin 
had damaged the catalytic subunits so that high affinity cGMP binding at one of the 
noncatalytic sites was permanently lost.
To distinguish these possibilities, we prepared purified catalytic dimers of PDE-S 
(PaP-S) from which all traces of the low molecular weight subunits had been removed 
(see “Experimental Procedures” and Fig. 1.1); this Pap-S preparation also lacked 
detectable amounts of endogenous cGMP at the noncatalytic sites. Purified Pap-S was 
able to bind 1 mol cGMP per mol PDE in the absence of Py, in agreement with the results 
with tPDE-S in Fig. 1.3. Following addition of increasing amounts of Py to PaP-S, we 
observed a progressive increase in [3H]cGMP binding that correlated with the inhibition 
of hydrolysis at the active site (Fig. 1.4). Addition of 2 mol Py per mol PaP-S permitted 
an additional 0.9 mol [3H]cGMP per mol Pap-S to bind, and inhibited 90% of the 
hydrolytic activity of the enzyme. [Identical results were obtained upon titration ofPaP- 
M with Py (data not shown).] In none of our experiments did we detect an effect of 
adding P8 on cGMP binding to high affinity sites on PaP-S or PaP-M.
Several interesting conclusions can be drawn from the above results. First, 
purified PaP dimers derived from PDE-S and PDE-M are able to bind 1 mol cGMP per 
PaP in the complete absence ofPy, P8 or their proteolytic fragments. Second, it follows 
that removal ofPy from PDE reduces the binding affinity of cGMP for one of the two 
noncatalytic sites below the level of detection of binding assay (K d  > 1 pM). Third, the 
proteolytic treatment of PaP is reversible upon addition of stoichiometric amounts ofPy.
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Figure 1.3. Activation of nPDE-S by limited proteolysis follows the same time course 
as ability to bind [3H]cGMP to one noncatalytic site on PDE. Purified nPDE-S was 
incubated with trypsin (45 pg/ml) at 4°C as described in “Experimental Procedures.” At 
the indicated times, portions were treated with soybean trypsin inhibitor to stop 
proteolysis, and the tPDE-S (590 nM) was then incubated at 37°C for 30 min to permit 
release and degradation of any rapidly exchangeable cGMP. The enzymatic activity 
(using 2 mM cGMP as substrate; circles) or ability to bind 1 pM [3H]cGMP (5 min at 
37°C, to minimize binding to non-activated sites; squares] were determined as described 
in the “Experimental Procedures ” These data points are from one of three representative 
experiments, and the curves represent a fit to a single exponential model.
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Figure 1.4. Addition of stoichiometric amounts of Py is sufficient to restore cGMP 
binding to the second high affinity noncatalytic binding site of PaP-S. Purified Pap- 
S was first depleted of endogenous cGMP by incubation at 37°C (<0.1 mol cGMP 
bound/mol Pap-S), as described in “Experimental Procedures.” The indicated amounts of 
purified Py were incubated with PaP-S for 30 min at 4°C prior to commencing activity 
(1.4 nM PDE) and binding assays (5 nM PDE). The hydrolytic activity was measured 
with 10 mM cGMP as substrate and normalized to the rate in the absence of added Py 
(5240 mol cGMP hydrolyzed/mol PDE/s). 1 pM [3H]cGMP was incubated for 30 min at 
37°C prior to filter binding. The symbols represent individual data points from one of 
three similar experiments.
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This shows that the Py subunit is the major target of action of trypsin, and that the limited 
proteolysis does not destroy the ability of PaP to bind cGMP at the “low affinity” site if 
Py is added back. Finally, in contrast to the two non-identical cGMP binding sites on 
Pap, no difference in binding affinity of Py to the two Py binding sites on PaP could be 
discerned for either PDE-S or PDE-M. We infer this from the observation that addition of 
1 Py per PaP restores approximately one-half of the total cGMP binding that requires Py 
binding to Pap.
Kinetic and equilibrium analysis ofcGMP binding to noncatalytic sites on PDE-S 
and PDE-M—To better understand the regulation of cGMP binding at the two non­
identical binding sites on the soluble and membrane-associated rod PDE isoforms, we 
analyzed the kinetics and equilibrium binding of cGMP to both nPDE and PaP 
preparations for both PDE-S and PDE-M. Equilibrium binding measurements were 
performed at 37°C over the range of 2 to 400 nM cGMP for each PDE preparation, and 
the Kd and Bmav determined (Fig. 1.5; see Table 1.1 for average values from several 
experiments). In all cases, the equilibrium binding data fit a model for a single class of 
non-interacting binding sites, even in the case of nPDE-S where the stoichiometry of 
binding indicated 2 binding sites per holoenzyme (Table 1.1). For the case of PDE-S, 
limited trypsin proteolysis of the enzyme resulted in the loss of detectable cGMP binding 
at one of the noncatalytic sites, and a 4-fold reduction in cGMP binding affinity at the 
remaining site. For the case of nPDE-M where only one site is available to exchange 
cGMP (the other retaining bound endogenous cGMP; Fig. 1.2), trypsinization reduces the 
binding affinity 3-fold; note, however, that we cannot distinguish whether the
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exchangeable or nonexchangeable site is responsible for the cGMP binding we detect in 
activated Pap-M.
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Figure 1.5. Equilibrium binding of cGMP to nonactivated and activated rod PDE 
isozymes. Purified PDE preparations were first incubated at 37°C to remove 
exchangeable, bound cGMP, as described in “Experimental Procedures.” Except for 
nPDE-M (~1 mol endogenous cGMP bound/mol PDE), each PDE preparation retained < 
0.1 mol endogenous cGMP/mol PDE following nucleotide depletion. Each preparation 
was diluted to 5 nM (final concentration) in Buffer B, and incubated with the indicated 
concentrations of [3H]cGMP at 37°C for 30 min prior to membrane filtration. Curves 
represent the fit to a single-site binding model. A. Binding of nPDE-M (squares), Kd = 
20 nM and BmaX = 0.95 mol cGMP/mol PDE; binding to Paf3-M (circles), Kd = 58 nM 
and Bmax = 1.04 mol cGMP/mol PDE. B. Binding of nPDE-S (squares), Kd -  19 nM, 
BmaX = 2.12 mol cGMP/mol PDE; binding to Potj3-S (circles), Kd = 54 nM and Bmav = 
1.08 mol cGMP/mol PDE. The symbols represent individual data points from a single 
experiment; see Table I for average values for n determinations.
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It is evident from comparing the Kd values of the two isoforms that the single 
exchangeable noncatalytic binding site we detect in nPDE-M has the same binding 
affinity for cGMP as the 2 sites that bind [3H]cGMP in nPDE-S. Likewise, trypsin 
activation of each isoform results in a loss of detectable binding to one of the two cGMP 
binding sites per PaP, and a uniform decrease in binding affinity (K d  ~ 60 nM) of cGMP 
at the other site. These results strongly suggest that PDE-M and PDE-S have very similar 
or identical cGMP binding sites on the PaP dimer. Further, association of Py and P5 with 
PaP each have distinct effects in modulating cGMP binding to the two noncatalytic sites 
ofPDE.
Kinetic analysis of the association and dissociation kinetics of cGMP binding to 
PDE provides an additional approach for understanding how cGMP binding to the 
noncatalytic sites is regulated. Fig. 6 shows that when the Py and P8 subunits are 
removed from the catalytic dimer to form PaP-S, both the association and dissociation 
rates of cGMP with the one remaining high affinity noncatalytic site are accelerated . The 
association rate constant (k+i) is increased 6-fold upon removal ofPy and P5 from PaP-S, 
while the dissociation rate constant (k_i) increases 16-fold (Table 1.1). Kinetic analysis of 
the noncatalytic sites on PDE-M (Table 1.1) is in general agreement with the results 
obtained with PDE-S. Upon removal of Py, the k+i ofPaP-M for the one high affinity 
binding site is increased 4-fold compared to nPDE-M, while the k.i is increased 17-fold 
by Py removal. The similar kinetic behavior of PDE-M and PDE-S indicates that the 
binding of Py—rather than P8—is the major factor affecting the ability of cGMP to bind to 
and dissociate from the noncatalytic sites on both PDE-S and PDE-M. Furthermore, the 
interaction ofPy with PaP has its greatest effect on the cGMP dissociation rate constant,
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rather than the k+i or the Kd. This is intriguing since it is the rate of cGMP dissociation 
from noncatalytic sites on PDE that is most relevant to proposed physiological roles of 
these sites in regulating PDE during recovery or light adaptation (see Discussion).
While we cannot measure detectable [3H]cGMP binding to the second 
noncatalytic site on PaP with our filter binding assay, some minimum values of the 
binding parameters can be inferred. The time required for filtration (~4 sec) sets a limit to 
highest dissociation rate constant that can be measured (Cote, 2000). Since the half-time 
for cGMP dissociation from the higher affinity site on PaP-S or PaP-M is -100 sec 
(Table 1.1), the lower affinity site must have a dissociation rate at least 25-fold larger in 
order for any bound cGMP to be released (and therefore not detected) during the filtration 
process. This implies that the Kd for the lower affinity site is likely to be >25-fold larger 
(>1.5 pM) than the value measured for PaP-S and PaP-M. We conclude that activation 
of PDE reduces the binding affinity at one site only 3-4-fold, while the other binding site 
undergoes a >25-fold reduction in affinity with a concomitant acceleration of the cGMP 
dissociation rate.
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Figure. 1.6. The kinetics of cGMP association and dissociation to PDE-S are 
accelerated upon enzyme activation. Purified nPDE-S and PaP-S were depleted of 
their endogenous nucleotides by incubation at 37°C for 16 and 2 h, respectively. A. 
Association kinetics were obtained at 37°C by adding -500 nM [3H]cGMP to 8 nM 
nPDE-S (circles) or Pap-S (squares) at time zero, and filtering samples at the indicated 
times. The data were analyzed as a pseudo-first order reaction with the association rate 
constant k+J = (kobs -  k-i)/[cGMP]tot., where kobs is the first-order rate constant for the 
single exponential, k_i is the dissociation rate constant (determined in part B.), and 
[cGMPJtot. is the total [3H]cGMP concentration. The data fit a single exponential junction 
for both nPDE-S (kobs = 9.8 ± 1.0 x 10'3 see1; Bmax = 1.7 ± 0.1 [3H]cGMP bound/PDE) 
and Pap-S (kobs = 0.068 ± 0.011 sec'1; Bmax = 0.9 ±0.1 [3H] cGMP/PDE). B. Dissociation 
kinetics were determined at 37°C by first adding 500 nM [3H]cGMP to -6  nM nPDE-S 
(circles) or PaP-S (squares) and incubating for 30 or 2 min, respectively. Dissociation 
was initiated by addition of 1 mM (final concentration) unlabeled cGMP, and samples 
were filtered at the indicated times thereafter. The curves represent the fit of the data to a 
single exponential decay function for both nPDE-S (Li = 5.8 ± 0.6 x 10'4 s'1; Bm«  = 1.9 ± 
0.1 cGMP/PDE) and Pap-S (k.x = 7.3 ± 0.7 x 10'3 s'1; Bmax .= 0.9 ± 0.1 cGMP/PDE). The 
symbols represent individual determinations from one experiment; see Table I for 
average values for n separate determinations of the rate constants.
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Table  1.1
Comparison o f the fHJcGMP binding properties o f bovine rod PDE isoforms 
The experimental conditions for the equilibrium binding measurements and the kinetics 
measurements are provided in the legends to Figs. 1.5 and 1.6, respectively. The data 
















Kd -  k-
i/k-i
(nM)"'
nPDE-ff 1.00 + 0.04
(3)
18 ± 2  (3) 3.9 ±0.1 x 
10*4 (3)
2.2 ± 0.6 x 104 
(4)
18
Pap-M 1.02 ± 0.04
(4)
56 ±4 (4) 6.8 ± 1.0 x 
10’3 (5)
9.8 + 1.9 x 104 
(8)
71
nPDE-S 1.85 + 0.09
(4)
14 + 2 (4) 4.5 ±0.9 x 
10‘4 (5)
2.3 ± 0.4 x 104 
(4)
20
PaP-S 0.93 + 0.03 
(3)
57 ± 13 
(3)
7.2 ± 0.4 x 
10° (5)
1.3 ± 0 .2 x l0 5 
(4)
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anPDE refers to PDE holoenzyme containing the low molecular subunits; Pa(3 refers to
activated PDE catalytic dimer lacking Py and/or P8. The -M and -S suffix refer to
membrane-associated and soluble forms of PDE, respectively.
bnPDE- M has one nonexchangeable site (Fig. 1.2) which cannot be detected in these
experiments.
cThe kinetic Kd is in general agreement with the measured Kd, indicating the internal 
consistency of the equilibrium binding and kinetic data.
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D isc u ssio n
We have shown that mammalian rod photoreceptor PDE isoforms can undergo 
substantial changes in cGMP binding to two non-identical, high affinity noncatalytic sites 
upon activation of the enzyme by removal of the Py subunits. We also report that the 
soluble and membrane-associated isoforms of bovine rod PDE have different binding 
properties in their nonactivated states. Finally, our results demonstrate that the Py subunit 
is primarily responsible for altering cGMP exchange upon activation, and that the P8 
subunit may interact with Py binding to the enzyme to permit cGMP exchange at a site on 
non-activated PDE that is nonexchangeable in PDE-M but exchangeable in PDE-S.
The two high affinity noncatalytic binding sites on bovine rod PDE are not 
identical—Previous work established that the PDE-M holoenzyme contains 2 high 
affinity cGMP binding sites that retain bound cGMP even following extensive 
purification (Gillespie and Beavo, 1989a). We have extended that work to demonstrate 
that the soluble isoform of rod PDE also contains 2 high affinity cGMP binding sites. Of 
greater significance is the demonstration that the two noncatalytic sites are not identical 
in their cGMP binding properties. The presence of one functionally nonexchangeable 
cGMP binding site on nonactivated PDE-M is in marked contrast to the two 
exchangeable sites found in bovine rod PDE-S (Fig. 1.2), cone PDE (Gillespie and 
Beavo, 1988), or the amphibian membrane-associated rod PDE (Cote et al., 1994).
Activation of bovine rod PDE reveals a fundamental difference between the two 
non-identical noncatalytic sites on both bovine rod isoforms. Removal of the Py subunits 
from PDE-M or PDE-S eliminates detectable binding (KD > 1 pM) of cGMP to one of 
the two classes of noncatalytic sites on the Pa(3 dimer. This effect represents a shift of >
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100-fold in overall cGMP binding affinity at this site, and a rate of dissociation that is too 
fast to detect by filter binding (ti/2 < 4 s). The remaining cGMP binding sites exhibit a 3- 
fold reduction in overall binding affinity upon removal of Py compared to the [3H]cGMP 
binding sites on nPDE-M or nPDE-S. We conclude that the Py subunit not only acts in its 
well-known role as an inhibitor of cyclic nucleotide catalysis at the active sites on PaJ3, 
but also serves to regulate the affinity of interaction of cGMP with the two distinct 
noncatalytic sites on the PaP dimer. The amphibian PDE, in contrast, shows no 
detectable cGMP binding to P«P when the Py subunits are removed by limited 
proteolysis (Yamazaki et al., 1980; Yamazaki et al., 1982; Yamazaki et al., 1982) or by 
extraction with activated transducin (Cote et al., 1994).
No intrinsic differences in the catalytic Pa/3 dimers derived from PDE-S and 
PDE-M—Based on the results of this study and previous work (Gillespie et al., 1989; 
Florio et al., 1996; Florio et al., 1996), it appears very likely that the catalytic subunits are 
identical in PDE-S and PDE-M. The molecular weights of a  and (3 are indistinguishable 
on SDS polyacrylamide gels (Gillespie et al., 1989), the catalytic constant of tPDE-S is 
identical to that of tPDE-M [see “Experimental Procedures” and ref. (Gillespie et al.,
1989)], and the noncatalytic cGMP binding sites show very similar kinetic and 
equilibrium binding behavior for the purified PaP dimers derived from PDE-S and PDE- 
M ( Figs. 5 - 6  and Table I).While a definitive statement awaits direct amino acid 
sequence comparisons of the a  and P subunits ofPDE-S and PDE-M, all available 
evidence indicates that binding of the P8 subunit to the PDE holoenzyme confers the 
differences in behavior seen with nPDE-S and nPDE-M.
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Two distinct actions o f PS on PDE—We report a new function that can be 
ascribed to the binding of the PS subunit to rod PDE: the ability of PS to permit cGMP 
release from a second noncatalytic binding site on nPDE-S that remains functionally 
nonexchangeable in PDE-M. How this effect of PS on PDE-S relates to the other known 
function of PS—namely to solubilize PDE that would otherwise remain attached to rod 
outer segment disk membranes (Florio et al., 1996)—is not clear at present. However, 
membrane association of PDE is not required for PS binding, since purified nPDE-M to 
which recombinant PS has been added is able to exchange endogenous cGMP at both 
noncatalytic sites in the absence of membrane attachment.
Physiological significance o f noncatalytic cGMP binding sites on mammalian rod 
PDE isoforms—In the dark-adapted photoreceptor, cytoplasmic cGMP levels are in the 
low micromolar range, and both noncatalytic sites on nPDE-S and nPDE-M will be frilly 
occupied. The mechanism by which transducin activates PDE to rapidly lower 
cytoplasmic cGMP levels during visual excitation is well understood, and quantitatively 
accounts for the rising phase of the photoresponse (for review, see (Olson and Pugh, Jr., 
1993)). Thus, there is no need to invoke the noncatalytic cGMP binding sites on bovine 
rod PDE to describe the regulation of PDE during the initial events of photo-excitation. 
We consider instead possible ways the noncatalytic cGMP binding sites may be involved 
in later stages of the visual transduction pathway, namely recovery from light stimulation 
and/or light adaptation.
A role for the noncatalytic sites to buffer free cGMP levels during the recovery 
phase of the flash photoresponse has been proposed for amphibian rod photoreceptors 
(Yamazaki et al., 1996). In this model, the noncatalytic sites serve to buffer cytoplasmic
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cGMP levels in the dark, and upon PDE activation release bound cGMP to accelerate the 
return to the resting state. Our data show that activation of mammalian rod PDE by 
removing the Py subunit results in the immediate loss of detectable binding to one of the 
noncatalytic sites on both PDE-M and PDE-S. This rapidly dissociating class of sites has 
the potential to release its bound cGMP on the same time scale as recovery phase of the 
photoresponse (<1 sec in mammalian photoreceptors (Baylor et al., 1984; Lyubarsky and 
Pugh, Jr., 1996; Lyubarsky and Pugh, Jr., 1996)). However, upon cGMP release from the 
bound state, it is likely that the free cGMP would be destroyed by the still-active catalytic 
sites, and therefore not contributes to elevating the cytoplasmic cGMP levels during 
photoresponse recovery. This conclusion is supported by recent measurements of cGMP 
dissociation and hydrolysis in amphibian rod outer segment suspensions (Calvert et al., 
1998).
An alternative hypothesis is that the noncatalytic sites on PDE may indirectly 
regulate the lifetime of transducin-activated PDE via modulation of Py binding affinity to 
PaP (Cote et al., 1994). This idea is based on the following observations in amphibian 
and mammalian photoreceptors: removal of bound cGMP from the noncatalytic sites in 
frog ROS reduces Py binding affinity to PaP (Arshavsky et al., 1992) and correlates with 
an accelerated transducin GTPase activity (Arshavsky and Bownds, 1992); in bovine 
ROS, Py serves as a GTPase accelerating factor (Angleson and Wensel, 1994; Arshavsky 
et al., 1994; Arshavsky et al., 1994) acting in concert with the RGS9 protein (He et al., 
1998; Tsang et al., 1998; Tsang et al., 1998). Accordingly, cGMP dissociation from the 
rapidly dissociating class of sites on activated PDE might signal Py to interact with RGS9
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to stimulate GTPase activity of transducin to inactivate PDE during the recovery phase of 
the photoresponse.
cGMP dissociation from the second, high affinity class of binding sites on bovine 
rod PDE is too slow (ti/2 -1 .6  min; Table 1) to be implicated in the recovery process of 
the dark-adapted photoresponse. It is possible that cGMP dissociation from these 
noncatalytic sites may act to gradually reduce the lifetime of activated PDE during 
adaptation to continuous illumination, and thereby lead to the smaller, faster responses 
characteristic of the light-adapted state. Coles and Yamane (Coles and Yamane, 1975) 
and Cervetto et al. (Cervetto et al., 1984) have shown a gradual acceleration of recovery 
of the flash photoresponse when amphibian rod photoreceptors are exposed to continuous 
illumination; this response acceleration slowly develops over the same general time 
frame as cGMP dissociation from the higher affinity noncatalytic sites on PDE. Future 
work is needed to establish whether a strict temporal correlation exists between 
occupancy of cGMP at the noncatalytic sites and the kinetics of the recovery phase of the 
light-adapted photoresponse, and whether these studies performed with lower vertebrates 
are relevant to the regulation of mammalian rod phototransduction.
In conclusion, cGMP binding and dissociation at the noncatalytic sites on the 
photoreceptor PDE may indirectly regulate the enzyme by affecting the strength of the 
interaction of the Py subunit with the catalytic subunits. This in turn may direct whether 
Py interacts with the Pap dimer to regulate catalytic activity, or with transducin and its 
GTPase accelerating protein, RGS9, to regulate the kinetics of transducin inactivation. In 
addition, there is conflicting evidence at present (Arshavsky et al., 1992; Granovsky et 
al., 1998; Granovsky et al., 1998) as to whether the noncatalytic sites can allosterically
68
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
regulate hydrolytic activity at the active sites, as has been demonstrated for PDE2 
(Martins et al., 1982). The results in this paper provide a strong foundation for unraveling 
the complex interplay between the noncatalytic and catalytic sites on photoreceptor PDE 
and the low molecular weight Py and PS subunits that interact with and regulate the 
action of this central effector enzyme in visual transduction.
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Chapter II
The catalytic and GAF domains of the rod cGMP phosphodiesterase 
(PDE6) heterodimer are regulated by distinct regions of its inhibitory y
subunit*
ABSTRACT
The central effector of visual transduction in retinal rod photoreceptors, cGMP 
phosphodiesterase (PDE6), is a catalytic heterodimer (aP) to which low molecular 
weight inhibitory y subunits bind to form the nonactivated PDE holoenzyme (aPy2). 
While it is known that y binds tightly to aP, the binding affinity for each y subunit to aP, 
the domains on y that interact with aP, and the allosteric interactions between y and the 
regulatory and catalytic regions on ap, are not well understood. We show here that the y 
subunit binds to two distinct sites on the catalytic aP dimer ( K d i  < 1 pM, Kru = 3 pM) 
when the regulatory GAF domains of bovine rod PDE6 are occupied by cGMP. Binding 
heterogeneity of y to aP is absent when cAMP occupies the noncatalytic sites. Two major 
domains on y can interact independently with o.p, with the N-terminal half of y binding 
with 50-fold greater affinity than its C-terminal, inhibitory region. The N-terminal half of 
y is responsible for the positive cooperativity between y and cGMP binding sites on «P, 
but has no effect on catalytic activity. Using synthetic peptides, we identified regions of 
the amino acid sequence of y that bind to aP, restore high-affinity cGMP binding to low-
*. This chapter was published in its entirety in J. Biol. Chem. (276, 27527-27534, 2001) 
and was Scientific Contribution #2088 from the New Hampshire Agricultural Experiment
70
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
affinity noncatalytic sites, and retard cGMP exchange with both noncatalytic sites. 
Subunit heterogeneity, multiple sites of y interaction with ap, and positive cooperativity 
of y with the GAF domains are all likely to contribute to precisely controlling the 
activation and inactivation kinetics of PDE6 during visual transduction in rod 
photoreceptors.
Station. This work was supported by National Institutes of Health Grant EY-05798 (to 
R.H.C.).
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I n tr o d u c tio n
The extent and lifetime of activation of the photoreceptor cGMP 
phosphodiesterase (PDE61; E.C. 3.1.4.35) must be precisely regulated in rod and cone 
cells in order to control the exquisite sensitivity, speed, and adaptational properties of the 
visual transduction pathway in vertebrate photoreceptors. The membrane-associated rod 
photoreceptor PDE6 consists of a dimer of two homologous catalytic subunits (Pap) to 
which two low molecular weight inhibitory subunits (Py) bind (holoenzyme 
stoichiometry: aPy2). The catalytic subunits contain GAF domains which are responsible 
for high-affinity, noncatalytic binding of two cGMP molecules per holoenzyme. It is well 
established that relief of the inhibitory constraint on PDE6 arises from the binding of 
activated heterotrimeric G-protein (transducin) to Py following photoactivation of the 
visual pigment, rhodopsin (reviewed in refs. (Pfister et al., 1993; Pugh, Jr. and Lamb, 
1993; Bownds and Arshavsky, 1995; Artemyev et al., 1998; Pugh, Jr. and Lamb, 1993; 
Bownds and Arshavsky, 1995; Artemyev et al., 1998)). However, the strength of the 
interaction between Py and Pap has been difficult to quantitate and Kd values vary 
widely [from picomolar (Wensel and Stryer, 1986; Hamilton et al., 1993; Skiba et al., 
1995; Hamilton et al., 1993; Skiba et al., 1995) up to nanomolar values (Otto-Bruc et al., 
1993; Yamazaki et al., 1996b; Yamazaki et al., 1996b)]. In addition, it has not been 
conclusively demonstrated whether both Py molecules bind with equal affinity to PaP to
1 The abbreviations used are: PDE, cyclic nucleotide phosphodiesterase; PDE6, PDE 
from photoreceptor cells; Pap, catalytic heterodimer of rod PDE6; Py, inhibitory 10-kDa 
y subunit of rod PDE6; a t, a-subunit of rod photoreceptor G-protein, transducin; K d , 
dissociation constant; kcat, turnover number for activated PDE6, based on the PaP 
concentration; Ki, inhibition constant; RGS-9, regulator of G-protein signaling-9; LY, 
Lucifer Yellow.
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form the nonactivated holoenzyme [although two different binding sites on Pap have 
been inferred using mutant Py; ref. (Berger et al., 1999)]. Finally, recent evidence 
suggests that binding of activated transducin to PDE6 relieves inhibition at only one of 
the two active sites, further supporting the idea of catalytic subunit heterogeneity with 
respect to Py binding (Melia et al., 2000; Norton et al., 2000; Norton et al., 2000).
Use of synthetic peptides to defined regions ofPy, as well as mutagenesis of the 
Py subunit, have revealed that Py has multiple sites of interaction with rod PaP, with the 
a-subunit of activated transducin (at*), and with the Regulator of G-protein Signaling-9 
(RGS-9). The C-terminal residues ofPy (amino acids 77 -  87) have been shown to 
interact directly with the catalytic sites of PaP to inhibit catalysis (Skiba et al., 1995; 
Lipkin et al., 1988; Brown, 1992; Granovsky et al., 1997; Brown, 1992; Skiba et al.,
1995; Granovsky et al., 1997). A second major site of interaction between Py and PaP 
has been identified in the lysine-rich central portion (amino acids 24-45) of the Py 
sequence (Lipkin et al., 1988; Artemyev and Hamm, 1992; Takemoto et al., 1992; Lipkin 
et al., 1993; Natochin and Artemyev, 1996; Artemyev and Hamm, 1992; Takemoto et al., 
1992; Lipkin et al., 1993; Natochin and Artemyev, 1996), but the function of this 
interaction is unclear. a t* has been shown to interact with Py at two distinct regions: one 
in its C-terminal domain (amino acid residues 65 -  87), and the second in the central, 
lysine-rich region ofPy (Lipkin et al., 1988; Brown, 1992; Artemyev and Hamm, 1992; 
Artemyev et al., 1992; Slepak et al., 1995; Slep et al., 2001; Artemyev et al., 1992; 
Artemyev and Hamm, 1992; Brown, 1992; Slepak et al., 1995; Slep et al., 2001). Finally, 
Py also serves to potentiate the GTPase-activating protein function of RGS-9 by
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interacting with the protein in the neighborhood of W70 (Slepak et al., 1995; Slep et al., 
2001; Tsang et al., 1998; Tsang et al., 1998; Slep et al., 2001).
In this paper, we show that the Kd of Py binding to rod PDE6 is in the picomolar 
to sub-picomolar range. Furthermore, Py does not bind with equal affinity to the two sites 
on PaP when cGMP occupies the noncatalytic regulatory sites located on the Pap dimer. 
We also demonstrate that the central region ofPy stabilizes high-affinity cGMP binding 
to the noncatalytic sites, and the affinity of the central region ofPy exceeds by 50-fold the 
affinity of its C-terminal region. Finally, using a series of synthetic peptides, we identify 
important residues in the central region that contribute to the stabilization ofPy binding 
to Pap.
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E x pe r im e n t a l  P r o c e d u r e s
Materials—Bovine retinas were purchased from W.L. Lawson, Inc. The Py mutant, Pyl- 
45C [consisting of the first 45 amino acids of bovine rod Py plus a C-terminal cysteine 
residue; ref. (Skiba et al., 1996)] was a kind gift of Dr. N.P. Skiba, while zaprinast was 
generously supplied by Rhone-Poulenc Rorer (Dagenham, UK). Crude synthetic peptides 
were prepared at New England Peptide or at the protein facility at the University of New 
Hampshire. Radiochemicals were from PerkinElmer Life Sciences. Gel electrophoresis 
and immunoblotting supplies were from Bio-Rad Laboratories. Ultima Gold scintillation 
fluid was from Packard Instrument Co., filtration and ultrafiltration products were from 
Millipore, protein assay reagents were from Pierce Chemical Co., and all other chemicals 
were from Sigma.
Preparation ofPDE6—Membrane-associated bovine rod PDE6 was purified to >90% 
homogeneity from frozen bovine retinas as described previously (Mou et al., 1999). The 
resulting nonactivated PDE holoenzyme (subunit stoichiometry: a{3y2) was stored in 50% 
glycerol at -20°. The PDE6 catalytic heterodimer (PaP) was prepared by limited 
proteolysis of the Py subunits, followed by Mono Q ion-exchange chromatography to 
remove proteolytic fragments of Py (Mou et al., 1999). The PaP preparation was >95% 
pure as judged from Coomassie-stained SDS-PAGE. No shift in the apparent molecular 
weight of the a  or P subunit was observed following this treatment. [Attempts to prepare 
PaP without resorting to proteolytic digestion of Py were unsuccessful.] Immunoblot 
analysis with an anti-peptide Py antibody (UNH9710) directed to the C-terminal region 
(amino acids 63-87) of Py revealed no detectable full-length Py; a 5 kDa band 
representing the major proteolytic product ofPy exhibited <5% of the original Py
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immunoreactivity (Mou et al., 1999; Cote, 2000; Mou et al., 1999). To remove 
endogenous cGMP bound to the noncatalytic regulatory sites on PaP, the PaP was 
incubated at 37° for 30 min prior to use.
Preparation and purification o f Pyand Pyl-45C—Full-length bovine rod Py or the N- 
terminal fragment, Pyl-45C, was expressed in E. coli using the pETl la expression vector 
(Slepak et al., 1995) and purified as described previously (Artemyev et al., 1998; Mou et 
al., 1999; Mou et al., 1999). The total Py concentration was initially determined 
spectrophotometrically (S277 = 7550 cm M'1), and verified by assaying its inhibitory 
activity (Cote, 2000); these two estimates varied by <10%. The concentration of Py 1-45 
was measured with a colorimetric protein assay (Smith et al., 1985). To fluorescently 
label Pyl-45C with Lucifer Yellow (Pyl-45C-LY), the procedure of Artemyev et al. 
(Artemyev et al., 1992) was used, followed by purification of Pyl-45C-LY by reversed- 
phase high-pressure liquid chromatography.
Peptide purification—Following automated peptide synthesis, peptides were cleaved 
from the resin with anhydrous HF and lyophilized. Crude, acidic peptides (Py55-75 and 
Py63-87) were first purified by anion-exchange chromatography using DEAE Sephadex 
A-25 and a linear NaCl gradient at pH 7.5. Other peptides were initially purified by 
cation exchange chromatography on CM Sephadex C25 using a linear NH4HCO3 
gradient at pH 8.0. All peptides were further purified by reversed-phase high-pressure 
liquid chromatography on a 22 x 250 mm, 300 angstrom Ci8 column (Vydac), using a 
linear gradient of 30 -  70% acetonitrile in 0.1% trifluoroacetic acid. After lyophilization, 
each peptide was resuspended in 10 mM Tris, pH 7.5, and its concentration determined
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with the bicinchoninic acid protein assay (Smith et al., 1985) using bovine serum albumin 
as a standard.
Analytical procedures and data analysis—The concentration of PDE and its catalytic 
activity were determined as described in detail elsewhere (Mou et al., 1999; Cote, 2000; 
Cote, 2000). Bovine serum albumin (250 fig/ml) was added when assaying enzyme 
concentrations in the sub-nanomolar range to prevent loss of activity. A membrane 
filtration assay was used to determine the equilibrium and kinetic properties of cGMP 
binding to high-affinity noncatalytic sites on PDE (Mou et al., 1999; Cote, 2000; Cote, 
2000). The PDE inhibitor, zaprinast (0.1 -  1.0 mM), was included in the assay solution to 
insure that <10% hydrolysis of [3H]cGMP occurred. Nonspecific binding was determined 
as described previously (Cote and Brunnock, 1993). The fluorescence assay of Pyl-45C- 
LY binding to Pap was conducted in an Aminco-Bowman Series 2 spectrofluorimeter 
using an excitation wavelength of 430 nm and an emission wavelength of 520 nm 
(Artemyev et al., 1992).
Except where noted, experiments were performed three times, and the results 
presented as the mean ± standard error of the mean (SEM). Nonlinear regression analysis 
of the data was performed using Sigmaplot 2000 (SPSS, Inc.).
For the results in Figs. 1 and 2, two different curve-fitting equations were used to 
fit the Py binding data. The first equation represents the standard equilibrium binding 
equation for a single class of noninteracting sites:
B = ^ m  (Eq.l)
KD+[Pr]
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where B is the amount of Py bound, Bmav is the maximum extent of binding, Kd is the 
dissociation constant, and the free Py concentration, [Py], is assumed to be approximated 
by the total added Py concentration (i.e., [Py] = [Py]x).
Because the free Py concentration was not experimentally measured, Eq. 1 can 
only be used to estimate the Kd when ligand depletion from solution is not significant. 
For high-affinity binding reactions, this condition is met when the total number of 
binding sites (Px) is near the Kd. However, if we substitute the conservation of mass 
equation ([Py]x -  B + [Py]) into Eq. 1, we can estimate the Kd for any Px without having 
to assume that [Py] s  [Py]T:
max
V J
where, x = -Kd -  Px -  [Py]x. This analytical approach was previously used to study high- 
affinity binding of GTPyS to transducin (Malinski et al., 1996).
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R esu l t s
Quantitative analysis o f Py binding toP afi—Given the > 100-fold range of reported Kd 
values for Py binding to PDE6 in the literature (see Introduction), we suspected that 
stoichiometric binding of Py to PaP was occurring in those instances where the PaP 
concentration exceeded the intrinsic Kd value for the binding reaction. To directly test 
this, we examined the ability of Py to inhibit catalysis as a function of the PaP 
concentration (Fig. 2.1 A). At PaP concentrations > 50 pM, there was a linear increase in 
the extent of inhibition up to the plateau as the Py concentration was increased; the 
concentration ofPy needed to attain >90% inhibition was approximately twice the 
concentration of PaP. This behavior represents a titration phenomenon in which added Py 
stoichiometrically binds to PaP with very high affinity until essentially all of the binding 
sites are occupied (2 mol Py per mol PaP). At PaP concentrations < 10 pM, the inhibition 
curve departed from stoichiometric behavior, and an excess ofPy was needed to fully 
inhibit the enzyme (Fig. 2.1 A).
The Py binding data in Fig. 2.1A was analyzed using two equations for 
equilibrium binding ofPy to Pap. The first approach (Eq. 1) assumed that the 
concentration of free Py, [Py], was approximately equal to the total added Py 
concentration, [Py]x (i.e., no ligand depletion). When Eq. 1 was used to estimate the 
binding affinity of Py at each concentration of PaP tested, we found that the value of the 
apparent Kd increased in direct proportion to the concentration of Pap. (Fig. 2. IB, 
circles). For example, at 1 pM PaP, the calculated Kd for Py binding was 1.6 pM, while
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at a concentration of 500 pM Pap, the curve-fitting to Eq. 1 gave an apparent Kd = 300 
pM.
We re-examined the Py binding data with Eq. 2 (which is not constrained by the 
assumption that [Py] = [Py]x) to estimate the apparent Kd for Py binding. Over the 
concentration range of 1 to 500 pM PaP, the calculated Kd showed little dependence on 
the PaP concentration. The convergence of the two estimates for the apparent Kd as the 
PaP concentration was lowered to 1 pM indicated that both Eq. 1 and Eq. 2 returned 
similar estimates when Pt < Kd and when the free Py concentration could be 
approximated as the total Py concentration. We conclude that the most reliable condition 
for determining the binding affinity ofPy is when the PaP concentration is in the low pM 
range.
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Figure 2.1. Inhibition of catalytic activity by Pyat various concentrations of Paj$.
PaP and Py were prepared as described in Experimental Procedures. A. The ability of 
increasing amounts ofPy to bind to and inhibit hydrolysis of cGMP was determined at 
the following PaP concentrations (in pM): 1.0 (•), 5.0 (A),  10 (♦), 50 (▼), 200 (■), and 
500 (o). The substrate concentration was 100 pM cGMP at < 50 pM PaP or 2.0 mM at 
200 and 500 pM Pap. The curves represent the fit of the data to Eq. 2. B. The affinity of 
Py binding to Pap (apparent Kd) was estimated using either Eq. 1 (o )  or Eq. 2 (□) at each 
indicated Pap concentration. The points represent individual determinations except for 1 
pM (mean ± SEM, n = 6).
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Heterogeneity in Py binding to Pafi—Closer examination of the results at the lowest PaP 
concentration we could easily test (1 pM) indicated that the two Py binding sites on Pap 
were not identical when we assayed Py inhibition of cGMP hydrolysis (Fig. 2.2, circles). 
When 1 pM PaP was incubated with up to 1 mol Py per mol PaP, stoichiometric binding 
ofPy to PaP was observed. This is evident from the fact that the data fit a straight line for 
the first 50% of the binding curve (Fig. 2.2, dotted line). After binding 1.0 Py per PaP, 
the remaining Py binding sites required an excess of free Py in order fully inhibit PaP. 
Attempts to fit the entire binding curve to Eq. 1 {upper dashed line, Fig. 2.2) or Eq. 2 
failed to generate statistically valid regression coefficients, so we fit the data to a 
modified form of Eq. 1 that included two independent classes of binding sites. This 
approach gave the best fit to the experimental data (Fig. 2.2, solid line), and resolved two 
classes ofPy binding sites with Kd values of 0.3 and 7 pM. [The 0.3 pM value is an upper 
limit for the higher affinity Kd. Because this site exhibits titration behavior, the true, 
binding affinity may be greater than the curve-fitting estimate.] Note that the data cannot 
distinguish between two independent classes ofPy binding sites and a model in which the 
first Py to bind reduces the binding affinity of Pap for the second Py (negative 
cooperativity).
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Fig. 2.2. Py binding affinity at 1 pM Pap reveals two classes of binding sites in the 
presence of cGMP. Pap (1.0 pM) was incubated with various concentrations of Py at 4° 
for 10 min, and then the extent of inhibition of cGMP (•, 100 pM concentration; n = 7) 
or cAMP (▲, 500 pM concentration; n = 6) hydrolysis was determined at 22°. The 
cAMP data was well fit as a single class ofPy binding sites using either Eq. 1 {dashed 
line: K d  = 3.7 ± 0.3 pM, Bmax = 1.80 ± 0.03 mol Py bound per mol PaP) or Eq. 2 (K d  = 
2.6 ± 0.3 pM, Bmax = 176 ± 0.04 Py per Pap; not shown). The cGMP data did not fit a 
single site model using either Eq. 1 {dashed line) or Eq. 2 (not shown), as judged by 
statistical analysis of the regression. For values of total added Py < 1.0, the binding curve 
fit a linear model {dotted line), consistent with stoichiometric binding (K d  < 1 pM) of 1 
mol Py per mol PaP in the presence of cGMP. A two-site model was also used (by 
extension of Eq. 1) to fit the entire data set {solid line), and resolved the binding curve 
into two classes of sites with Kdi = 0.3 ±0.1 pM and Kd2 = 6.6 ± 2.3 pM.
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cGMP binding to noncatalytic sites on Pafi is responsible fo r P y binding heterogeneity— 
We have previously demonstrated that bovine rod PaP (in the absence of Py) contains 
high- (K d  = 60 nM) and low-affinity (K d  > 1 pM) cGMP binding sites, and that the low- 
affmity site is restored to its high-affinity state upon Py addition (Mou et al., 1999). We 
hypothesized that the Py binding heterogeneity in Fig. 2.2 might result from 
heterogeneity in cGMP binding to the noncatalytic sites. To test this, we needed to 
measure Py binding when the noncatalytic sites are not occupied with cGMP. cAMP is an 
alternate substrate for PDE6 catalysis and binds with negligible affinity to amphibian 
PDE6 (K d  > 40 mM) (Hebert et al., 1998). Fig. 2.3 {triangles) demonstrates that cAMP is 
able to weakly bind to bovine PaP, as judged by its ability to compete with cGMP 
binding to the one high-affinity site present on PaP (Mou et al., 1999). Assuming simple 
competition between cGMP and cAMP binding, cAMP binds to the high-affinity 
noncatalytic site with a Kd ~ 200 pM.
When we re-examined the binding affinity ofPy to PaP in the presence of 500 
pM cAMP, we found that Py binds to PaP with a single Kd value of 3 pM (Fig. 2.2, 
triangles). No evidence of binding site heterogeneity or cooperativity was evident when 
Py interaction with PaP was assayed based on its inhibition of cAMP hydrolysis. This 
implies that cAMP binding to noncatalytic sites does not affect Py binding to Pap. In 
contrast, binding of cGMP to noncatalytic sites induces an allosteric transition that 
increases Py binding affinity > 10-fold to one site on Pap. The other Py binding site 
maintains an affinity for Pap similar to the Kd observed when cAMP is present.
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Lack o f direct allosteric communication between the catalytic and noncatalytic sites on 
bovine P aft—Because cGMP binding induces a conformational change in Paf3 that 
enhances Py affinity, we hypothesized that the GAF domain might also allosterically 
regulate hydrolytic activity in the catalytic domain [in analogy to the cGMP-stimulated 
PDE, PDE2; ref. (Martins et al., 1982; Yamamoto et al., 1983; Yamamoto et al., 1983)]. 
To test this, we compared the kinetic parameters of Potj3 using cGMP or cAMP as the 
substrate. Table 2.1 shows that when cGMP is the substrate, PaJ3 achieves a catalytic 
efficiency (k oat/KM  = 4x108 IVfY1) approaching the diffusion-controlled limit for a 
bimolecular collision. PDE6 has a 100-fold greater specificity for cGMP compared to 
cAMP, as judged by the decrease in the kcat/KM value when cAMP is the substrate. Most 
of the reduction in substrate specificity for cAMP can be ascribed to the 65-fold increase 
in its Km value (Table 2.1). For both cGMP and cAMP, no cooperativity could be 
detected (Table 2.1), but this is not unexpected since the high-affinity noncatalytic site on 
PaP is occupied over most of the concentration range we were able to test.
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Table 2.1
Kinetic parameters for cyclic nucleotide hydrolysis by bovine rod P a f  
Pap was depleted of endogenous, bound cGMP by incubation at 37° for 30 min. 5 pM 
Pap (for cGMP as substrate) or 50 pM PaP (for cAMP measurements) was added to 0.1 










cGMP substrate 14 ± 1.0 5440± 80 3.9x10* 0.9 ±0.1
cAMP substrate 910+100 3060± 100 3.4xl06 0.9 ±0.1
cAMP substrate + cGMP 
occupying noncatalytic 
sitesa
830 ± 60 3160 ±70 3.8xl06 1.0±0.1
aTo load cGMP on the noncatalytic sites of Pap, 200 nM PaP was first incubated with 5 
pM cGMP, 100 pM zaprinast, and 10 pM Py 1-45. To remove unbound low molecular 
weight compounds, the PaP was concentrated by ultrafiltration. The PaP was washed 
three times by resuspending in buffer (containing Pyl-45) and re-concentrating. The final 
PaP preparation contained 1.1 -  1.6 mol cGMP bound per mol PaP
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To directly test whether cGMP occupancy of the noncatalytic sites affected 
catalysis, we first pre-incubated Pap with cGMP and the N-terminal half of Py (Pyl-45) 
to load cGMP onto both noncatalytic sites. [Pyl-45 has no effect on catalysis of PaP 
(data not shown), but stabilizes high-affinity cGMP binding at both noncatalytic sites on 
PaP; see below.] The complex of PaP with bound Pyl-45 and cGMP was then incubated 
with increasing concentrations of cAMP to determine its kinetic parameters. No 
significant change in Km, kcat or Hill coefficient could be discerned when compared with 
PaP incubated with cAMP alone (Table 2.1). These results confirm and extend previous 
observations with amphibian PDE6 (Arshavsky et al., 1992; D'Amours and Cote, 1999;
D'Amours and Cote, 1999) that no direct allosteric mechanism regulates catalysis via the 
state of occupancy of the GAF domains on PDE6, as is the case for PDE2 (Martins et al., 
1982; Yamamoto et al., 1983; Yamamoto et al., 1983). Thus, the differences in the Km 
and kcat values for cAMP and cGMP are due to differences in substrate specificity at the 
active site, not on the state of occupancy of the GAF domain.
The N-terminal half o f P y binds to P afi with much greater affinity than the C-terminal 
region—Previous work has documented that two major domains of interaction with Pap 
exist on Py: the C-terminal residues and the polycationic central region (see Introduction). 
To understand how distinct binding domains on Py contribute to the very high-affinity 
binding ofPy to PaP, we assayed the ability of these individual domains ofPy to bind to 
Pap. We first assayed the ability of the C-terminal peptide, Py63-87, to bind to, and 
inhibit, cyclic nucleotide hydrolysis at the active site. Based on previous work 
(Granovsky et al., 1997), we expected that Py63-87 would act as a simple competitive 
inhibitor with respect to cyclic nucleotides. When cAMP is used as substrate, Py63-87
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acts as a simple competitive inhibitor of catalysis with an inhibition constant, Ki, equal to 
3.5 pM (Fig. 2.4). The affinity of this inhibitory domain is 6 orders of magnitude weaker 
than the entire Py molecule (Kd = 3 pM), indicating that the N-terminal 62 amino acids 
most likely contain the major site(s) of high-affmity interaction.
To directly measure the binding affinity of the N-terminal half of Py to Pap, we 
assayed the interaction of Pyl-45 covalently labeled with Lucifer Yellow (Pyl-45-LY) 
with Pap. Fig. 2.5A demonstrates that either in the absence of cyclic nucleotides or in the 
presence of cAMP, PaP binds to Pyl-45-LY as a single class of binding sites with a Kd = 
68 ± 15 or 62 ± 14 nM, respectively. In both cases, the maximum extent of binding was 
the same.
To test how the fluorescent probe altered the binding affinity of Pyl-45, we also 
tested the effectiveness of Pyl-45 in restoring high-affinity cGMP binding to the low- 
affinity site on PaP (Mou et al., 1999). In the absence ofPy or Pyl-45, PaP is able to 
bind 1 mol cGMP per mol PaP at micromolar levels of [3H]cGMP (see Fig. 2.3, 
triangles). Addition of increasing amounts of Pyl-45 in the presence of 600 nM 
[3H]cGMP stimulates cGMP binding to a second site on PaP (Fig. 2.5B) with a Kd -  80 
nM, a value in good agreement with the Kd for binding ofPyl-45-LY to Pap.
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Figure 2.3. cAMP binding affinity for the noncatalytic sites of bovine rod P ap  in the 
absence of Py or upon addition of Py or Pyl-45. 1 pM [3H]cGMP and the indicated 
concentrations of cAMP were added to 10 nM PaP in the absence of Py (A), or 
following pre-incubation with 20 nM Py (•) or 10 pM Pyl-45 (□, mean ± range for n = 
2). The ability of cAMP to compete with [3H]cGMP binding to noncatalytic sites was 
determined by filter binding, and the data was fit to a single class of non-interacting sites 
to obtain the following K1/2 and B^ax values, respectively: PaP, 4.0 mM, 0.9 cGMP/Pap; 
PaP+Py, 0.4 mM, 2.0 cGMP/PaP; Pap+Pyl-45,0.3 mM, 2.0 cGMP/Pap. The Kd for 
cAMP binding was calculated from the K1/2 value (Cheng and Prusoff, 1973) using Kd = 
60 nM for cGMP binding.
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Figure 2.4. Competitive inhibition of Py63-87 with cAMP at the active site of Pap.
PaP (2 nM) was incubated with 1.0 (open circles), 2.0 (upside-down triangles), 5.0 
(triangles), 10 (squares) or 20 (filled circles) pM Py63-87 for 10 min at room temperature 
before adding the indicated amounts of cAMP and determining the initial rate. The data 
were plotted as the reciprocal of fraction of the maximum rate (v* = v/Vmax) versus the 
reciprocal of the substrate concentration. The inhibition constant, Ki, for Py63-87 was 
calculated to be 2.9 ± 0.3 pM from a replot of the slopes versus the corresponding 
inhibitor concentrations. The data is representative of three experiments with an average 
Ki = 3.5 ±0.5 pM.
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We conclude that the N-terminal half of Py (Pyl-45) binds to PaP about 50-fold 
more tightly than the C-terminal region (Py63-87). Furthermore, if each binding domain 
were to interact with PaP independently, the sum of the interaction energies of Pyl-45 
and Py63-87 (Kd ~ 10'13 M) would account reasonably well with the measured Kd for 
full-length Py.
Relationship between occupancy o f the GAF domain and Py binding affinity—In Fig. 2.2, 
we showed that heterogeneity in Py binding to PaP (assayed by inhibition of cyclic 
nucleotide hydrolysis) was dependent on the state of occupancy of the noncatalytic sites. 
The cGMP-dependent enhancement of full-length Py binding affinity is also observed 
with the fluorescently labeled N-terminal half of Py. Fig. 2.5A shows that Pyl-45-LY 
undergoes a 2.3-fold increase in binding affinity, with no significant change in maximum 
binding, when the GAF domains are occupied by cGMP compared to empty or cAMP- 
filled sites. Thus, occupancy of the noncatalytic site by cGMP is required to induce the 
conformational change in PaP that enhances Py binding affinity.
These results and our previous study with bovine rod PaP (Mou et al., 1999) are 
in accord with a simple reciprocal relationship: cGMP occupancy of the noncatalytic sites 
enhances Py affinity to one of its binding sites and, conversely, Py binding to PaP 
enhances cGMP binding affinity to its low-affinity noncatalytic site. Unexpectedly, this 
correlation does not apply when cAMP occupies the noncatalytic sites. Fig. 2.3 shows 
that addition ofPy or Pyl-45 to PaP enhances 10-fold the ability of cAMP to compete 
with cGMP for binding to both noncatalytic sites. This suggests that Py binding induces a 
conformational change in PaP that enhances the affinity of both cGMP and cAMP for
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PaJ3. However, Fig. 2.5A reveals that cAMP occupancy of the noncatalytic sites is not 
sufficient to induce an increase in Pyl-45-LY binding to Pa|3. It appears that cGMP, but 
not cAMP, is needed to induce a conformational change in PaP that enhances Py binding 
affinity. This conclusion is supported by experiments with cGMP analogs that show 
intermediate effects on the relationship between cyclic nucleotide occupancy and 
enhanced Py binding affinity (H.M. and R.H.C., unpublished observations).
Defining the amino acid residues responsible fo r high-affinity interactions ofPy  
with Pafi—We prepared a set of synthetic peptides corresponding to various regions of 
the Py primary sequence to identify regions ofPy that stabilized high-affinity binding of 
Py. We first measured the ability of these peptides to compete with full-length, 
endogenous Py bound to nonactivated PDE6, as judged by the increase in catalytic 
activity at the active site. Fig. 2.6A shows that two peptides, Pyl-45 and Py 18-41, were 
able to compete with full-length Py to activate PDE6 to 70-80% of its maximal rate and 
with K1/2 values of 1 and 11 pM, respectively. The Py21-46 peptide showed a significant 
drop in its ability to compete with Py when compared with Pyl8-41, suggesting that 
amino acid residues 18-20 may stabilize a peptide conformation of Pyl8-41 that enhances 
its interaction with Pap. Several other peptides were able to stimulate cGMP hydrolysis 
to a limited extent (20-40% activation) and with low affinity (K1/2 ~ 400 -  500 pM), 
including Pyl-18, Py 10-30, and Py35-56. The peptide Py55-75 was completely ineffective 
in competing with Py. These results indicate that the interaction ofPy with PaP may 
consist of multiple low-affinity sites of interaction along the N-terminal half of the Py
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Figure 2.5. High-affinity binding of P y l - 4 5  to P a P .  A. The relative increase in 
fluorescence (F/F0) of Pyl-45 labeled with Lucifer Yellow (Pyl-45-LY) was measured 
after addition of the indicated amounts of Pap. The buffer used for these assays 
contained 10 mM HEPES, pH 7.8,100 mM NaCi, 1 mM MgCk, 200 pM zaprinast, and 
either no nucleotide (•), 10 mM cAMP ( A )  or 10 pM cGMP (■). The curves represent 
the fit of each data set to a hyperbolic function: no nucleotide, Kd ~ 68 ± 15 nM, 
(F/F0)max = 3.3; cAMP, KD -  62 ± 14 nM, (F/FoW = 3.4; cGMP, KD = 28 ± 5 nM, 
(F/Fo)max = 3.5. No evidence for cooperativity was detected using the Hill equation to fit 
the data. B. The ability of Pyl-45 to restore high-affinity cGMP binding to a low affinity 
class of noncatalytic sites on Pap (10 nM) was measured following incubation of PaP 
with the indicated concentration of Pyl-45 and 600 nM [3H]cGMP. The data represents 
the average of 4 different experiments, and the curve is the fit of the data to a hyperbolic 
function (Kd = 83 nM; 6 ^  = 1.9 mol cGMP bound per mol Pafi).
94
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
s^  - 6 . 0  
05
C
o - 5 . 0
©
!  -4'0: 
©s
"SL -3 o• ®
Q- < - 3 . 0 I
21
I I 







- 7 . 0 -
- 6 . 0 -
- 5 . 0 -
- 4 . 0 —
< - 4 . 0 i i i i i
1 21 41 61









Q 20 r -
0 — 1  II
21 81 87
95
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Figure 2.6. Ability of Py peptides to interact with Pap. A. The catalytic activity of 
nonactivated PDE6 holoenzyme (5 nM) was tested following incubation of PDE6 with 
increasing concentrations of Py peptides. The maximum extent of activation and the K1/2 
for the Py peptides were determined by fitting the concentration dependence to a 
hyperbolic function. The ordinate represents the log(Ki/2) for each peptide and the 
abscissa visually depicts each Py peptide tested. The maximum percent activation of 
cGMP hydrolysis induced by each peptide was: Pyl-45, 81%; Pyl8-41, 69%; Py 10-30, 
42%; Py35-56, 32%; Py21-46, 25%; Pyl-18, 18% ; Pyl5-26, 14%; Py35-46, 11%; Py35- 
41, 9%; Py55-75, <5%. B. The ability of Py peptides to restore high-affinity cGMP 
binding to low affinity sites on PaP was determined as described in the legend to Fig. 5B, 
and the Kd values plotted on the ordinate on a log scale. The Bmay for restoring high- 
affinity binding (% of restoration observed with Py = 100%) was: 100% (Py, Pyl-45, 
Pyl0-30, Py 18-41), 90% (Py21-46), 70% (P/35-56, Py35-46), 40% (Py35-41), and 0% 
(Pyl-18, Py 15-26, Py55-75, Py63-87). C. The [3H]cGMP dissociation kinetics were 
determined at 22° by pre-incubating 5 nM PaP with 0.6 pM [3H]cGMP and 200 pM of 
the indicated Py peptide until binding equilibrium was attained. Dissociation of bound 
[3H]cGMP was initiated by addition of 2 mM unlabeled cGMP, and the data fit to a 
single exponential decay function to determine the tin  from the equation: ti/2 = 0.693/k.i, 
where k_i is the dissociation rate constant.
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We showed above that the N-terminal half of Py, Pyl-45, could restore high- 
affinity cGMP binding to a low affinity class of noncatalytic sites on PaP (Figs. 2.3 & 
2.5B). To better define this region on Py, we tested the ability of peptides to bind to PaP 
and restore high-affinity cGMP binding to this class of sites. Fig. 2.6B shows that Pyl8- 
41 and Py21-46 both fully restored cGMP binding to PaP with a binding affinity reduced 
approximately 10-fold compared to Pyl-45. Pyl0-30 was also able to fully restore cGMP 
binding, but its interaction with Pap was 10-fold further reduced. Even though Py 15-26 
failed to interact with PaP to restore cGMP binding, the overall results with several other 
peptides suggest that residues 18 to 30 ofPy are important in stabilizing Py binding to 
Pap.
We also tested peptides covering amino acids 35 -  56 of the Py sequence (Fig. 
2.6B). While full restoration of cGMP binding could not be observed with Py35-56 or 
smaller peptides, all three peptides showed Kd values in the 20 -  30 pM range. The 
effectiveness of the shortest peptide, Py35-41, to stimulate cGMP binding to Pap 
indicates that these residues are important in direct binding to PaP and in stabilizing a 
high-affinity conformation of the second noncatalytic site on PDE6.
Although Pyl-45 has 10-fold higher affinity for PaP than Py 18-41, we could not 
detect any interaction of the peptide Pyl-18 with PaP in terms of restoring high-affinity 
cGMP binding (Fig. 2.6B). It is possible that some of the N-terminal residues may 
stabilize a conformation of Pyl-45 that favors its binding to PaP compared to Py 18-41. 
Two other peptides, Py55-75 and Py63-87, completely lacked the ability to restore cGMP 
binding even at 300 pM peptide concentrations.
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The binding affinity of cGMP for the noncatalytic sites was determined in the 
presence of 200 pM of each peptide to examine whether the low- and high-affinity 
noncatalytic sites could be distinguished (data not shown). All Py peptides that were 
competent to restore cGMP binding to the low-affinity sites failed to alter the Kd for 
cGMP binding ( K d  range: 5 1 - 6 3  nM). No evidence for binding site heterogeneity could 
be detected. We conclude that binding of Py or central region Py peptides induces a 
conformational change in the low-affinity noncatalytic site that enhances its affinity for 
cGMP to a value indistinguishable from the high-affinity noncatalytic site.
The restoration of cGMP binding shown in Fig. 2.6B describes the ability ofPy 
peptides to act on the low-affinity noncatalytic sites on Paj3. To examine both high- and 
low-affinity noncatalytic sites, we examined whether Py peptides could alter the rate of 
[3H]cGMP dissociation from the noncatalytic sites of PaP. Fig. 2.6C shows that most of 
the peptides were able to retard the rate of [3H]cGMP dissociation from the noncatalytic 
sites. In all instances, the dissociation kinetics was fit to a single exponential loss of 
[3H]cGMP binding; no evidence for two distinct classes of sites was evident (not shown). 
As expected, Pyl-45 retarded most effectively cGMP exchange at both noncatalytic sites 
on PaP, causing a 16-fold increase in the half-time for [3H]cGMP release from 
noncatalytic sites. The Py peptides Py 18-41 and Py 10-30 also retarded cGMP exchange 
by greater than 10-fold. Comparison of Pyl8-41 (ti/2 = 84 min) with Py21-46 (ti/2 = 41 
min) supports the importance of amino acid residues 18-20 in stabilizing binding ofPy 
peptides to PaP. The Py peptide, Py35-46, is nearly as effective as the larger Py21-46 in
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slowing the rate of cGMP dissociation from Pap, while the seven amino-acid Py35-41 
also acted to increase the half-time for cGMP dissociation 3-fold.
Two peptides, Py55-75 and Py63-83, were unable to affect cGMP dissociation 
compared to PaP lacking Py peptides (ti/2 = 6 min), in agreement with their inability to 
restore cGMP binding to low affinity sites (Fig. 2.6B). The fact that the Pyl-18 and Pyl5 
26 peptides slowed cGMP dissociation ~ 3-fold from the high-affinity noncatalytic sites 
of PaP (Fig. 2.6C) without being able to restore cGMP binding to the low-affinity site 
(Fig. 2.6B) suggests that this region ofPy may affect only the high-affinity GAF domain 
ofPDE6.
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D isc u ssio n
This paper shows that Py binds to two distinct high-affinity binding sites on Pa(3 
when cGMP occupies the noncatalytic sites. Our work also describes the reciprocal 
allosteric regulation of PDE6 resulting from Py binding to PaP and cGMP binding to 
high-affinity sites in the GAF domains of PaP. Since no direct allosteric communication 
between the GAF domains and the active sites is detected, we conclude that the Py 
subunit is required to facilitate allosteric communication between the regulatory and 
catalytic domains of PDE6. Finally, we have mapped regions within the N-terminal half 
of the molecule that interact with Pap, some of which induce conformational changes at 
the GAF domain.
Implications o f high-affinity, two-site P y binding to Pafffor PDEfunction. Our 
quantitative analysis ofPy binding to PaP helps to make sense of the wide range of 
apparent binding affinities reported in the literature. The majority of studies of the Py 
affinity for PaP have been carried out with concentrations of enzyme much greater than 
the Kd value for Py binding. Under these conditions, Py will bind in a stoichiometric 
manner (Fig. 2.1). Even when the appropriate model is applied to the binding data (i.e., 
Eq. 2), it is difficult to extract meaningful values for the Kd values. For example, we 
were unable to satisfactorily fit data obtained at > 800 pM PaP concentrations to Eq. 2, 
primarily because the estimate of the free Py concentration is very uncertain (H.M and 
R.H.C., unpublished). In previous reports where the PDE concentration was lowered into 
the picomolar range [e.g., refs. (Wensel and Stryer, 1986; Hamilton et al., 1993;
D'Amours and Cote, 1999; Hamilton et al., 1993; D'Amours and Cote, 1999)], the
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binding affinities of Py for PaP were much closer to the values we report. Previous 
evidence supporting two distinct Py binding sites on PaP has mostly been obtained 
indirectly, based on heterogeneity in transducin activation of PDE6 (Melia et al., 2000; 
Norton et al., 2000; Bennett and Clerc, 1989; Bruckert et al., 1994; Bruckert et al., 1994; 
Melia et al., 2000; Norton et al., 2000). However, Berger et al. (Berger et al., 1999) have 
reported two classes ofPy binding sites on PaP when probed with a fluorescently labeled 
mutant ofPy.
The functional heterogeneity in Py binding to PaP is a consequence of the state of 
occupancy of the noncatalytic sites with cGMP (Fig. 2.2)—but not cAMP. Since the 
membrane-associated bovine rod PDE6 holoenzyme has one exchangeable and one 
nonexchangeable cGMP binding site (Mou et al., 1999), we hypothesize that the very 
high affinity (K d  < 1 pM) Py binding site may correlate with this nonexchangeable cGMP 
site. This Py binding site associated with the nonexchangeable cGMP site is unlikely to 
function during visual transduction. Instead, it may serve a structural role in stabilizing 
the native conformation of the PDE6 holoenzyme. This idea is supported by studies 
showing that mutations in the GAF domains of PDE6 [(Gal et al., 1994); reviewed in ref. 
(Dryja et al., 1999)] or a disrupted or mutated Py gene (Tsang et al., 1996) can affect the 
levels of expression and/or activation of PDE6. It might also explain the difficulty in 
expressing functional PDE6 in various expression systems (Piriev et al., 1993; Qin and 
Baehr, 1994; Granovsky et al., 1998; Qin and Baehr, 1994; Granovsky et al., 1998) if co­
expression of catalytic and Py subunits must occur to properly fold the nascent 
polypeptide chains of PDE6.
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Allosteric regulation o f PDE6 requires P yto communicate between the GAF domain and 
the catalytic domain. In addition to a catalytic domain near the C-terminus that is 
conserved in all members of the vertebrate PDE superfamily, most PDE families contain 
N-terminal domains that serve regulatory functions. It has been proposed (Conti, 2000) 
that a common regulatory feature of the N-terminal domain is to alter the inhibitory 
constraint on catalysis via conformational changes in the catalytic dimer. Almost half of 
the known PDE families (PDE2, PDE5, PDE6, PDE 10, and PDE11) contain two tandem 
GAF domains (Aravind and Ponting, 1997) which in most cases code for functional, 
noncatalytic cGMP binding sites. For PDE2 and PDE5, binding of cGMP to the GAF 
domain induces a conformational change in the catalytic dimer that either directly or 
indirectly stimulates catalysis (Martins et al., 1982; Yamamoto et al., 1983; Bums et al., 
1992; Corbin et al., 2000; Yamamoto et al., 1983; Bums et al., 1992; Corbin et al., 2000). 
For PDE6, we show that loading the GAF domain with cGMP has no direct influence on 
PDE6 kinetic parameters (Table 2.1).
Nonetheless, cGMP binding to the GAF domain of PDE6 does induce a 
conformational change in the catalytic dimer. Occupancy of the noncatalytic sites 
enhances the interaction of Py (Fig 2.2) or Pyl-45 (Fig. 2.5 A) to the catalytic dimer. This 
effect is specific for cGMP (Fig. 2.5A). Conversely, addition ofPy to bovine rod PaP 
enhances cyclic nucleotide binding affinity to the noncatalytic sites (Fig. 2.3) in a 
reciprocal manner. For cGMP, Py acts to restore high-affinity binding to a low affinity 
class of sites on bovine Pap; the other, high-affinity class of cGMP sites undergoes no 
change in affinity (Mou et al., 1999). For cAMP, addition ofPy or Pyl-45 to PaP 
increases the binding affinity 10-fold to both noncatalytic sites on PaP (Fig. 2.3).
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We conclude that unlike PDE2 or PDE5, the GAF domain in the PDE6 catalytic 
subunit is allosterically uncoupled from its catalytic domain unless Py is bound to bridge 
the two domains. Furthermore, the heterogeneity in Py binding to PaP suggests that only 
one Py binding site on PaP is sensitive to cGMP occupancy of the noncatalytic sites. 
Future efforts will identify which catalytic subunit contains the cGMP-sensitive Py 
binding site and the high-affinity noncatalytic site on Pap.
Pyis a multi-functional subunit with several sites o f interaction with the PDE6 
transduction complex. The Py subunit of PDE6 contains within its 87 amino acid 
sequence numerous sites of interactions with PaP, transducin, RGS-9 and perhaps other 
proteins (see Introduction). In this study, we have focused on Py-Pap interactions, and 
find that the N-terminal half ofPy binds 50-fold more tightly to the catalytic dimer than 
the C-terminal region (Py63-87). This high-affinity binding domain in the region of 
residues 18 -  41 of Py explains why a t* activation of the PDE6 holoenzyme sometimes 
displaces the inhibitory constraint of Py without causing complete dissociation ofPy from 
Pap (Wensel and Stryer, 1986; Clerc and Bennett, 1992; Clerc and Bennett, 1992). The 
correlation ofPy dissociation from transducin-activated PDE with loss of cGMP from the 
GAF domain (Norton et al., 2000) also makes sense based on the reduced binding affinity 
ofPy or Pyl-45 in the absence of cGMP (Figs. 2.2 & 2.5).
Within the central region of the Py subunit, amino acids 18 -  20 and 35 -41  both 
contribute to stabilizing Py binding to PaP (Fig. 2.6). Other Py interaction sites probably 
exist within this polycationic region that went undetected with our selected peptides, 
including potential sites of regulation via phosphorylation at T22 and/or T35 (Tsuboi et
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al., 1994; Xu et al., 1998; Matsuura et al., 2000; Xu et al., 1998; Matsuura et al., 2000) or 
via ADP-ribosylation at R33 or R36 (Bondarenko et al., 1997).
Our results demonstrate that the N-terminal 18 amino acids of Py play no direct 
role in inhibiting catalysis or stimulating high-affinity cGMP binding to PaP (Fig. 2.6), 
contrary to a previous study (Yamazaki et al., 1996a). However, the N-terminus of Py 
probably contains weak sites of interaction with PaP and may help stabilize a high- 
affinity conformation of the 18-41 region ofPy.
Significantly, the one peptide that shows no detectible interaction with PaP, 
namely Py55-75, contains a major site of interaction with activated transducin, a t* (see 
Introduction). A recent structural determination of the interaction of the C-terminal half 
ofPy with a t* has shown that a t* binds to several residues in the vicinity of W70 ofPy to 
cause the displacement of the C-terminal residues ofPy known to block the active site 
(Slep et al., 2001).
Summary. Our results extend previous models postulating two major sites of 
interaction between PDE6 and activated transducin—both of which are mediated through 
the inhibitory Py subunit. The extreme C-terminus ofPy functions to block catalysis at 
the active site, but has relatively low affinity for Pap. It is the high-affinity interactions 
of the central, polycationic region ofPy (particularly residues 18-41) that stabilize 
binding to PaP, thereby insuring that a very small fraction of PDE6 holoenzyme is 
catalytically active prior to light activation. High levels of cGMP in dark-adapted 
photoreceptor cells result in saturation of the noncatalytic sites on PDE6, further 
enhancing Py affinity to one binding site on the PDE6 holoenzyme. Upon activation of 
the phototransduction cascade, binding of activated transducin to the PDE6
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holoenzyme—specifically in the vicinity of W70 of Py—is sufficient to displace the Py 
C-terminus and cause activation at one active site on Pa(T [The very high-affinity Py 
binding site (K d  < pM) when cGMP is present likely prevents at* displacement ofPy at 
the second active site (Melia et al., 2000; Norton et al., 2000; Norton et al., 2000)]. At 
early times following light stimulation, a t* remains associated with the PDE6 
holoenzyme, and does not physically dissociate as a a t*-Py complex. Following PDE6 
activation, cGMP levels in the outer segment drop and remain low until the inactivation 
process re-inhibits PDE6. The positive cooperativity between the GAF domains and the 
central region ofPy suggests that a sustained lowering of cGMP levels (e.g., during light 
adaptation) will lead to cGMP dissociation and a lowered Py affinity for Paf3. This 
cGMP-dependent allosteric transition could cause the multi-functional Py subunit to 
become available to interact with RGS-9 to facilitate an enhanced GTPase rate on a t*, 
consistent with biochemical and structural studies (Slep et al., 2001; Arshavsky and 
Bownds, 1992; Calvert et al., 1998; He et al., 1998; Calvert et al., 1998; He et al., 1998; 
Slep et al., 2001).
While homology modeling of the GAF domain (Ho et al., 2000) and the catalytic 
domain (Xu et al., 2000; Granovsky and Artemyev, 2000; Granovsky and Artemyev,
2000) of PDE complement recent structural information on Py binding to at* (Slep et al.,
2001), we still lack crystal structures revealing the interactions of each Py molecule with 
the a  and J3 subunits of the rod PDE6 heterodimer. The present study provides the 
biochemical basis for understanding how the central and C-terminal domains of Py bridge 
the regulatory and catalytic domains of the rod PDE6 heterodimer to control the
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magnitude and duration of PDE activation during visual excitation, recovery, and light 
adaptation.
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Chapter III 
Regulation of PDE6 by phosphorylation of the inhibitory y subunits and 
the catalytic ap subunits 
Abstract
Many proteins in the visual transduction pathway become phosphorylated upon 
light activation. Since PDE6 is the key effector enzyme in phototransduction, it is quite 
possible that PDE function is regulated by reversible phosphorylation of its subunits. In 
this study, we first examined the effect of phosphorylation of the inhibitory rod PDE y 
subunit (Py) on its interaction with the PDE6 catalytic subunits (PaP) after 
phosphorylation at Thr22 by mitogen-stimulated protein kinase (MAPK) and at Thr35 by 
cAMP-dependent protein kinase A (PKA). Our results showed that phosphorylation of 
Py neither abolishes the heterogeneity in Py binding to Pap nor greatly affects the 
potency ofPy to inhibit both trypsinized PDE and transducin-activated PDE. However, 
phosphorylation at Thr22 mildly decreases the ability of the central region ofPy to bind to 
PaP and to stabilize the cGMP binding at the GAF domains. Py bound to PaP is a poor 
substrate for phosphorylation, but transducin activation enhances its ability to be 
phosphorylated in bovine rod outer segments (ROS). PaP can also be phosphorylated by 
PKA and MAPK under in vitro conditions. PKA prefers PP as a substrate while MAPK 
can phosphorylate both Pa and Pp. An unknown protein kinase from ROS membrane 
associates with PDE with a moderate affinity and phosphorylates PDE at its a  subunit.
No alteration in kcat and Km has been detected after the phosphorylation of PaP. However,
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cGMP occupancy at the noncatalytic sites reciprocally regulates the phosphorylation of 
Pap. These results suggest a potential role of Py and PaP phosphorylation in regulating 
PDE6 by regulating cGMP levels in the photoreceptor cells. Other possible physiological 
roles of Py and Pap phosphorylation in regulating PDE during phototransduction are 
discussed.
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Introduction
Photoactivation of the visual pathway starts when a photon of light stimulates a 
molecule of rhodopsin, initiating a transduction cascade involving the sequential 
activation of rhodopsin (R), transducin (Gt) and cGMP phosphodiesterase (PDE). PDE is 
the key effector enzyme in visual transduction and functions to hydrolyze the second 
messenger cGMP upon activation [for reviews, see (Pugh, Jr. et al., 1999)]. The decrease 
in cGMP concentration causes dissociation of cGMP from the cGMP-gated ion channels. 
This causes the channels to close, resulting in a hyperpolarization of the membrane.
Protein phosphorylation plays a central role in regulating the function of several 
phototransduction proteins. Many protein kinases have been found to exist in vertebrate 
rod outer segments: rhodopsin kinase (RK) (Lee et al., 1981); cyclin-dependent protein 
kinase 5 (cdk5) (Hayashi et al., 2000); protein kinase C (PKC) (Kelleher and Johnson, 
1985; Udovichenko et al., 1997; Udovichenko et al., 1997); cAMP-dependent kinase 
(PKA) (Walter, 1984), casein kinase II (CKH) (Hollander et al., 1999); Ca2+/calmodulin- 
dependent protein kinase II (CaMKH) (Liu et al., 2000); cGMP-dependent kinase (PKG) 
(Taylor and Uhler, 2000), mitogen-stimulated protein kinase (MAPK) (Ko et al., 2001) 
and protein-tyrosine kinase (Bell et al., 2000). Rhodopsin phosphorylation by RK has 
been studied as a mechanism to terminate the initial step of the light-activated 
biochemical process (Wilden, 1995; McDowell et al., 2001; Hurley et al., 1998; Krupnick 
and Benovic, 1998; Wilden, 1995; Hurley et al., 1998; Krupnick and Benovic, 1998; 
Kennedy et al., 2001; McDowell et al., 2001). Phosphorylation of phosducin by CaMKH 
regulates transducin through regulation of Gt|3y function (Bauer et al., 1992; Lee et al., 
1992; Gaudet et al., 1999; Thulin et al., 2001; Gaudet et al., 1999; Bauer et al., 1992; Lee
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et al., 1992). Phosphorylation of the cGMP-gated channel by a tyrosine kinase is another 
mechanism to regulate cGMP sensitivity in addition to calmodulin regulation (Muller et 
al., 2001). RGS9-1 (regulator of G protein signaling 9) is also found to be phosphorylated 
by an endogenous protein kinase in rod outer segments (Hu et al., 2001).
Most work on PDE6 phosphorylation has focused on Py phosphorylation. 
Currently, Py phosphorylation has been studied in vivo (Hayashi, 1994; Hayashi et al., 
2000; Hayashi et al., 2000) and in vitro using several protein kinases including 
phosphatidylinositiol (Pl)-stimulated kinase (Hayashi et al., 1991), PKC (Udovichenko et 
al., 1994; Udovichenko et al., 1996; Udovichenko et al., 1994), PKA (Xu et al., 1998), 
cdk5 (Tsuboi et al., 1994b; Tsuboi et al., 1994a; Sharma et al., 1999; Hayashi et al., 2000; 
Matsuura et al., 2000; Hayashi et al., 2000; Sharma et al., 1999; Tsuboi et al., 1994b; 
Tsuboi et al., 1994a). The physiological function of Py phosphorylation in the current 
scheme of phototransduction is not well understood. The central region of Py contains 
most of the predicted phosphorylation sites and the central domain of Py is also a major 
site at which Py interacts with PaP (Artemyev and Hamm, 1992; Mou and Cote, 2001; 
Mou and Cote, 2001; Mou and Cote, 2001). Yamazaki and colleagues have proposed that 
Py phosphorylation at either Thr35 (by PKA) or at Thr22 by (cdk5) enhances almost 10- 
fold the interaction of Py with Pap (Tsuboi et al., 1994b; Xu et al., 1998; Hayashi et al., 
2000; Tsuboi et al., 1994b; Tsuboi et al., 1994a; Matsuura et al., 2000; Hayashi et al., 
2000). However, their conclusions are open to alternative interpretations. For example, 
they have not carefully evaluated the Kd of Py binding to Pap with or without 
phosphorylation. Actually, the experimental conditions chosen (nanomolar concentration 
of PDE) in their studies would prevent the Py binding affinity for bovine or frog Pap
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from being discerned because Py interacts with Pa(3 with such high affinity ( K d  < 10 
pM) (Wensel and Stryer, 1986; Mou and Cote, 2001; Mou and Cote, 2001) that both non- 
phosphorylated Py and phosphorylated Py should inhibit the catalysis of Pap in a titration 
manner. In addition, they have not studied if Py phosphorylation would affect cGMP 
binding to GAF domains on PDE6. The effect of Py phosphorylation on the ability of Py 
to serve as a GTPase-activating protein (GAP) for transducin has also been reported. Xu 
et al. have shown that, once phosphorylated, Py had less ability to deactivate transducin 
and displace bound GTPyS from its binding site on Gta  (Xu et al., 1998). However, direct 
measurements of Py-transducin interactions were not performed in their study.
Several members of the PDE family are regulated and activated by 
serine/threonine phosphorylation of the catalytic subunits, including PDEl(Florio et al., 
1994; Florio et al., 1994), PDE3 (Macphee et al., 1988), PDE4 (Lim et al., 1999) and 
PDE5 (Thomas et al., 1990; Beltman et al., 1993; Corbin et al., 2000; Beltman et al., 
1993; Corbin et al., 2000). Phosphorylation of PDE5 may be most relevant to PDE6, 
since the structure of PDE5 is the most closely related to PDE6 (McAllister-Lucas et al., 
1993; Tcheudji et al., 2001; Tcheudji et al., 2001). Phosphorylation of PDE5 is 
allosterically enhanced by cGMP occupancy of cGMP binding sites (Turko et al., 1998). 
No major effect of phosphorylation on the maximum rate of catalysis and the potency of 
PDE5 inhibitors has been described. However, a modest decrease in the Km for cGMP 
hydrolysis and Kd for cGMP binding has been observed (Corbin et al., 2000). To date, 
only one report has suggested that PDE6 serves a substrate for PKA and ROS PKC in 
vitro (Udovichenko et al., 1993). They showed that PKA phosphorylated PDE at both 
subunits, but removal of Py by trypsinization abolished the phosphorylation by PKA.
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PKC only phosphorylated the Pa subunit and this phosphorylation was independent of 
trypsinization. A synthetic peptide AKVISNLLGPREAAV (Pa30-44) inhibited 
phosphorylation of PDE catalytic subunits by PKC from ROS, suggesting that Ser34 of 
Pa subunit is a potential phosphorylation site for PKC. The effect of phosphorylation on 
PDE6 catalysis and cGMP binding properties has not been described. In addition, no in 
vivo phosphorylation of PDE6 has been reported.
In this study, we have repeated the stoichiometric phosphorylation of Py at Thr35 
by PKA and at Thr22 by MAP kinase in vitro. We have measured the Kd of 
nonphosphorylated and phosphorylated Py binding to Pap and found no apparent effect 
of phosphorylation on the ability ofPy to inhibit both trypsinized and transducin- 
activated PDE. However, phosphorylation ofPy at Thr22 mildly decreases the ability of 
the central region ofPy to stabilize cGMP binding to the GAF domains and to displace 
the endogenous full-length Py from its binding sites in the catalytic domain ofPDE. We 
have also observed an increase in Py phosphorylation upon light activation of bovine 
ROS, but the stoichiometry is low. Based on these observations, we conclude that the 
phosphorylation ofPy is unlikely to regulate PDE catalysis directly, but may be involved 
in regulating its noncatalytic cGMP binding. It remains possible that other signaling 
pathways intersect with visual excitation by recognizing Py in its phosphorylated state.
Our results show that PDE catalytic subunits are also substrates for 
phosphorylation by PKA, MAP kinase, and by an unknown ROS membrane-associated 
“PDE6 kinase”. When the GAF domains lack bound cGMP, PaP phosphorylation is 
enhanced, opposite to the case for PDE5. We have not found the apparent effect of PDE6 
phosphorylation on its catalysis. However, phosphorylation of PaP restores high affinity
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cGMP binding to low-affinity noncatalytic sites. The possible physiological role of PaP 
phosphorylation in regulating PDE during phototransduction will be discussed.
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Material and Experimental Procedures
Materials—Bovine retinas were purchased from W.L. Lawson, Inc. [3H]cGMP was from 
NEN Life Sciences Products and [y-32P]ATP was from ICN Biochemicals. Filtration and 
ultrafiltration products were from Millipore. Scintillation fluid (Ultima Gold) was from 
Packard Instrument Corporation. Zaprinast was a gift of Rhone-Poulenc Rorer 
(Dagenham, UK). BCA protein assay reagent was from Pierce. Superdex 200 and Mono 
Q columns were from Pharmacia, and the C l8 reverse-phase HPLC column (300A, 22 x 
250 mm) was from Vydac. cAMP-dependent protein kinase (PKA) catalytic subunit and 
MAP kinase 2 (Co-expressed with Erk2) were from Upstate Biotechnology. Bacterial 
strains containing Py22C and Py35C are kind gifts of Dr. N O. The mutants Py22C and 
Py35C both had a substitution of Ser at Cys68 of the bovine rod Py sequence, in addition 
to a Cys substitution for the naturally occurring Thr at positions 22 or 35, respectively 
(Granovsky et al., 1998). Artemyev and bacterial strains containing Pyl-45C (Py amino 
acid residues 1-45 plus a cysteine tagged at the C-terminal end) was provided by Dr. 
N.P.Skiba (Skiba et al., 1996). All other chemicals were obtained from Sigma. 
Preparation o f bovine rod outer segments (ROS) — Purified bovine ROS was prepared 
from frozen retinas in the dark under IR illumination following the method of McDowell 
(McDowell, 1993). 50 retinas were suspended with 45 ml of solution A (0.1 M potassium 
phosphate monobasic, pH 7.0, 1.0 mM MgCL, 0.1 mM Na2-EDTA, 1 mMDTT, 0.2 mM 
PMSF) in a flask. The ROS were detached from the retina by stirring on a magnetic plate 
for 10 min while keeping the flask on ice. After spinning at 5000 rpm for 30 minutes, the 
crude ROS was collected through 4 layers of gauze. The sucrose was diluted 1.5 fold 
with solution A, followed by spinning for 1 hour at 7500 rpm. The ROS-containing pellet
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was resuspended in solution A supplemented with 25.5% of sucrose (d = 1.105 g/ml), 
then loaded on a discontinuous sucrose gradient containing 5 ml of 27.1% sucrose (d = 
1.135 g/ml) and 5 ml 32.3% of sucrose (d = 1.115 g/ml). The sucrose gradient was 
centrifuged at 27,000 rpm in SW27.1 rotor at 4°C for 1 hour. The ROS layer found in the 
lower interface (1.115 g/ml and 1.135 g/ml) was removed with 15 g needle. The ROS 
was then diluted with solution A and centrifuged (17K in SS-34 rotor for 60 minutes).
The purified ROS pellet was stored at -80°C until use.
Preparation o f non-activated membrane-associated PDE (PDE-M) and Pa/S dimer — 
Bovine rod membrane-associated PDE was prepared from frozen bovine retinas and 
purified by using ion-exchange, immunoaffinity and gel-filtration chromatography using 
procedures described previously (Mou et al., 1999). The purified PDE was concentrated 
with Biomax-50K and stored in PDE storage buffer (100 mM NaCl, 2 mMMgCfe, 10 
mM Tris, 7.5, 2 mM dithiothreitol, 0.4 mM Pefabloc) containing 50% glycerol at -20°C. 
PDE catalytic subunits (PaP) were prepared by limited proteolysis of purified PDE by L- 
1 -tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin and Py fragments were 
removed by Mono-Q chromatography, as described in detail previously (Mou et al.,
1999). The purity of the PaP was found to be >95%. The concentration of PDE was 
determined as described previously (Mou et al., 1999; Cote, 2000; Cote, 2000). 
Purification and quantitation o f Pyand Py mutants (P/22C, P /35C  and truncated 
mutant Pyl-45C) — The recombinant bovine rod full-length Py and Py mutants were 
expressed using the pETlla-Py, pETl la-Py22C, pETl la-Py35C and pETl la-Pyl-45C 
vectors. The expression and purification procedures were the same as described in Mou et 
al. (Mou et al., 1999). The concentration of purified Py, Py22C and Py35C were measured
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spectrophotometrically at 277 nm with an extinction coefficient of 7550 cm-M'1 (Cote, 
2000). The concentration of purified Pyl-45C was determined by the bicinchoninic acid 
(BCA) protein assay with bovine serum albumin (BSA) as the protein standard.
Py peptide synthesis and purification—Vy\8-41 and two singly phosphorylated peptides 
[Pyl8-41(22P) and Pyl8-41(35P)] were synthesized at the Protein Facility in the 
Department of Biochemistry and Molecular Biology at the University ofNew Hampshire. 
Cleavage of peptides from the resin and protecting groups were accomplished with 
anhydrous hydrofluoric acid (HF). The peptides were first purified with cation exchange 
chromatography on CM Sephadex C25 equilibrated with 1 mM NH4HCO3, pH 8.0 and 
eluted with a linear 0-1.0 M NH4HCO3 gradient. After ion-exchange chromatography, 
the peptides were further purified with a preparative C l8 reverse-phase column (300A,
22 x 250 mm) using a linear gradient of 30-70% acetonitrile in 0.1% trifluoroacetic acid. 
The dried peptides were resuspended in 10 mM Tris, pH 7.5. The concentration ofPy 
peptides was routinely measured by BCA protein assay.
Phosphorylation ofpurified recombinant Py, Py mutants, PDE-M by PKA or/and MAP 
kinase — The phosphorylation assay was performed in final volume of 30-100 pi assay 
dilution buffer [20 mM MOPS, pH 7.2, 25 mM [3-glycerol phosphate, 5 mM EGTA,
ImM sodium orthovanadate, ImM dithiothreitol, 15 mM MgCb], plus 100 pM ATP 
(with or without 0.02-0.05 pCi/pl [y-32P]ATP), 1:50 phosphatase inhibitor cocktail-1 
(Sigma, cat. # P2850; a mixture of inhibitors that will inhibit the L-isozymes of alkaline 
phosphatase as well as serine/threonine protein phosphatases such as PP1 and PP2A) and 
the desired concentration of Py, Py mutants or PDE-M. The phosphorylation reaction was 
initiated by adding PKA (-  20 ng/pg protein) or MAP kinase (10-20 ng/pg protein). Two
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methods were used to detect the incorporation of [32P]. The first one was to apply the 
phosphorylation mixture to P81 phosphocellulose paper squares (Roskoski, Jr., 1983), 
then rinsed three times in 0.75% phosphoric acid to remove the free [32P]ATP. The 
radioactivity was measured in a scintillation counter. The second method was to first 
separate the proteins by SDS-PAGE and then detect incorporation of [32P] by 
autoradiography.
In situ phosphorylation o f Pyand PDE catalytic subunits in bovine ROS — Bovine ROS 
homogenates ([rhodopsin] = 50-100 pM) were incubated with 200-500 pM [y-32P]ATP 
under nonactivated (in the darkness and without GTPyS) or activated (exposed to light 
and in the presence of 100 pM GTPyS) conditions. The free [32P]ATP and soluble 
proteins were removed by centrifugation at 13000 rpm for 10 minutes (loss of Py even in 
the present of GTPyS was less than 5%). For the detection of Py phosphorylation, Py was 
extracted by adding a final concentration of 20-40% of acetonitrile and heating at 80°C 
for 10-20 min. For the detection of PDE catalytic subunit phosphorylation, PDE-M was 
first extracted from ROS by washing ROS membranes at least three times with hypotonic 
buffer (5 mM Tris, pH 7.5, 1 mM MgCl2, 1 mM DTT, 0.2 mM Pefabloc) or lOmM 
CHAPS in ROS buffer. After extraction, Py was partially purified on a Sep-Pak Cl 8 
cartridge using 50% of acetonitrile/0.1 % trifluoroacetic acid to elute Py; PDE-M was 
concentrated with 10K Centricon ultrafiltration device. The stoichiometry of 
phosphorylation was determined by comparison with [32P] incorporation into 
recombinant Py or purified PDE-M by PKA in vitro.
Assay for PDE hydrolytic activity and measurements o f cGMP binding to noncatalytic 
sites on Pa/3 — Two different methods (a radiotracer assay and a colorimetric assay) were
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used to quantify the PDE hydrolytic activity (Cote, 2000). The equilibrium binding and 
kinetics of [3H]cGMP binding to the noncatalytic sites were measured with a filter 
binding assay as described (Cote, 2000). For experiments in which the Py or Py peptides 
were used, Py or Py peptides were added to the mixtures 10 min before cGMP or cAMP. 
Data analysis -  All experiments were performed at least three times and the results 
presented are the mean ± S.E.M. unless noted otherwise. Fitting of the data was 
performed using Sigmaplot (SPSS, Inc.), as described in the legends. Quantitation of 
protein phosphorylation after autoradiography was performed using Quantiscan (Biosoft).
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Results
Part I: Regulation of PDE6 bv Py phosphorylation 
Pyis phosphorylated by PKA at Thr35 and by MAP kinase at Thr22— Previous 
phosphorylation studies have shown that Thr35 and Thr22 on rod Py can be phosphorylated 
by PKA and cdk5 in vitro (Xu et al., 1998; Matsuura et al., 2000; Matsuura et al., 2000). 
Here, we confirmed that recombinant Py could achieve stoichiometric levels of phosphate 
incorporation when incubated with PKA or MAP kinase. As shown in Fig. 3.1. A, the 
phosphorylation level of wild-type Py by PKA was close to 1 mole of phosphate 
incorporated per mole of Py. The site of phosphorylation on Py by PKA was confirmed 
by 32P labeling of T35C and T22C Py mutants. Incubation of the T22C mutant with PKA 
resulted in stoichiometric phosphate incorporation, whereas the T35C mutant lacked a 
significant level of phosphorylation. Phosphorylation ofPy by MAP kinase has not been 
previously described, but based on the substrate specificity of MAP kinase [Pro-X- 
(Thr/Ser)-Pro; (Stokoe et al., 1992)], we predicted that the proline-rich region ofPy 
would support phosphorylation at Thr22. As shown in Fig. 3.1.B, about 1 mol phosphate 
was incorporated into Py. The Py mutant in which Thr22 was replaced with cysteine failed 
to incorporate significant amounts of [32P] compared to wild-type Py or Py substituted at 
Thr35 with a cysteine residue, suggesting that Thr22 was the site of phosphorylation. 
Additional support for the PKA and MAP kinase substrate specificity was observed when 
the Py peptides (Mou and Cote, 2001) were used for phosphorylation. The peptides 
containing Thr35 (but lacking Thr22) could be phosphorylated only by PKA, while the 
peptides containing Thr22 (but lacking Thr35) could be phosphorylated by only MAP 
kinase (data not shown).
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Figure 3.1. Phosphorylation of Py and Py mutants (Py35C and Py22C) by PKA or 
MAP kinase. The ability of PKA and MAP kinase to phosphorylate bovine rod Py at 
Thr35 and Thr22 was determined by 32P labeling of wild type Py and two Py mutants: 
PyT35C and PyT22C. The phosphorylation assay was performed in a final volume of 50 
pi assay dilution buffer containing 1.0 pM final concentration ofPy orPy mutants, 100 
pM [y-32P]ATP and either 50 ng PKA per tube (A) or 50 ng MAP kinase per tube (B). 
After incubating at 30°C for various times, aliquots were applied to a P81 phosphocelluse 
paper squares (see Experimental Procedures)
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P y phosphorylation at either ThP2 or Thr35 only slightly modifies its inhibitory activity to 
Pap— The inhibition of the catalysis of PDE by Py is the primary mechanism to regulate 
PDE function in visual transduction. Thus, it is important to investigate if Py 
phosphorylation will affect its inhibitory function. Previous studies have proposed that Py 
phosphorylation either at Thr35 or Thr22 greatly enhanced the inhibitory potency of Py 
(Tsuboi et al., 1994b; Udovichenko et al., 1994; Xu et al., 1998; Matsuura et al., 2000; 
Tsuboi et al., 1994a; Tsuboi et al., 1994b; Udovichenko et al., 1994; Matsuura et al.,
2000). However, in most cases, nanomolar concentrations of PDE were used and a 
predicted stoichiometric inhibition of catalysis of Py or phosphorylated Py should be 
observed (Wensel and Stryer, 1986; Mou and Cote, 2001; Mou and Cote, 2001). It is not 
clear how an enhancement ofPy inhibition could be detected under these conditions. 
Therefore, we decided to re-examine whether phosphorylation ofPy can directly alter its 
potency to inhibit PDE catalysis. We used a very low concentration of PDE (1 pM) to 
ensure that the equilibrium binding ofPy and PaP could be observed (Fig. 3.2). A 1-site 
model did not fit well to the binding data, so a two-site model (Mou and Cote, 2001) was 
chosen. The results shown in Fig. 3.2 indicated that Py binding heterogeneity was not 
abolished upon phosphorylation at either or both threonine positions. In all four cases, 
the very high affinity binding site had a predicted Kb value of < 0.5 pM and displayed 
titration behavior. Such an extremely high affinity makes this Py binding site highly 
unlikely to be regulated by phosphorylation. Indeed, this Py might never dissociate from 
the PDE catalytic dimer during phototransduction, and perhaps functions as a scaffolding 
protein to stabilize PDE in its native conformation. For the second, lower affinity Py 
binding site, phosphorylation at Thr22 or Thr35 decreased the interaction ofPy with PaP 2
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to 2.5-fold, which was in sharp contrast to the 10-fold enhancing effects of Py 
phosphorylation reported previously (Tsuboi et al., 1994b; Udovichenko et al., 1994; Xu 
et al., 1998; Matsuura et al., 2000). Based on the above results, we concluded that 
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Figure 3.2. Affinity of Py for PaP was not greatly affected by phosphorylation at
Thr22, Thr35-or both sites. Bovine PaP was prepared by limited trypsin proteolysis and 
purified before use (see Experimental Procedures). Py phosphorylated at position Thr22, 
Thr35 or doubly phosphorylated at both sites (Thr22,35) was prepared by incubating Py 
with MAP kinase, PKA, or both kinases. Non-phosphorylated Py was treated identically, 
except that the protein kinase was omitted. To measure the binding affinity ofPy or 
phosphorylated Py for PaP, PaP was diluted to 1 pM and then incubated for 10 min with 
the indicated concentration ofPy or phosphorylated Py. Inhibition of cGMP (100 pM) 
hydrolysis was determined with the radiotracer assay. The data (averaged from three 
experiments) were fit to a double hyperbolic function, assuming two equal classes of 
binding sites. The higher affinity class of sites had predicted Kd values of < 0.5 pM in all 
four cases and displayed titration behavior (dotted line). The lower affinity class of sites 
had Kd values of 2.7 (Py, circles), 4.9 pM (Py35P, squares). 6.3 pM (Py22P, triangles) 
and 6.9 pM (Py22P35P, diamonds)
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Py phosphorylation does not modify its interaction with transducin-activated PDE — 
Several studies have suggested that Py phosphorylation reduces or abolishes the affinity 
of Py for activated transducin a-subunit (Gta*) so that Py will dissociate from Gta* upon 
phosphorylation and re-inhibit the catalysis of PDE (Xu et al., 1998; Hayashi et al., 2000; 
Hayashi et al., 2000). If this is true, the phosphorylation of Py would serve to deactivate 
PDE without the turnoff the Gta*. In this study, we re-examined ifPy phosphorylation 
would modify its ability to inhibit transducin-activated PDE. It had previously been 
shown that inhibition of transducin-activated PDE (taPDE) in frog ROS homogenates 
requires excess Py since Py binds to Gta  - GTPyS as well as to the active site of PDE 
(Norton et al., 2000). As shown in Fig.3.3, the IC50 values for Py to inhibit bovine taPDE 
was 3.9 Py/PDE, which was somewhat lower than in frog ROS homogenates (Norton et 
al., 2000). Py phosphorylated at Thr22 (IC50 = 3.5 Py/PDE) or at Thr35 (IC50 -  4.3 Py/PDE) 
did not differ significantly from the non-phosphorylated control. Doubly phosphorylated 
Py (Py22P35P) was also tested, and the inhibitory curve was also similar to that of the Py 
itself (data not shown). Therefore, the reported dramatic effect ofPy phosphorylation on 
inhibition of taPDE was not observed in our study. This indicated that Py has the similar 
affinity for transducin-activated PDE regardless of its state of phosphorylation.
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Figure 3.3. Affinity of Py for activated transducin was not greatly affected by 
phosphorylation at Thr*2 or Thr35. Purified bovine ROS (20-30 nM PDE) was 
incubated with increasing amounts of Py or phosphorylated Py for 10 minutes. 100 pM 
GTPyS was added 1 minute prior to 10 mM cGMP addition and PDE activity was 
measured. Maximal transducin-activated PDE activity (1100-1200 s'1) was defined as the 
activity in the absence of added Py. The IC50 value for each Py was determined by fitting 
the data to a 4 parameter logistic function: non-phosphorylated Py (circles) IC50 = 3.9 Py/ 
PDE; Py35P {squares), IC50 = 4.3 Py/PDE; Py22P {triangles), IC50 = 3.5 Py/PDE. This 
experiment is representative of three others.
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Py phosphorylation has a moderate effect on the affinity o f the Py central peptides for  
PaJ3 — It is possible that the effect of phosphorylation is confined to the central region of 
Py where the phosphorylation sites are located. The effect of phosphorylation on the 
overall binding affinity of Py to PaP might be offset in large part by other regions ofPy 
in which its interaction with PaP is not modulated by phosphorylation. Therefore, we 
tested whether phosphorylation has any effect on the interaction of the Py central region 
for Pap. The central region of bovine rod Py is able to restore high-affmity cGMP 
binding to a low-affinity noncatalytic binding site on bovine PDE and to stabilize cGMP 
binding to both binding sites (Mou and Cote, 2001). In this study, we have synthetically 
prepared peptides corresponding to amino acids 18-41 with and without 
phosphothreonine residues at Thr22 or Thr35. As shown in Fig.3.4, phosphorylation at 
either Thr22 or Thr35 did not affect the ability of Py 18-41 to restore cGMP binding to a 
second low-affinity class of binding sites. In all cases, the highest cGMP binding levels 
approached the expected ~2 moles of cGMP bound per mole of PDE. After initiating 
cGMP dissociation from the noncatalytic sites, however, a reduced affinity ofPyl8- 
41(22P) can be inferred based on the 2-fold faster rate of cGMP dissociation. In contrast, 
the phosphorylation at position 35 enhanced 1.7-fold the ability of the peptide to stabilize 
cGMP binding to Pap. We conclude that phosphorylation at Thr22 weakens the intrinsic
s
affinity of the central region ofPy to interact with PDE6 while phosphorylation at Thr35 
may have a slight stabilizing effect on binding.
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Figure 3.4. Phosphorylation of the Pyl8-41 peptide at Thr22 reduced its affinity for 
PaP as indicated by its potency to stabilize cGMP binding to PaP: 5 nM bovine Pap 
was incubated with 0.6 pM [3H]cGMP with or without 20 pM of the indicated Py 18-41 
synthetic peptides. Dissociation of bound [3H]cGMP was initiated at time zero with 2 
mM cold cGMP, and portions filtered at the indicated times. The curves represent a 
single exponential decay function: Py 18-41 (filled circles), ty2 = 29.5 min; Pyl8-41(22P) 
(squares): ti/2= 13.8 min; Pyl8-41(35P) (triangles), t\a = 50.2 min; no peptide (open 
circles), ti/2 = 2.15 min. This experiment is representative of three others.
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Next, we examined whether phosphorylation of Py peptides altered their ability to 
displace endogenous Py from its binding sites on the PDE holoenzyme (Papyy). This 
competition experiment took advantage of the fact that the central region ofPy binds with 
high affinity to PaP but is unable to inhibit catalysis (Mou and Cote, 2001). Both the 
central peptide (Pyl8-41) and the N-terminal half ofPy (consisting of amino acid residues 
1-45) were tested. Pyl-45 with a phosphorylated residue at position 22 or 35 was 
prepared by incubation with MAP kinase or PKA, respectively. The data in Fig.3.5 
illustrated that Pyl-45 could compete with full-length Py to induce 70-100% of the 
maximal catalytic activity, while Py 18-41 could stimulate up to 60% of the maximal 
activity. Phosphorylation at position 22 reduced 4-fold the ability of the peptide to 
stimulate catalytic activity. This result is consistent with our direct binding measurements 
ofPy with PaP in Fig. 4 that Py phosphorylation at Thr22 decreases its interaction with 
PDE6. We also noticed that although Pyl-45 also showed a significant drop in the 
stimulated catalysis when Thr22 was phosphorylated, this effect was more apparent in 
shorter peptide (Py 18-41), where the maximal activation dropped from 58% to 16% when 
Thr22 was phosphorylated. This result supported the idea that the effect of 
phosphorylation is confined to a small region ofPy where the phosphorylation sites are 
located.
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Figure 3.5. Phosphorylation at Thr22 reduced the ability of Py peptides to displace 
bound Py. Bovine PDE holoenzyme (5 nM) was incubated with increasing 
concentrations Py peptides to exchange with the endogenous Py bound to Pap. In the 
absence of peptide, the basal activity was 200 cGMP/PDE/sec, about 4 % of the folly 
activated rate. The extent of activation and the K1/2 values for each peptides were 
determined by fitting the concentration dependence to a hyperbolic function: Pyl -45, 
vmax = 89.3 %, K1/2 = 3.6 pM; Pyl-45 (35P), Vmax = 97.0 %, K m = 3.5 pM. Pyl-45 
(22P), Vmax = 65.7 %, Km = 2.8 pM; Pyl8-41, Vmax = 57.8 %, K1/2 = 17.2 pM; Pyl 8-41 
(35P), Vmax = 56.2 %, Km  = 25.2 pM; Pyl8-41 (22P), Vmax = 15.6 %, K m  = 13.0 pM; 
This experiment is representative of four others.
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Pycomplexed with PDE is a poor substrate for phosphorylation —  To test the 
conditions under which Py is readily phosphorylated, we first checked if Py complexed 
with PDE catalytic subunits was a good substrate for phosphorylation. Equal amounts of 
Py (either bound to bovine rod PaP or free in solution) were incubated with protein 
kinases and the extent of phosphorylation was measured at various times (Fig.3.6). We 
found that when Py was bound to PaP, very low levels of phosphorylation were detected. 
In contrast, free Py was readily phosphorylated with both PKA and MAP kinase, 
consistent with the results obtained with PKC (Udovichenko et al., 1994) and cdk5 
(Matsuura et al., 2000). We confirmed this result by phosphorylating an increasing 
amount of recombinant Py in the absence or in the presence of fixed amount of PaP 
(Fig.3.7). When the added Py concentration was less than the concentration of binding 
sites on PaP, Py formed a complex with PaP and was poorly phosphorylated. Once all 
binding sites on PaP were occupied, PKA was able to incorporate phosphate into Py as 
easily as into free Py lacking Pap. We conclude that free Py is a better substrate for both 
kinases than Py complexed as PaPyy, suggesting that Thr35 and Thr22 are involved in the 
interaction ofPy with Pap.
129
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Pocf3yy Py
I PKA 
P y -*  '■*,
1 2 3 4 5 6 7 8 9 10 11 12
Figure 3.6. Py bound to PaP was a poor substrate for phosphorylation. Purified 
bovine PDE6 holoenzyme (~100 nM, lane 1-6) or free Py (~200 nM, same total Py 
concentration, lane 7-12) were phosphorylated in a final volume of 30 p.1 assay dilution 
buffer containing 50 pM [y-32P]ATP and either 50 ng PKA (lanes 1-3 and 7-9) or MAP 
kinase (4-6 and 10-12) per tube. The reactions were stopped with 10 pi of 5x gel loading 
buffer after 10 min (lane 1, 4, 7, 10), 30 min (2, 5, 8, 11) or 2 h (3, 6, 9, 12). The proteins 
were separated by SDS-PAGE and the incorporation of [32P] into Py was detected by 
autoradiography.
MAPK H PKA MAPK |
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Figure 3.7. Phosphorylation of Py by PKA in the presence of PaP* The 
phosphorylation Py by PKA in the absence or in the presence of PaP was performed in a 
final volume of 30 pi assay dilution buffer containing 50 pM [y-32PJATP and 3.4 finol 
purified PaP (lane 1), increasing amounts of recombinant Py (from 2.5 -  30 finol) in the 
presence of -3.4 finol PaP (lane 2-7), or in the absence of PaP (lane 8-13). 50 ng PKA/ 
tube was added to initiate the phosphorylation. After incubating at ~21°C for the 3 hours, 
proteins were quenched and separated on 15% SDS-acrylamide gel and the incorporation 
of 32P into Py was detected by autoradiography (A). The Py binds bands were also 
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We considered the possibility that transducin activation of PDE6 might induce a 
conformational change in the central region of Py, allowing Py phosphorylation sites to be 
exposed. To test this, we incubated bovine ROS homogenates with [y-32P]ATP and 
phosphatase inhibitors under dark-adapted and light-activating conditions (i.e., light plus 
100 pM GTPyS to activate transducin; see Experimental Procedures). We found that 
under dark-adapted conditions (nonactivated), almost no Py in ROS could be 
phosphorylated (Fig.3.8, lane 1, 4). For transducin-activated samples, some [32P] was 
incorporated into Py (lane 2), but the total extent of Py phosphorylation was less than 3% 
of the level for free Py. Incubation of bovine ROS with the recombinant PDE 5 subunit 
(P8) (lane 3) before adding [y-32P]ATP only slightly changed the degree ofPy 
phosphorylation, suggesting that membrane-association of PDE is not important for Py 
phosphorylation. Furthermore, addition of a PKA inhibitor to ROS did not abolish Py 
phosphorylation (lane 5), suggesting that PKA is not the only protein kinase responsible 
for Py phosphorylation in bovine ROS homogenates. Based on the above results, we 
conclude that Py could be phosphorylated in an activation-stimulated manner, although 
the extent of phosphorylation does not approach stoichiometric levels. However, the sub- 
stoichiometric phosphorylation ofPy in ROS constrains its potential role in regulating 
PDE in visual transduction pathway.
132
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Figure 3 .8. Phosphorylation of Py in dark-adapted or light-activated bovine ROS.
Purified bovine ROS homogenates (60 pM rhodopsin) containing phosphatase inhibitors 
were incubated with 100 pM [y-32P]ATP for 5 h with in the dark (-GTPyS, lane 1, 4) or in 
the light (+100 pM GTPyS, lane 2, 3, 5). To investigate the effect of P5 on Py 
phosphorylation, 2 pM of the recombinant P5 (lane 3) was incubated with bovine ROS at 
4°C overnight before phosphorylation. For lane 5, 20 pi of the PKA inhibitor was added 
to test whether the endogenous PKA activity is responsible for Py phosphorylation in 
ROS. After quenching the phosphorylation reaction, Py was released from ROS 
membranes with 20% acetonitrile, and partially purified on a Sep-Pak C-18 column. The 
same amount of recombinant Py was phosphorylated by PKA in vitro (lane 6) to estimate 
the stoichiometry ofPy phosphorylation in bovine ROS.
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Part II: Regulation of PDE6 bv PaB phosphorylation
Phosphorylation o f PDE catalytic subunits by PKA cmd MAP kinase — In part I, we have 
shown that both PKA and MAP kinases could phosphorylate Py stoichiometrically. In 
this part, we investigated whether these two kinases could phosphorylate the PDE a  and 
P catalytic subunits in vitro. As shown in Fig.3. 9 ,32P was incorporated into PDE catalytic 
subunits with either PKA or MAP kinase. Quantitation of the amount of 32P incorporated 
into phosphorylated PDE (Fig.3.10) indicated that phosphorylated PDE contained a 
maximum o f-1.0 mol of phosphate per PDE when PKA was used as the kinase. Longer 
incubations could not enhance further phosphate incorporation into PDE, suggesting that 
PKA only phosphorylates one site on either Pa orPp. This result was inconsistent with a 
previous report that both PDE catalytic subunits can be phosphorylated by PKA 
(Udovichenko et al., 1993). However, in agreement with Udovichenko et al. 
(Udovichenko et al., 1993), we found that Pap, prepared by limited-trypsinization, could 
not be phosphorylated by PKA (data not shown). In addition, trypsinization also 
gradually removed the radioactivity from [32P]-labeled PDE by PKA (data not shown). It 
is possible that the potential phosphorylation site for PKA is localized in the C-terminal 
region of PaP that is sensitive to trypsin proteolysis (Catty and Deterre, 1991). When 
MAP kinase was used to phosphorylate PDE, more than 1.0 mol of phosphate per PDE 
was incorporated. Longer time of incubation resulted in about 1.4 mol of phosphate per 
PDE (Fig.3.10, triangles). Therefore, MAP kinase phosphorylates PaP at two or more 
different sites. Similar to the case of PKA, the potential sites for MAP kinase are 
sensitive to proteolysis by trypsin (data not shown).
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Figure 3.9. Phosphorylation of the catalytic subunits of the PDE holoenzyme by PKA 
and MAP kinase. Purified PDE holoenzyme was diluted to a final concentration of 200 
nM with assay dilution buffer and 100 pM [y32P] ATP. Phosphorylation was initiated at 
room temperature by adding PKA (5 ng kinase/pg protein) or MAP kinase (5 ng 
kinase/pg protein) to the reaction mixture. After incubating at room temperature for 
various times, 20 pi aliquots were quenched and phosphorylation of PDE was detected by 
15% SDS-PAGE followed by autoradiography.
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Figure 3.10. Time course of phosphorylation of bovine PDE by PKA and MAPK. 
Purified bovine PDE holoenzyme (15 pmol) was phosphorylated with 100 pM [y- 
32P]ATP (0.5 Ci/ pmol PDE) and 200 ng of PKA (circles) or MAP kinase (triangles) at 
22°C in assay dilution buffer. At various times, aliquots were withdrawn, spotted onto 
phosphocellulose P81 paper and immersed in 75 mM phosphoric acid to terminate the 
reaction. The radioactivity was measured by liquid scintillation counting.
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Phosphorylation o f PDE by an unknown endogenous PDE6 kinase — After establishing 
that PDE holoenzyme could be phosphorylated by PKA and MAP kinase in vitro, we 
next wanted to determine if PDE served as a substrate for phosphorylation in situ. After 
incubating bovine ROS homogenates with exogenous [y-32P] ATP, we found that 32P 
could be incorporated into PDE catalytic subunits in a light-stimulated manner. However, 
the total level of phosphorylation was low (about 0.1-0.3 mol phosphate per mol PDE), 
compared to the control containing the same amount of purified PDE with exogenous 
PKA added (data not shown). In bovine ROS homogenates, PDE interacts with many 
proteins to form a supramolecular complex (Korschen et al., 1999). It is possible that 
these interactions might block the PDE phosphorylation sites so to result in a low 
stoichiometry of phosphorylation.
When we separated ROS membranes from soluble proteins followed by washing 
ROS membrane extensively with isotonic buffer, we found that ROS membranes retained 
their ability to incorporate phosphate into PDE catalytic subunits upon addition of the 
exogenous [y-32P]ATP (data not shown). This suggested that a membrane-associated 
kinase was responsible for the phosphorylation of PDE6. This membrane-associated 
protein kinase could be extracted by hypotonic buffer together with PDE-M (Fig.3.11, 
lane 1). It bound PDE-M tightly and was resistant to several purification steps (lane 2-4). 
PDE-M had two activity peaks on Mono-Q chromatography. PDE-M in peak I which 
contained no kinase activity was loaded on the gel-filtration to get purified PDE-M 
sample free of the endogenous kinase (lane 5). PDE-M in peak II was also further 
purified on gel-filtration without loss of kinase activity (data not shown), suggesting that
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this endogenous kinase complexed with PDE with a high affinity. Soluble PDE fractions 
were also checked. After separating cone PDE (PDE-C) and soluble rod PDE (PDE-S) on 
a Q-Sepharose column, PDE-C could be phosphorylated by an unknown protein (lane 6), 
while no kinase activity was observed in the PDE-S peak (lane 7).
1 2 3 4 5 6 7
Figure 3.11. Phosphoiylation of PDE at different purification steps. Bovine rod PDE 
was extracted from ROS membrane with hypotonic buffer (lane 1) and purified 
sequentially on a Q-Sepharose ion-exchange column (lane 2), ROS-1 immunoaffinity 
column (lane 3) and Mono-Q ion exchange column (lane 4). Two PDE activity peaks 
were detected after Mono-Q chromatography. The PDE peak II containing kinase activity 
was loaded in lane 4. The PDE peak I free of kinase activity was further purified on a 
Superdex 200 gel-filtration column (lane 5). Soluble proteins from bovine retinal extract 
were loaded on a Q-Sepharose ion-exchange column to separate cone PDE (lane 6) and 
PDE-S (lane 7). The same amount of PDE from each purification step (based on an 
activity assay) was incubated with 100 pM [y-32P] in the assay dilution buffer. No 
exogenous protein kinase was added. After incubating the phosphorylation mixtures at 
room temperature for 0.5 (a) or 2 h (b), all samples were quenched and separated on 15 % 
SDS-PAGE followed by autoradiography.
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In order to identify the catalytic subunit of PDE being phosphoiylated by protein 
kinases, we used a low percentage bisacrylamide gel (15% acrylamide and 0.04% 
bisacrylamide) to separate Pa and P$ (Catty and Deterre, 1991). We found that the 
endogenous kinase phosphorylated only the Pa subunit, and PKA preferably 
phosphorylated the PP subunit. MAP kinase could phosphorylate PDE Pa and PJ3 equally 
well (Fig.3.12). Thus, it appeared that the endogenous kinase is neither PKA nor MAP 
kinase. To date, we have not identified the protein kinase responsible for phosphorylating 
PDE in vivo. However, PKC is one candidate for the PDE kinase, since it is present in rod 
outer segment (Wolbring and Cook, 1991), and has been reported to phosphorylate only 
the Pa subunit in vitro (Udovichenko et al., 1993).
Figure 3.12. Subunit specificity for phosphorylation by an endogenous kinase, PKA 
or MAP kinase. For lane 1, PDE purified by ROS-1 affinity chromotography was diluted 
to -50 nM with assay dilution buffer and a final concentration of 100 pM [y-32P]ATP. No 
exogenous kinase was added. For lane 2 and 3, PDE was purified by ROS-1 affinity 
chromatography, Mono-Q chromatography and gel-filtration chromatography (see Fig. 
11); only trace amount of endogenous kinase have been detected to exist in this purified 
PDE sample. PDE was phosphorylated in the similar way except that PKA (5 ng 
kinase/pg protein) or MAP kinase (5 ng kinase/pg protein) was used. All reactions were 
incubated at 22°C for 5 hours. Pa and PP were separated on a 15% acrylamide, 0.04% 
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Depletion o f noncatalytic cGMP binding enhances PDE catalytic subunit 
phosphorylation — Work done with PDE5 has suggested that binding of cGMP to 
allosteric sites of PDE5 is required to expose the site of phosphorylation (Ser92) by the 
cGMP-dependent protein kinase (Thomas et al., 1990; Turko et al, 1998; Francis et al., 
1990; Turko et al., 1998). Since PDE6 is the closest to PDE5 both structurally and 
functionally, it is plausible that the GAF domains also allosterically regulate the 
phosphorylation of PDE6. In order to investigate this hypothesis, PDE holoenzyme with 
different states of cGMP occupancy were tested. PDE was depleted of its endogenous 
cGMP by incubating at 37°C overnight. P5 was added to one PDE preparation to 
facilitate the dissociation of cGMP from the non-exchangeable binding sites (Mou et al., 
1999). The results in Fig.3.13 show that depletion of cGMP from its binding sites 
enhanced the phosphorylation by increasing the rate of [32P] incorporation. This 
enhancement was not due to the interaction of P5 with PDE, since P8 itself could not 
change the rate and degree of PDE phosphorylation when both noncatalytic cGMP 
binding sites were occupied (Fig.3.14).
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Figure 3.13. Depletion of cGMP from the noncatalytic cGMP binding sites enhanced 
the phosphorylation of PDE holoenzyme. ROS 1-affinity chromotography purified 
bovine rod PDE-M was incubated at 37°C overnight to deplete the endogenous cGMP 
from its GAF domains, for one samples (lanes 7-9), PS was added to allow cGMP 
exchange at an otberwsie nonexchangeable site (Mou et al., 1999). After overnight 
incubation, PDE lost less than 20% its total PDE activity. For lane 1-3, PDE-M was 
replenished with 20 pM cGMP and 200 pM zaprinast immediately before 
phosphorylation. PDE was diluted to ~50 nM with assay dilution buffer and incubated 
with a final concentration of 100 pM [y-32P]ATP. No exogenous kinase was added. The 
reactions were stopped at 0.5,3 and 6 hours by addition of 10 pi of gel sample buffer. 
PDE was separated on a 15% acrylamide, 0.04% bisacrylamide SDS-PAGE (18 h at 100 
V), followed by autoradiography.
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Figure 3.14. Interaction of PS with PDE has no effect on the rate or extent of PDE 
phosphorylation when the noncatalytic cGMP binding sites are occupied. 50 nM
PDE holoenzyme (gel-filtration purified) was phosphorylated by 50 ng PKA in assay 
dilution buffer containing 200 pM zaprinast, 20 pM cGMP, 100 pM [y-32P] ATP and 
increasing concentrations of PS (lane 1 and lane 2: 0 nM; lane 3: 30 nM; lane 4: 60 nM; 
lane 5: 120 nM; lane 6: 300 nM; lane 7: 600 nM). PKA was omitted in lane 1. After 
incubating at 22°C for 40 minutes or 6 hours, the reactions were stopped by addition of 
10 pi of electrophoresis sample buffer. PDE was separated by 10% SDS-PAGE, followed 
by autoradiography.
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Effect o f phosphorylation on the regulation o f PDE function—  The possible function of 
PDE6 catalytic subunit phosphorylation has been studied. After phosphorylation, both 
PDE3 and PDE5 gain a higher koat and lower Km for substrate at the active sites 
(Macphee et al., 1988; Beltman et al., 1993; Turko et al., 1998; Corbin et al., 2000; 
Macphee et al., 1988; Corbin et al., 2000; Turko et al., 1998). For PDE6, no alteration in 
kcat or Km has been observed upon phosphorylation of the catalytic subunits (data not 
shown). However, we discovered that the cGMP binding stoichiometry of bovine rod 
PDE at the noncatalytic sites was increased from 2 to 3-4 cGMP bound per Pocj3 if ROS 
homogenates were incubated beforehand with ATP. The total amount of increase varied 
in different ROS preparations from no change to 2 cGMP per PDE (Fig.3.15). The reason 
for this variation is not known. In addition, this effect of phosphorylation on cGMP 
binding is much less apparent with purified PDE6. It is also not clear whether there is a 
direct relationship between the stoichiometry of phosphorylation and the extent of cGMP 
binding to Pa(3. The increase in cGMP binding stoichiometry upon ATP addition was 
also seen in frog ROS homogenates when exogenous ATP was added (Grazio, 1997). It is 
possible that phosphorylation of PDE6 induces a conformational change in the GAF 
domains on Pap so to convert low affinity cGMP binding sites to a state of higher 
binding affinity for cGMP.
143
with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
ATP+PS
Control
Figure 3.15. Effect of PDE phosphorylation on cGMP binding to the GAF domains.
Purified bovine ROS was first diluted to 6.6 pM rhodopsin (-20 nM PDE) in 77 mM 
KC1, 35 mM NaCl, 2.0 mM MgCl2, 1.0 mM CaCl2, 1.18 mM EGTA ([C a2+free] = 240 
nM), 10 mM HEPES, pH 7.5, 5.0 mM dithiothreitol, 2.5 pg/ml leupeptin, 1 mM 
Pefabloc, 3.5 pg/ml pepstatin, and 200 pM zaprinast. 1 pM of [3H]cGMP was added to 
the binding mixture followed by incubating at 30°C for 24 hours to exchange the 
endogenous nucleotides for radioactive-labeled cGMP (column 1). The function assay 
determined after incubation indicated that loss of PDE activity was less than 20% over 
the 24 h period. To investigate the effect of P5 and phosphorylation ofPaP on the 
noncatalytic cGMP binding, 2 pM purified PS (column 2) or 200 pM of ATP (column 3) 
or 2 pM PS plus 200 pM ATP (column 4) was also added to the binding mixture. The 
amount of [3H]cGMP bound to PDE was determined by filter binding assay: cGMP 
binding to bovine ROS itself: Vmax = 1.60 mol cGMP/mol PDE; bovine ROS + PS: Vmax 
= 1.97 mol cGMP/mol PDE; bovine ROS + ATP: Vmax = 3.52 mol cGMP/ mol PDE; 
bovine ROS + P5 + ATP: Vmax = 3.38 mol cGMP/mol PDE. This figure represents one of 
three similar experiments.
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Discussion
Functional effects and potential physiological role ofphosphorylation o f Pyat Thr22 and 
Thr35. Several G-protein independent pathways for modulating PDE6 activity and 
lifetime have been suggested, such as GARP2-dependent inactivation of PDE6 (Korschen 
et al., 1999) and solubilization of PDE6 by P8 (Cook et al., 2001). In this work, the role 
of Py phosphorylation in modulating the interaction between Py and Pap was studied.
Our results failed to support the previous idea that Py phosphorylation is involved in a G- 
protein-independent pathway by directly enhancing the inhibitory ability of Py (Tsuboi et 
al., 1994a; Tsuboi et al., 1994b; Xu et al., 1998; Matsuura et al., 2000). We did not detect 
an increase in Py binding affinity or its inhibitory potency for PDE6 upon 
phosphorylation of Py at either Thr35 or Thr22. On the contrary, we observed that Py 
phosphorylation decreases the ability of the central region of Py to bind to PDE, as well 
as modestly reducing its inhibitory potency. The reason for the discrepancy between our 
results and previously published work is probably due to the different experimental 
conditions used, as well as different interpretation of the observed results. In most of the 
published papers, nanomolar concentrations of PDE were used and it was difficult to 
extract meaningful binding affinity values. In this study, we used conditions where the 
Kd for Py could be accurately assessed as a result of phosphorylation.
Although no direct modulation of Py phosphorylation in the interaction of Py with 
PDE has been found, we did observe that transducin activation stimulates Py 
phosphorylation in bovine ROS, in agreement with previous reports (Tsuboi et al., 1994b; 
Hayashi et al., 2000). Together with the finding that Py complexed with PDE is a poor
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substrate for phosphorylation, we suggested that the condition under which Py is likely to 
be phosphorylated is when Py is displaced from Pap binding sites by activated transducin. 
However, less than 5% of total pool ofPy could be phosphorylated in bovine ROS, which 
makes the importance of this post-translation modification ofPy in visual transduction 
questionable. It is unlikely that such a small effect could act directly onto PDE. We 
speculate that the light-induced increase in Py phosphorylation may have some alternative 
function in connecting the visual transduction pathway with other signaling pathways in 
the rod outer segment. The central region ofPy contains a potential Type II SH3 domain 
ligand binding site, which is known to be involved in protein-protein interactions. The 
fact that Py is expressed in non-retinal cells (Tate et al., 1998) and can serve as a novel 
intermediate regulating p42/p44 MAP kinase signaling (Wan et al., 2001) suggests that 
Py may indeed act on other signaling pathways. Whether Py phosphorylation regulates its 
function in these novel pathways in photoreceptors is a subject for further study.
At this time, we are not clear which residues on Py are phosphorylated in vivo. To 
clarify this question, we will need to extract Py from the intact retinas or intact ROS 
under different dark and light conditions and to perform the mass spectrometric analysis 
ofPy to determine the occurrence and site(s) ofPy phosphorylation.
Functional effects and potential physiological role o f phosphorylation o f the catalytic 
subunits o f PDE6: The occurrence and significance of phosphorylation of the PDE6 
catalytic dimer for PDE6 regulation was studied in this work since many of known PDE 
families (PDE1, PDE3, PDE4, PDE5) have been reported to be regulated in a 
phosphorylation-dependent manner. In addition, phosphorylation of PDE6 catalytic dimer 
might represent an additional G-protein-independent pathway during light adaptation.
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Our results showed that the PDE catalytic dimer is a substrate for several protein kinases, 
including PKA and MAP kinase in vitro, as well as an unknown endogenous, membrane- 
associated “PDE6 kinase” from bovine ROS. Protein kinase activity co-purifies with 
bovine PDE through several stages of purification, and represents one candidate for a 
PDE-binding protein.
No direct regulation of catalysis by the phosphorylation of PDE6 catalytic dimer 
has been found in our work. However, our results showed for the first time that the 
phosphorylation of PDE6 is allosterically regulated by its GAF domains. Depletion of 
cGMP from the GAF domains enhances phosphorylation of the PDE6 catalytic dimer, 
suggesting that occupancy of the GAF domains of PDE6 elicits a conformation change 
that masks the phosphorylation sites on Pa and/or Pp. After PaP phosphorylation, low 
affinity cGMP binding sites are converted to their high affinity state, similar to the case 
for PDE5 (Corbin et al., 2000). Therefore, it is possible that PaP phosphorylation 
represents a negative feedback mechanism to regulate cGMP levels and to regulate the 
lifetime of active PDE during light adaptation. In this scenario, when photoreceptors are 
exposed to bright light or continuous light, the cytoplasmic cGMP will be decreased to a 
certain level to induce cGMP dissociation from the GAF domains. The unoccupied GAF 
domains in turn induce a conformational changes in Pap to decrease Py affinity for better 
GAP activity, consequently shortening the lifetime of active PDE. However, the empty 
GAF domains also will enhance the phosphorylation ofPap. Upon Pap phosphorylation, 
high affinity cGMP binding is restored to the low affinity binding sites leading to re­
binding of cGMP which also promote Py association with PaP.
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SUMMARY
The major objective of this study is to explore what is the functional significance 
of cGMP binding, as well as Py and Pap phosphorylation, for the mechanism of PDE 
regulation.
First, we characterized the cGMP binding properties to bovine rod PDE. We 
showed that two mammalian rod photoreceptor PDE isoforms (soluble and membrane- 
associated PDE) have two non-identical, high-affinity noncatalytic sites. Interaction of P8 
with PDE-S permits cGMP release from a second noncatalytic binding site on nPDE-S 
that remains functionally nonexchangeable in PDE-M. The Py subunit not only acts as an 
inhibitor of cyclic nucleotide catalysis at the active sites on Pap, but also serves to 
regulate the binding affinity of cGMP on the Pap dimer. Upon activation of PDE by 
removal of the Py subunits, one of the two classes of noncatalytic sites on the Pap dimer 
eliminates its detectable binding (K d  > 1 pM) of cGMP. The remaining cGMP binding 
sites exhibit a 3-fold reduction in overall binding affinity. In addition, we also 
demonstrated that Py subunit is primarily responsible for altering cGMP exchange upon 
activation.
Interactions between Py and the PaP are essential for the regulation of PDE 
function in vertebrate rod photoreceptors during visual transduction. In this study, we for 
the first time measured Kd of Py binding to mammalian rod PDE and found that the value 
is in the range of picomolar to sub-picomolar. Py binds to two distinct high-affinity 
binding sites on Pap when cGMP occupies the noncatalytic sites. Our work also
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describes the reciprocal allosteric regulation of PDE6 resulting from Py binding to PaP 
and cGMP binding to high-affinity sites in the GAF domains of Pap. By using synthetic 
peptides, we revealed that Py has multiple sites of interaction with rod PaP: the C- 
terminus functions to inhibit the catalysis, while the central region functions to restore 
and stabilize cGMP binding to the GAF domain. We also mapped regions within the N- 
terminal half of the molecule that interact with Pap, some of which induce 
conformational changes at the GAF domain.
The role of Py phosphorylation in modulating the interaction between Py and PaP 
was also studied. Our results showed that Py binding affinity or its inhibitory potency for 
PDE6 was not increased upon phosphorylation of Py at either Thr35 or Thr22. In contrast, 
Py phosphorylation decreases the ability of the central region of Py to bind to PDE, as 
well as modestly reduces its inhibitory potency. We speculate that the light-induced 
increase in Py phosphorylation may have some alternative function in connecting the 
visual transduction pathway with other signaling pathways in the rod outer segment, 
rather to be involved in a G-protein-independent pathway by directly enhancing the 
inhibitory ability of Py .
Finally phosphorylation of the PDE6 catalytic dimer was studied to evaluate if it 
represents a G-protein-independent pathway to regulate PDE during light adaptation. Our 
results showed that the PDE catalytic dimer is a substrate for several protein kinases, 
including PKA and MAP kinase in vitro, as well as an unknown endogenous, membrane- 
associated “PDE6 kinase” from bovine ROS. We also for the first time showed that the 
phosphorylation of PDE6 is allosterically regulated by its GAF domains. Depletion of 
cGMP from the GAF domains enhances phosphorylation of the PDE6 catalytic dimer.
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After PaP is phosphorylated, low affinity cGMP binding sites are converted to their high 
affinity state, similar to the case for PDE5. Therefore, it is possible that Pap 
phosphorylation represents a negative feedback mechanism to regulate cGMP levels and 
to regulate the lifetime of active PDE during light adaptation.
The above work helps us understand how PDE is regulated during the visual 
transduction and light adaptation. In dark-adapted rod outer segments, the cytoplasmic 
cGMP concentration is about 4 pM. In this condition, both noncatalytic sites on nPDE-S 
and nPDE-M will be fully occupied. Py binds to Pap tightly and inhibits its catalysis. 
When photoreceptor cells are exposed to light, Gta* -GTP binds to Py and displaces it 
from its inhibitory site on Pap, causing activation of PDE. During the recovery phase of 
the flash photoresponse, activation of PDE results in the immediate loss of cGMP binding 
to one of the GAF domains on both PDE-M and PDE-S. As a result, its bound cGMP is 
released rapidly to the cytoplasmic space on the same time scale as recovery phase of the 
photoresponse to buffer free cGMP levels. However, upon cGMP release from the bound 
state, it is likely that the free cGMP would be destroyed by the still-active catalytic sites, 
and therefore not contributes to elevating the cytoplasmic cGMP levels during 
photoresponse recovery. Activation of PDE also reduces cGMP binding affinity 3-4 fold 
at the second cGMP binding site on PDE.
The noncatalytic sites might be indirectly involved in regulating the lifetime of 
transducin-activated PDE via modulation of Py binding affinity to Pap. In chapter II, we 
showed that there exists a reciprocal relationship between cGMP binding to the GAF 
domains and the binding affinity of Py to Pap. In bovine ROS, Py serves as a GTPase 
accelerating factor, acting in concert with the RGS9 protein. Therefore, dissociation of
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bound cGMP from the noncatalytic sites reduces Py binding affinity to PaP and Py is 
partitioned from PaP to transducin. Consequently, Py interacts with RGS9 to stimulate 
GTPase activity of transducin to inactivate PDE during the recovery phase of the 
photoresponse.
Dissociation of Py from Pap together with Gta  also makes Py a good substrate for 
phosphorylation. Upon phosphorylation, Py may act on other proteins in a 
phosphorylation-dependent manner so that the several signaling pathways are connected. 
In addition to Py, PDE catalytic subunits are phosphorylated when the GAF domains 
becomes empty. Phosphorylation of Pap will elicit a conformation change on Pap so that 
low affinity cGMP binding sites are converted to their high affinity state, which also 
promotes Py re-association with Pap. In this scenario, Pap phosphorylation serves as a 
negative feedback mechanism to regulate cGMP levels and to regulate the lifetime of 
active PDE during light adaptation.
Although our work has made a significant advance in our understanding of the 
regulation of PDE during the visual excitation and adaptation, there are still many 
questions needing to be answered. For example, which cGMP binding site on PDE-M is 
the non-exchangeable site? Is the heterogeneity in Py binding correlated with the 
heterogeneity in two GAF domains as well as the different subunit composition of PaP? 
How does Py phosphorylation communicate with other signal pathways? Which 
endogenous protein kinase is responsible for phosphorylating Pap? Under what 
condition is Pap phosphorylated during visual transduction, and how does its 
phosphorylation contribute to a novel negative feedback mechanism to regulate cGMP 
levels and PDE function. All of these questions will be subjects for further study.
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